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4Abstract
Biliary tract cancer (BTC) is difficult to diagnose, in part related to the lack of
reliable tumour markers. The aim of this project was to use whole genome
RNA expression profiling in order to identify novel biomarkers for diagnosis
and prognosis in biliary tract cancer.
Chapter 1 summarises clinical aspects of BTC as well as current diagnostic
and prognostic tests.
Chapter 2 addresses the identification of circulating tumour cells for the
diagnosis of BTC. It includes details of a study investigating measurement of
circulating cytokeratin 19 fragments (CYFRA 21-1), demonstrating that
CYFRA 21-1 is a more specific, but less sensitive diagnostic marker than
CA19-9, and predicts a poor prgnosis in BTC.
Chapter 3 investigates the potential for using RNA isolated from archived
formalin fixed, paraffin embedded (FFPE) surgical and explanted liver tissues
from patients with primary sclerosing cholangitis (PSC) with and without
cholangiocarcinoma, for use in whole genome RNA expression analysis. We
demonstrate that, although technically possible, the rarity of samples and
RNA degradation that occurs as a result of the tissue processing, are such
that further evaluation using these materials is not feasible at this time.
Chapter 4 addresses and validates methodology for isolating RNA from
samples of biliary brushings taken at the time of endoscopic retrograde
5cholangiopancreatography (ERCP). We demonstrate that RNA isolated from
biliary brushings is of low quantity and degraded, and that this degradation
occurs in vivo. However, we demonstrate that such RNA is still useful for
downstream applications such as quantitative real time PCR and is therefore
suitable for whole genome RNA expression analysis using microarray
technology.
Chapter 5 describes the methods and results obtained from using whole
genome RNA expression analysis using microarray of RNA isolated from
ERCP biliary brushings. The results are presented as a shortlist of candidate
genes requiring further validation.
Chapter 6 provides results of qPCR studies performed in order to validate the
gene expression profile identified by microarray. A selection of candidate
genes are investigated using TaqMan Array and SYBR Green qPCR and
demonstrate a high correlation with the pattern of expression shown by
microarray.
Chapter 7 investigates whether a selection of the genes identified in
malignant biliary brushings are similarly upregulated in fresh frozen surgical
resection material from patients with benign and malignant biliary diseases. In
addition, we provide evidence for gene translation and upregulation at the
protein level by immunohistochemistry for a selection of the protein products.
Chapter 8 discusses the main conclusions drawn from the work as well as
potential future studies.
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Chapter 1.
1 Biliary tract cancer
1.1 Introduction
Biliary tract cancer (BTC) includes the primary liver cancers
cholangiocarcinoma and gallbladder cancer, which are both thought to arise
from biliary epithelial cells. Cholangiocarcinoma (CC) is usually classified
according to its location as intra-hepatic or extra-hepatic (Figure 1) but some
older classifications and publications include a separate peri-hilar type (intra-
hepatic in current classification) which has caused confusion in estimating
incidence rates and understanding the biology of the disease (Welzel,
McGlynn et al. 2006; Matull, Khan et al. 2007; Blechacz, Sanchez et al. 2009).
Peripheral, intra-hepatic CC tends to form mass lesions within the hepatic
parenchyma. It is more common in East Asia and has a strong association
with chronic infestation with the liver fluke (Opisthorchis or Clonorchis spp).
Extra-hepatic CC is the commoner type in the western world and tends to
infiltrate along the major bile ducts, but may also form mass lesions. Extra-
hepatic CC is likely to be a biologically different disease to the peripheral type
more commonly seen in East Asia. The incidence of cholangiocarcinoma
appears to be rising with an incidence of approx 1000 cases per year in the
United Kingdom in 2001 and more recent data from the Office of National
Statistics recording 2650 cases in 2005. (Taylor-Robinson, Toledano et al.
2001; Toledano, Mehtan et al. 2009). The rising incidence is partly related to a
rise in the intra-hepatic type, for which the cause is unknown but may also be
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related to alteration in disease classification or diagnostic accuracy (Taylor-
Robinson, Toledano et al. 2001; Khan, Taylor-Robinson et al. 2002).
Figure 1. Left: Anatomy of the main hepatobiliary system with description of main
anatomical classification of biliary tract cancers. Right: Bismuth classification of extra-
hepatic CC (reproduced from (de Groen, Gores et al. 1999).
The pathobiology of BTC is poorly understood. Most cases of extra-hepatic
cholangiocarcinoma are sporadic with no known cause. Identifiable risk
factors account for a small percentage of cases but include age, smoking,
choledochal cysts, exposure to Thorotrast X-ray contrast medium and causes
of chronic biliary inflammation including chronic typhoid, Opisthorchis
infection, choledocholithiasis and primary sclerosing cholangitis which carries
a high lifetime risk of up to 20% (Bergquist, Ekbom et al. 2002) and remains
the most significant known risk factor for cholangiocarcinoma in Western
countries.
Cholangiocarcinoma usually presents with symptoms and signs of biliary
obstruction (jaundice, dark urine and pruritis), abdominal pain, weight loss
and/or features of cholangitis (fevers, rigors and pain). There are few
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symptoms or signs in early disease and as a result, disease usually presents
at an advanced stage.
One of the greatest challenges in BTC is the difficulty in diagnosis, particularly
differentiating benign from malignant biliary strictures in conditions such as
primary sclerosing cholangitis. The growth of CC follows 3 forms; 1) peri-
ductal infiltrating, 2) papillary or 3) mass forming (Lim and Park 2004).
Spreading intra-ductal disease is more common than the mass forming type
so that there is often no mass lesion identified on imaging, adding to the
difficulties in diagnosis.
Patients with BTC have a poor prognosis, in part related to difficulties and
delays in diagnosis. Most patients present at an advanced stage with five year
survival rates of less than 5% and median survival of only six to nine months.
The only potentially curative treatment is hepatic resection or, in highly
selected cases, liver transplantation (Khan, Davidson et al. 2002; Becker,
Rodriguez et al. 2008). Series from the US suggest that highly selected cases
in PSC disease have 5 year survival rates of up to 82% when treated with
preoperative chemotherapy and radiotherapy followed by transplantation
(Rea, Heimbach et al. 2005; Wu, Johlin et al. 2008). However, in most
countries (including the UK), CC remains a contraindication to liver
transplantation because of the high rates of recurrence observed in older
series (Khan, Davidson et al. 2002).
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Most treatments for CC are given with palliative intent. Results of radiotherapy
have been disappointing and there is currently little role for radiotherapy in the
treatment of cholangiocarcinoma in the UK (Khan, Davidson et al. 2002). CC
has been considered a relatively chemo-resistant cancer with moderate
response rates of up to 30% reported with gemcitabine and 5-fluorouracil (5-
FU) based regimen (Thongprasert 2005). However a recent report of the
largest chemotherapy study undertaken to date in BTC (ABC-02), shows
significant progress with chemotherapy (Valle, Wasan et al. 2010). In this
phase III study, 410 patients with locally advanced biliary tract cancer (CC,
gallbladder and ampullary cancer) were randomised to treatment with
gemcitabine plus cisplatin over gemcitabine alone. The patients treated with
combination of gemcitabine plus cisplatin had a significant survival advantage
(11.7 months versus 8.2 months, p=0.002) and better progression-free
survival (8.0 months versus 5.0 months, p<0.001) than in the gemcitabine
alone arm, without significant differences in adverse events between the two
groups (Valle, Wasan et al. 2010). As a result, chemotherapy with the
combination of gemcitabine and cisplatin is the current standard of care for
suitable patients with BTC. Combination of chemotherapy with other systemic
therapies such as small molecule or antibody blockade of tyrosine kinase
receptors may further improve treatment regimens in the future.
More novel physical and biological therapies including photodynamic therapy
(Chapman and Pereira 2009) and the use of biological agents such as
tyrosine kinase inhibitors are currently being assessed in phase II and III
32
clinical trials including the PHOTOSTENT-02 trial coordinated by the CRUK
and UCL Cancer Trial Centre (Dr Pereira, Principal investigator).
Biliary stent insertion remains the most common palliative intervention. It has
no impact on tumour progression but aims to improve a patient’s quality of life
by relief or prevention of jaundice, pruritis and cholangitis. Stents may be
placed endoscopically or percutaneously, depending on the nature of the
stricture and ease of endoscopic access. Both metal and/or plastic stents may
be used once pathological diagnosis has been confirmed. There are few
randomised controlled trials comparing outcome using plastic or metal stents
in BTC (Wagner, Knyrim et al. 1993), but based on studies in pancreatic
cancer, metal stents may provide better palliation, result in fewer procedures
and are cost effective in those with a life expectancy over 6 months (Flamm,
Mark et al. 2002). Either or both the percutaneous and endoscopic routes may
be suitable for insertion of biliary stents, but failure to achieve adequate
drainage leads to a poor outcome in those patients. A study of 85 patients
undergoing percutaneous or endoscopic metal stent insertion showed that in
those with inadequate biliary drainage, the prognosis was much poorer
(median 1.8 months versus 8.7 months, p=<0.001)(Paik, Park et al. 2009)
The difficulty in diagnosing BTCs is a particular issue in patients with primary
sclerosing cholangitis (PSC). In this condition widespread benign bile duct
structuring is characteristic. However, CCA is not uncommon and
differentiating benign from malignant biliary strictures is a regular clinical
challenge. PSC is an immune-mediated chronic liver disease characterised by
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inflammation, fibrosis and destruction of intra- and/or extra-hepatic bile ducts
leading to cholestasis, bile duct strictures and hepatic fibrosis, which in turn
may progress to cirrhosis, portal hypertension and hepatic decompensation
(Chapman, Arborgh et al. 1980). One of the biggest clinical problems in
managing patients with PSC is the difficulty in differentiating benign from
malignant biliary strictures. The incidence of cholangiocarcinoma in PSC is
between 0.6% and 1.5% per year with a prevalence of 6-13% and a lifetime
risk of up to 20% (Bergquist, Ekbom et al. 2002; Boberg, Bergquist et al.
2002; Burak, Angulo et al. 2004). In up to half of cases, cholangiocarcinoma is
identified within a year of diagnosis of PSC and may be the reason for
presentation of previously unrecognised PSC (Chapman, Witmann et al.
2008) (Abtrast 1, Figure 73, Appendix). The incidence of cholangiocarcinoma
is highest in those with dominant strictures with up to 76% located within the
peri-hilar region (Ahrendt, Pitt et al. 1999). To date, no cholangiocarcinoma's
have been reported in patients with small duct PSC except for a single report
of a patient progressing to classical large duct PSC prior to developing
cholangiocarcinoma (Bjornsson, Olsson et al. 2008). Therefore, most cases of
CC should be within reach of ERCP sampling. It is often not possible to
distinguish benign from malignant biliary strictures using imaging alone, such
as magnetic resonance cholangiopancreatography (MRCP). Biliary brush
cytology at ERCP is the standard investigation for possible malignant biliary
stricture but despite good specificity, reported sensitivity in most centres is
poor. Our experience of CC in PSC are summarised in abstract form in the
appendix (Abstract 1, Figure73 (Chapman, Witmann et al. 2008)).
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1.2 Current diagnostic investigations for biliary
tract cancer
As discussed above, the diagnosis of cholangiocarcinoma is well recognised
as being a difficult clinical problem. As with many cancers, diagnosis requires
cytologic or histologic confirmation of adenocarcinoma with immunostaining in
keeping with biliary tract cancer. However, this involves invasive procedures
with significant risk of complications. Other indicators of disease, such as
circulating biomarkers or improved imaging techniques, would greatly
enhance clinical decision making and improve diagnostic algorithms. Current
diagnostic tests for BTC are summarised below.
1.2.1 Imaging
1.2.1.1 Ultrasound
Ultrasound is normally performed as the first imaging modality in patients with
abnormal liver biochemistry. Mass lesions are not typical in
cholangiocarcinoma and therefore are usually not seen on ultrasound
scanning. Dilatation of intra-hepatic bile ducts in the presence of normal
calibre extra-hepatic bile ducts is suggestive of biliary stricturing but does not
differentiate benign from malignant disease. Bile duct thickening may be seen
but is non-specific. Other findings such as the identification of hepatic venous
or arterial thrombosis may assist in assessing staging and prognosis.
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1.2.1.2 Computed tomography (CT)
CT is more sensitive in identifying mass lesions but has similar limitations to
ultrasound when no mass lesion is present. CT is useful for staging disease in
order to plan and monitor treatment. Studies assessing the accuracy of CT in
determining resectability of CC report sensitivities and specificities of 94-
100% and 48-79% respectively (Tillich, Mischinger et al. 1998; Cha, Han et al.
2000; Lee, Kim et al. 2006; Aloia, Charnsangavej et al. 2007). Multi-slice CT
cholangiography has improved the diagnostic accuracy for benign and
malignant biliary disease. A prospective study (n=36) comparing magnetic
resonance cholangiopancreatography (MRCP) with CT cholangiography
demonstrated an accurate diagnosis using CT in 34 of the 36 cases of biliary
obstruction (benign and malignant pancreatobiliary disease) (Zandrino,
Curone et al. 2005). A further study of CT cholangiography in 34 patients with
biliary obstruction reported accurate diagnosis of 93% of patients with benign
disease and 94% in those with malignant obstruction (pancreatic and biliary
cancer) (Ahmetoglu, Kosucu et al. 2004). However, these studies included
both pancreatic and biliary malignancy and the experience of most clinicians
is that imaging is far less accurate in routine clinical practice, particularly in
cases of cholangiocarcinoma.
1.2.1.3 Magnetic resonance imaging (MRI) and magnetic
resonance cholangiopancreatography (MRCP)
The non invasive nature of MRI/MRCP means that it is considered the
investigation of choice for imaging biliary anatomy. Studies investigating the
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accuracy of MRCP in differentiating benign from malignant biliary obstruction
have been mostly performed in patients with PSC. The largest study in 230
patients with PSC (23 with CC) reported a sensitivity of 63% and specificity of
79% with a PPV of 40% for the diagnosis of CC (Charatcharoenwitthaya,
Enders et al. 2008). In unselected biliary disease, MRCP is reported to have
sensitivities of 48-88% and specificities of 71-95% for the diagnosis of
malignant biliary strictures (Rosch, Meining et al. 2002; Romagnuolo, Bardou
et al. 2003; Domagk, Wessling et al. 2004).
1.2.1.4 Endoscopic retrograde cholangiopancreatography
(ERCP)
ERCP is an important investigation for the investigation of suspicious biliary
strictures (Figure 2). It provides accurate delineation of the pattern and extent
of stricturing, is sensitive in assessment of secondary complications such as
the presence of stones, and provides access for tissue sampling of bile and
biliary strictures. However, ERCP has a risk of complications and is therefore
only indicated when therapeutic interventions such as brush cytology, stricture
dilatation or stent insertion are required.
The most difficult clinical scenario with regards investigating strictures is
differentiating benign from malignant strictures in patients with PSC, although
similar problems arise for many causes of biliary strictures. Studies
investigating the accuracy of ERCP over MRCP for the diagnosis of CC in
PSC suggest that both have comparable accuracy. These data come from
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studies primarily assessing the role of MRCP in diagnosis of benign PSC
disease which report sensitivities and specificities of 83%to 100% and 92% to
100% of MRCP for the diagnosis of PSC (Ernst, Asselah et al. 1998; Angulo,
Pearce et al. 2000; Textor, Flacke et al. 2002; Berstad, Aabakken et al. 2006).
Since cholangiography, either by MR or the endoscopic approach, is
insufficient for diagnosis of malignancy, the main role for ERCP in diagnosis
remains its ability to obtain tissue samples for diagnosis.
Figure 2 Endoscopic retrograde cholangiopancreatography (ERCP) showing a
cholangiogram of a stricture (arrow) in the common hepatic duct (left),
endobiliary brush for cytology sampling (top right) and diagram of the local
anatomy (bottom right, image from Medical Illusatration Group, Chelsea and
Westminster Hospital).
1.2.1.5 Cholangioscopy
Development of ultra-thin fibre-optic fibres has allowed the manufacture of
small calibre cholangioscopes introduced through the papilla at ERCP. These
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allow direct visualisation of suspicious biliary strictures in order to further
characterise and direct biopsies towards abnormal tissues. Early studies
investigating the accuracy of cholangioscopy reported a sensitivity of 71-
100% and specificity 86-100% for the diagnosis of malignant biliary strictures
(Fukuda, Tsuyuguchi et al. 2005; Chen and Pleskow 2007). A study
investigating the use of cholangioscopy compared to cholangiography alone
in PSC reported an improved sensitivity from 66% to 92% and specificity from
55% to 93% for the diagnosis of CC (Tischendorf, Kruger et al. 2006).
1.2.1.6 Endoscopic ultrasound and intra-ductal (miniprobe)
ultrasound
Intra-ductal ultrasound probes were developed in order to improve imaging of
bile wall thickening, presence of small stones and involvement of surrounding
tissues for tumour staging. Studies report sensitivities of 89-91% and
specificities of 50-80% for the diagnosis of malignant biliary strictures
(Tamada, Ueno et al. 1998; Menzel, Poremba et al. 2000). EUS-guided fine
needle aspiration cytology and biopsy may further improve accuracy in the
diagnosis of malignant strictures (Eloubeidi, Chen et al. 2004).
1.2.1.7 Fluoro-2-deoxy-D-glucose, positron emission
tomography (FDG-PET)
PET scanning uses radiolabelled compounds that incorporate into normal
cellular pathways in tissues of interest. The fluorine-18 radiolabelled FDG
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reagent is a hexokinase subtrate that is taken up and concentrated in cells
with high levels of aerobic glycosylation such as tumour cells. The diagnostic
accuracy of FDG-PET has been investigated in small studies. A retrospective
study of 30 patients with indeterminate biliary strictures reported a sensitivity
and specificity of 90% and 78% respectively for the diagnosis of malignant
obstruction (Wakabayashi, Akamoto et al. 2005).
An early report suggested positron emission tomography (PET) scanning may
be useful for surveillance or investigation of suspected cholangiocarcinoma in
patients with PSC (Keiding 1998). However, a further study of 36 patients with
suspected cholangiocarcinoma demonstrated a sensitivity of 85% for mass
forming tumours, 65% for metastases but only 18% for infiltrating tumours
(Anderson, Rice et al. 2004). Others have also demonstrated a low sensitivity
of PET and high false positive rates in the presence of cholangitis (Fevery,
Buchel et al. 2005). The likely reasons for this are that the FDG substrate is
not specific for cancer cells and is taken up by all metabolically active cells
such as glial cells in the brain and activated leukocytes (particularly
neutrophils and macrophages) in areas of inflammation or infection, such as
cholangitis. Also, the ductal infiltrating subtype of some tumours may account
for some of the lower sensitivity due to the lack of mass formation to
concentrate the tracer detected during scanning. Therefore, PET is not
routinely utilised for diagnosis or surveillance of cholangiocarcinoma in PSC.
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1.2.2 Histology and cytology
Pathological diagnosis using cytology or histopathology are required for
confirmation of malignancy and so remain crucial in the investigation of biliary
strictures. One study retrospectively assessed 185 patients undergoing major
surgical resections for presumed malignant bile duct strictures and reported
that 17% were benign on assessment of resected tissue, the alternative
primary diagnosis being IgG4 disease (Erdogan, Kloek et al. 2008). When
mass lesions are identified on cross sectional imaging, percutaneous biopsy
for histopathology may be used and has a specificity > 95% for the diagnosis
in BTC. The sensitivity has been little reported but is likely to be approximately
50% -70%. However, the procedure is uncomfortable for patients, may cause
tumour seeding in potentially resectable disease and has risks including
bleeding and biliary leak or perforation of neighbouring structures. The
accuracy of percutaneous biopsy for the diagnosis of BTC is poorly reported
in the literature but suggest tissue confirmation rates of 29-49% in larger
modern series (Mansfield, Barakat et al. 2005; Witzigmann, Berr et al. 2006;
Connor, Barron et al. 2007). The sensitivities for biopsy diagnosis are not
reported in these series. In our own retrospective review of 105 cases at UCH
(appendix), the sensitivity of percutaneous biopsy for pathological
confirmation of BTC was 71%, with a specificity of 100% (Mills, Chapman et
al. 2009).
The most commonly used method for gaining confirmation of malignancy is
biliary brush cytology taken at the time of ERCP. However, the accuracy of
this technique depends greatly on tissue sampling and processing techniques
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as well as expertise of the cytopathologist (de Bellis, Sherman et al. 2002).
Cytological interpretation and diagnosis is based on morphological changes
which are partly subjective. One commonly used classification describes five
categories; unsatisfactory, negative, atypical, suspicious and positive for
malignancy (Logrono and Waxman 2001). Findings of atypia are common in
the presence of inflammation and biliary stenting and usually represent benign
disease. Presence of suspicious high grade dysplastic change has a high
likelihood of malignancy. A review of 230 cases of bushings for biliary
strictures in patients with PSC reported that suspicious change has a
sensitivity of 46% and specificity of 97% for the diagnosis of malignancy
(Charatcharoenwitthaya, Enders et al. 2008).
Biliary brush cytology sampling is a relatively straightforward procedure
performed at the time of ERCP. A wire guided endobiliary brush is repeatedly
passed across a stricture under the guidance of contrast radiography. The
brush is removed and smeared across several microscope slides and then
fixed using alcohol or preparatory cytology fixatives such as Cytofix™ and
PreservCyt™. In some centres, brushes are cut off into saline or liquid
fixatives and processed as ‘wet samples’ spun down in the laboratory and the
pellet used for spreading on slides for assessment.
The specificity of brush cytology is very high and often reaches 100% (range
90-100%). However, there is a very wide range of reported sensitivity which is
often disappointingly low (range 18-69%) (see Table 1 for a summary of
results). One study suggests that therapeutic manipulation of strictures (such
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as dilatation) before sampling may increase the sensitivity from 57% to 85%
(Farrell, Jain et al. 2001).
The reported sensitivity of brush cytology in detecting CC in PSC is between
30 and 73% even when high grade dysplasia is included as a marker of
underlying adenocarcinoma (Ponsioen, Vrouenraets et al. 1999; Khan,
Davidson et al. 2002; Boberg, Jebsen et al. 2006). The sensitivity of cytology
from bile aspirates is even lower. Other markers such as the presence of
aneuploidy in biliary brushings or Kras and p53 in bile have been evaluated
but are not sufficiently sensitive nor specific to be useful for screening or
diagnostic tests (Kubicka, Kuhnel et al. 2001; Moreno Luna and Gores 2006).
Table 1 Biliary brush cytology for the diagnosis of malignant biliary strictures
Reference n Sensitivity (%) Specificity (%)
(Foutch, Kerr et al. 1991) 30 33 100
(Kurzawinski, Deery et al. 1993) 93 69 100
(Lee, Leung et al. 1995) 149 35 100
(Pugliese, Conio et al. 1995) 94 54 97
(Ponchon, Gagnon et al. 1995) 204 35 100
(Mansfield, Griffin et al. 1997) 43 42 100
(Glasbrenner, Ardan et al. 1999) 78 56 90
(Macken, Drijkoningen et al. 2000) 106 57 100
(Jailwala, Fogel et al. 2000) 133 30 100
(Harewood, Baron et al. 2004) 113 24 100
(Baron, Harewood et al. 2004) 100 18 98
(Mills, Chapman et al. 2009) 96 31 100
Endobiliary biopsy may be performed by passing a biopsy forceps into the bile
ducts and sampling tissues in areas of interest identified by contrast
radiography. Reports of complications are higher than brush cytology but are
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still low. Specificity reaches 100% and sensitivity is reported to range between
43-81% (Kubota, Takaoka et al. 1993; Ponchon, Gagnon et al. 1995;
Pugliese, Conio et al. 1995; Sugiyama, Atomi et al. 1996; Schoefl, Haefner et
al. 1997; Jailwala, Fogel et al. 2000). Our series of endobiliary biopsies (n=36)
(Appendix) had a lower sensitivity of 41% but specificity of 100% (Mills,
Chapman et al. 2009). EUS guided fine needle aspiration cytology and needle
biopsy may also increase sensitivity but are more commonly applied to
investigation of pancreatic pathology. Two small studies in CC (n=28 and 44)
suggest that the sensitivity for diagnosis was increased to 86-89% by the use
of EUS (Eloubeidi, Chen et al. 2004; Fritscher-Ravens, Broering et al. 2004).
However, another study in CC suggested that EUS guided FNAC does not
improve sensitivity (46%) in the absence of identifiable mass lesions (Rosch,
Hofrichter et al. 2004).
Aspiration bile cytology is the simplest and safest method of obtaining
samples for cytological assessment. Like biliary brushings, bile cytology has a
very high specificity (reaching 100%) but has a lower sensitivity of 6-32% (see
Table 2). Attempts to improve sensitivity by disruption of the stricture by
dilatation prior to bile aspiration, may increase sensitivity from 29% to 63%
(Mohandas, Swaroop et al. 1994). Other studies were unable to confirm this
result and suggest that addition of bile aspiration cytology adds little to
diagnostic accuracy if biliary brush cytology has been used (Kurzawinski,
Deery et al. 1993; Mansfield, Griffin et al. 1997).
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Table 2 Sensitivity of bile aspiration cytology for the diagnosis of malignant biliary
strictures
Ref n Sensitivity Specificity
(Desa, Akosa et al. 1991) 80 30 100
(Foutch, Kerr et al. 1991) 30 6 100
(Davidson, Varsamidakis et al. 1992) 62 30 100
(Kurzawinski, Deery et al. 1993) 93 32 100
(Sugiyama, Atomi et al. 1996) 43 32 100
(Mansfield, Griffin et al. 1997) 43 15 100
1.2.2.1 Chromosomal aberrations
Chromosomal aberrations are common in cancers. A study investigating the
use of fluorescence in situ hybridisation (FISH) and digital image analysis
(DIA) for detection of aneuploidy, tetraploidy and polysomy in suspicious
biliary strictures reported a sensitivity and specificity of 88% and 63%
respectively (Charatcharoenwitthaya, Enders et al. 2008). In PSC, the
presence of any chromosomal change in biliary brushings had a sensitivity
and specificity of 63% and 90%, respectively, for the diagnosis of BTC
(Charatcharoenwitthaya, Enders et al. 2008).
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1.2.3 Biomarkers and Tumour markers
A biomarker is any measurable biological parameter that alters with a disease
state. These have historically been mostly protein products such as peptides
identified by antibodies in ELISA tests or by immunohistochemistry but more
recently the advent of high throughput technologies such as genomics,
proteomics and metabolomics has opened up the possibilities for more
complex biomarkers based on patterns of multiple gene expressions as
biomarkers in the future. Biomarkers are often categorised as:
1. Diagnostic markers; markers that are associated with the presence of a
disease. Eg, the presence of serum anti-mitochondrial antibodies are
strongly associated with primary biliary cirrhosis.
2. Prognostic markers; markers that are associated with predicting
outcome from a disease. Eg, predicting early or late death from an
untreated cancer.
3. Predictive markers; markers that predict a response to an intervention.
Eg, use of KRAS mutation analysis to determine the likely response to
EGFR blocking drugs in colorectal cancer.
Tumour markers are measurable molecular markers that aim to identify the
presence of cancers but few tumour markers to date are cancer specific. Most
are protein antigens that have been identified using antibody studies. These
can be diagnostic, prognostic and/or predictive. A number of tumour markers
are considered to be very useful and remain widely used in routine clinical
practice. These include prostate specific antigen (PSA) in prostate cancer,
carcinoembryonic antigen (CEA) in colorectal cancer and carbohydrate
46
antigen 125 (CA-125) in ovarian cancer. Over recent years there has been a
drive to use high throughput techniques such as proteomics and genomics to
screen diseased tissues in order to identify new biomarkers. These
techniques show great promise (Perou, Sorlie et al. 2000; Dhanasekaran,
Barrette et al. 2001; Garber, Troyanskaya et al. 2001; Iacobuzio-Donahue,
Maitra et al. 2002).
Sensitivity, specificity and positive predictive calculations using
biomarkers.
Clinical applicability of biomarkers depends on a number of factors such as
how common the condition is, whether they are required for screening, the
importance of not making an incorrect diagnosis, ease of testing (both for
patients and laboratories) and cost. For example, a screening test requires a
very high sensitivity so that most or all tests are positive in the presence of a
disease in order that clinical cases are not missed. Screening tests with a high
sensitivity may suffer from lower specificity- ie the positive test may not be
related to the disease of interest. For example, random blood glucose testing
may be a good screening test for identifying people with diabetes mellitus but
can have false positive results if tested soon after meals. The specificity can
be improved by using fasting blood glucose which if abnormal is much more
specific but can lose sensitivity in early disease. In cancer, a high sensitivity is
important so that disease is not missed but also, a very high specificity is
crucial to avoid mis-diagnosis of cancer with the potential for severe distress
and inappropriate treatments being delivered to patients.
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The positive and negative preditictive index (or precision rate) is the likelihood
that a disease is present or absent based on measurement of a biomarker. A
positive or negative predictive value (PPV/NPV) of 99% would make the
likelihood of a disease being present or absent being very high or low
respectively and so aid clinical decision making about the need for further
confirmatory or excluding tests. Calculations for determining sensitivity,
specificity and predictive indices are made using standard calculations below,
measured against a gold standard for diagnosis (eg histopathology).
 Sensitivity= Number of true positives
Number of true positives + number of false negatives
 Specificity= Number of true negatives
Number of true negatives + number of false positives
 PPV= Number of true positives
Number of true positives + number of false positives
 NPV= Number of true negatives
Number of true negatives + number of false negatives
Few tumour markers to date are sufficiently specific for the confirmation of
cancer so most cancers still require a pathological confirmation of diagnosis
using cytology or histopathology. An exception is an elevated AFP in the
presence of supportive imaging which, in combination, is considered sufficient
for the diagnosis of hepatocellular carcinoma without biopsy confirmation.
However, most tumour markers are currently used for supportive evidence of
early diagnosis or for prognostication and predictive use, eg monitoring CEA
in colorectal cancer to demonstrate a response to chemotherapy and/or
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providing evidence of disease recurrence, or measuring PSA to identify
patients becoming resistant to hormonal treatment in prostate cancer.
Currently there are no tumour markers specific for BTC. Here we summarise
tumour markers that have been investigated or are used for the diagnosis and
prognosis in BTC.
1.2.3.1 Liver biochemistry
Liver biochemical tests are invariably abnormal at presentation of BTC.
However, any cause of biliary obstruction, cholestasis, cholangitis or hepatitis
can cause abnormal liver biochemistry and so liver biochemical tests have a
very low specificity for BTC. They are useful mainly for monitoring severity of
biliary obstruction and response to treatments such as biliary drainage.
1.2.3.2 Carbohydrate Antigen 19-9 (CA 19-9)
Carbohydrate antigen 19-9 (CA19-9) is the most established tumour marker
used in the diagnosis and follow up of patients with suspected BTC. CA19-9 is
a complex glycoprotein first described in 1979 (Koprowski, Steplewski et al.
1979). The primary epitope is a sialylated carbohydrate component of the
sialyl Lewisa antigen, which is not produced by approximately 7% of the
population and thus, CA19-9 is undetectable in these individuals (Steinberg
1990). Published series of patients with benign and malignant biliary
obstruction report sensitivities and specificities of 50% to 90% and 54% to
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98% respectively (Table 3) with a positive predictive value of 56% in one off
the larger studies (Levy, Lymp et al. 2005). Many of the published series were
in the setting of primary sclerosing cholangitis which accounts for a minority of
cases of BTC and the utility of CA19-9 as a tumour marker in sporadic
disease is less clear. It is also well recognised that any cause of benign biliary
obstruction or cholangitis can cause falsely elevated levels of CA19-9 which
falls following relief of obstruction or treatment of cholangitis (Bjornsson,
Kilander et al. 1999; Madonia, Aragona et al. 2007).
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Table 3 Accuracy of serum CA 19-9 for the diagnosis of BTC
Reference
CA19-9
threshold
(U/ml)
n
(CC) Sensitivity Specificity Comments
(Chalasani,
Baluyut et
al. 2000)
100 26 75 80
CA19-9 only available in
half cases. Addition CEA
not helpful. PSC study
(John,
Haghighi et
al. 2006)
35 68 78 76
CA19-9 not associated
with operability or
prognosis. Higher CA 19-9
levels improved specificity
but lower sensitivity
(Nichols,
Gores et al.
1993)
100 9 89 86
Includes cohort described
in later series from same
unit (Levy 2005)
(Levy,
Lymp et al.
2005)
63
129 14
90
78.6
98
98.5
Patients with elevated
CA19-9 were all inoperable
(Bjornsson,
Kilander et
al. 1999)
37 9 63
85 (in
combinatio
n with
CEA)
High false positive rate in
patients with cholestasis.
No benefit of measurement
in bile.
(Ramage,
Donaghy et
al. 1995)
200 15 60 90
Also used CA19-9
+(CEAx40) >400 with
sensitivity of 66% and
specificity of 100%
(Hultcrantz,
Olsson et
al. 1999)
37 4 Notreported
Not
reported
Prospective study.
Insufficient numbers to
calculate sensitivity and
specificity but suggest both
low
(Patel,
Harnois et
al. 2000)
100 103 53 76-92 Sporadic BTC
(Fisher,
Theise et
al. 1995)
74 3 50 54.5 PSC patients undergoingOLT
(Burak,
Angulo et
al. 2004)
180 44 66.7 97.7 PSC study
(Siqueira,
Schoen et
al. 2002)
180 55 67 98 PSC study
(Lindberg,
Arnelo et al.
2002)
100 57 67 89 PSC study
(Kim, Kim
et al. 1999) 37 322 73 63 PSC study
(Buffet,
Fourre et
al. 1996)
40 308 92 72 Biliary and pancreaticcancer
51
A further characteristic of CA19-9 is that it tends to be elevated predominantly
in advanced disease. Ideally, a useful tumour marker would be able to detect
early, treatable disease but reports suggest that significantly elevated levels
(eg.>129 U/ml determined by ROC curves) are only present in inoperable
cases (Charatcharoenwitthaya, Enders et al. 2008). Cha et al studied 61
surgically resected ‘early bile duct cancer’ patients (“carcinoma with invasion
confined within the fibromuscular layer of the extra-hepatic bile duct”) and
reported a CA19-9 sensitivity as low as 33% with the threshold set at
>37U/mL and of only 15% when the CA 19-9 threshold was raised to
>100U/mL (Cha, Kim et al. 2006). In addition, CA 19-9 levels are also raised
in many other malignant conditions, including, pancreatic cancer (sensitivity,
68% - 94%, specificity 76% - 100%), colorectal, gynaecological and gastric
carcinomas (Rhodes 1999).
Measurement of CA19-9 has been advocated for the surveillance of CC in
patients with PSC (Table 4). However, despite many clinicians using this
tumour marker in clinical practice, there is little evidence that it facilitates early
diagnosis or alters outcome in such patients (Levy, Lymp et al. 2005).
Table 4 Accuracy of CA19-9 for the diagnosis of BTC in PSC, using a selection of
low and high cut-off levels. (Reproduced from Charatchoenwitthaya et al 2008)
CA 19-9 cut-off level (U/ml)
20 40 100 129 200
Sensitivity (%) 78 57 22 13 13
Specificity (%) 67 84 99 100 100
PPV (%) 23 30 71 100 100
NPV (%) 96 94 91 90 90
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Measurement of CA19-9 in bile in addition to measurement of serum levels
does not improve the accuracy for the diagnosis of BTC (Ker, Chen et al.
1991).
1.2.3.3 Carcinoembryonic antigen (CEA)
CEA, like CA19-9, is a complex glycoprotein and is commonly used for
monitoring response to treatment and disease recurrence in colorectal cancer
(Duffy 2001). CEA has a reported sensitivity of 33 to 68% and specificity of 81
to 86% for the diagnosis of BTC (Ramage, Donaghy et al. 1995; Bjornsson,
Kilander et al. 1999; Siqueira, Schoen et al. 2002). The combination of CA19-
9 and CEA has been advocated as a more reliable tumour marker but still has
a reported sensitivity and specificity of only 33% and 85%, respectively
(Bjornsson, Kilander et al. 1999).
1.2.3.4 Carbohydrate antigen-125 (CA-125)
The reported sensitivity and specificity for carbohydrate antigen 125 (CA 125)
for the diagnosis of cholangiocarcinoma are <70% and 76% (Chen, Shiesh et
al. 2002). As with the other tumour markers, it may be falsely elevated in other
cancers (particularly ovarian), peritoneal disease and cirrhotic ascites
(Miralles, Orea et al. 2003).
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1.2.3.5 Mucin 4 (MUC4) and mucin 5AC (MUC5AC)
Epithelial surfaces express tissue specific patterns of mucins which may
change in neoplasia. A study from our group reported that biliary MUC4 and
serum MUC5AC had a sensitivity of 58% and specificity of 87% for the
diagnosis of BTC. The presence of MUC5AC in serum was also a marker of
poor prognosis (Matull, Andreola et al. 2008). However, patients with PSC
commonly had elevated levels of these mucin biomarkers, so reducing their
value as biomarkers for malignancy in this patient population.
1.2.3.6 Minichromosome maintenance markers (mcm)
DNA replication during the process of cell division is tightly regulated in the
cell cycle by a number of inhibitory and stimulatory proteins. Mcm 2-7 are a
group of proteins that combine with other ‘licensing’ proteins, such as the
ORC (origin recognition complex) and CDC6, onto chromatin as part of the
pre-replicative complex that initiates DNA replication. They are expressed
during the cell cycle in actively proliferating cells such as cancer cells but are
down-regulated in non-replicating, mature, differentiated cells. Important
proteins inhibiting the process of DNA replication include Cdk1, Cdk2 and
geminin which are bound and inactivated by other proteins such as APC/C.
Over-expression of mcm’s is an early feature of cancer and these mcm’s have
been shown to be shed from epithelial surfaces and act as markers for other
malignancies such as bladder cancer (Stoeber, Swinn et al. 2002). A study by
our group has demonstrated that measurement of mcm5 in bile samples
(n=102) is a marker of malignancy and has an improved sensitivity (66%
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versus 20%) and similar specificity (94%-100%) to biliary brush cytology of
indeterminate biliary strictures (Ayaru, Stoeber et al. 2008). This is supported
by a much higher rate of immunohistochemical staining for mcm2 and mcm5
in tissue sections from patients with malignant versus benign biliary strictures
(median 76.5% mcm2 positivity for malignant strictures and 5% in benign
disease, P<0.005) (Ayaru, Stoeber et al. 2008). A larger, multicentre,
prospective study on the use of mcm’s as diagnostic markers in pancreobiliary
cancer is planned.
1.2.3.7 Other circulating tumour markers
There are limited data on a number of other potential biomarkers in the
diagnosis and prognosis of BTC. These include a small prospective trial
assessing the utility of CA-242 and CA50 in patients with PSC and suggest
poor sensitivity and specificity and are not recommended for use (Hultcrantz,
Olsson et al. 1999). CK19 represents a promising method of detecting
circulating tumour cells in patients with BTC or other adenocarcinoma's
(Takada, Masuda et al. 1995; Brechot, Chevret et al. 1997; Nakata,
Takashima et al. 2004; Pujol, Molinier et al. 2004; Andreadis, Touloupidis et
al. 2005) and we have further investigated the role of CK19 fragments
(CYFRA 21-1) in chapter 2.
1.2.3.8 Genetic markers of BTC
Mutations in the K-RAS gene are described in many cancers including BTC.
Studies assessing the accuracy of K-RAS mutations in biliary brushings report
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sensitivities of 27-64% and specificities of 62-100% (Saurin, Joly-Pharaboz et
al. 2000; Wang, Yamaguchi et al. 2002). Mutations in the tumour suppressor
gene p53 have also been investigated with a prevalence of 52% in
cholangiocarcinoma (Liu, Zhang et al. 2006).
Other potential genetic markers in BTC have been investigated, most
commonly using immunohistochemistry in surgical specimens. These include
p16, c-MET and telomerase (Morales, Burdick et al. 1998; Klump, Hsieh et al.
2003; Enjoji, Nakamuta et al. 2004). None have good sensitivity for diagnosis.
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1.2.4 Conclusions: Diagnosis of BTC
BTC remains challenging to diagnose, particularly in conditions with pre-
existing or predisposing complex biliary stricturing such as PSC. Currently,
cytopathology and/or histopathology remain the only definitive methods for
diagnosis. However, these involve invasive procedures with significant risks
and the sensitivities for such tests are low (range 18%-69% for biliary brush
cytology).
Although some non-invasive tests such as MRCP or serum CA19-9 levels are
relatively useful in diagnostic algorithms, none have sufficient accuracy to be
reliable tests for diagnostic or screening purposes. Recent advances in
surgical and palliative treatment mean that more patients may be suitable for
therapy in the future. However, these approaches require a definitive
diagnosis prior to therapy, particularly with reports of high rates of benign
disease in patients undergoing major hepatic resections for presumed CC
(Erdogan, Kloek et al. 2008). New improved biomarkers are needed to
improve the clinical care of patients with BTC, and this was the overall
rationale for the thesis.
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1.3 Approaches to biomarker discovery.
There are a number of potential approaches to biomarker discovery. Most
methods are based on the principle of detecting differences between normal
and diseased tissues. Many of the tumour markers in current use, including
AFP, CA19-9 and CA125, were discovered by screening of poyclonal
antibodies raised against different tissues and disease states. Some of these
antibodies bound with relative specificity to cancer tissues. The antigenic
components were later identified and improved antibodies to those antigens
have been produced and used in protein detection assays such as tumour
marker ELISA tests. The current most widely used methods for biomarker
discovery use high throughput techniques described below with the addition of
complex computer software analysis programmes to screen the large
quantities of data generated. Nomenclature for the methods used vary
between authors and centres but formal definitions are being developed.
Many of the methods and disciplines are complementary and may be carried
out in parallel to gain different but inter-related information of biological
systems, often with the support of bioinformatics software and expertise.
Genomics loosely refers to the application of genome scale technologies for
biological investigation. Genomic studies include investigation of DNA
mutations, DNA methylation status, single nucleotide polymorphisms, gene
expression analysis by measuring mRNA expression, assessment of splice
varients using exon arrays and investigation of non coding RNA molecules
including microRNA. The term transcriptomics has been introduced to
separate out investigation of the transcriptome, defined as the whole set of
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RNA products produced by the genome at a particular point in time. The
genome is essentially stable in time with the exception of development of new
mutations and alteration in splice variants. However, the transcriptome is
dynamic and changes with normal physiology and disease, depending on the
relative abundance and activity of different RNA species including mRNA,
rRNA, microRNA and other small interfering RNA species. We chose to use a
transcriptomic approach to biomarker discovery for this project concentrating
on gene expression measured by mRNA expression microarrays. The most
commonly used high throughput assays are cDNA microarrays with
complementary probes which span sequences of expressed mRNA of genes
throughout the entire genome. These are indicators of gene expression rather
than structural alterations in the source genes and are discussed in more
detail in Chapter 5 using the example of mRNA expression arrays used in our
work.
Other important genetic alterations are also crucial to cancer biology but are
not further investigated in this thesis. These include DNA mutations where,
depending on the nature of the mutation, a mutated gene may or may not be
transcribed or transcribed to an abnormally functioning protein. For example,
point mutations in the KRAS gene can be implicated in various
gastrointestinal cancers where an abnormal variant of the protein is translated
but this is functionally altered so that it is activated in an uncontrolled fashion
independently of the many usual upstream activators such as activation of the
EGFR receptor complex.
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Proteomics is another field of research commonly used for biomarker
discovery. It involves the large scale study of protein expression and function.
A potential advantage over genomic studies is that the protein products being
investigated are at later stages in biological pathways and diseases of
interest. Although siginifiant post translational modification of proteins occurs,
this is less significant than the large scale post transcriptional modification that
occurs in gene expression pathways. Protein modifications, such as protein
phosphorylation and methylation, are crucial to the normal functioning of
proteins and may differ in disease. Biomarker discovery using proteomics
aims to identify alterations in disease states. The most widely used
techniques include 2D gel electrophoresis, high pressure liquid
chromatography and mass spectroscopy assays including MALDI and SELDI-
TOF. Our group, in collaboration with Dr John Timms (Cancer Proteomics
Laboratory, Institute for Women’s Helath, UCL), is investigating the use of
proteomics for biomarker discovery in BTC alongside the genomic studies
described in this thesis. Data from these proteomic studies are not described
in this thesis. Similar studies in pancreobiliary cancer have been published in
recent years and provide an additional source of data on proteins that may be
further investigated. Examples include Annexin IV, Golgi Membrane Protein 1,
AGR2 and S100A10, (Kristiansen, Harsha et al. 2008; Sitek, Sipos et al.
2009).
Other approaches used less commonly include lipidomics (the study of lipids)
and metabolomics (the study of metabolites). Like proteomics, both have
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strength in biomarker discovery in that they measure end products of
biological pathways which may identify alterations specific to disease. Both
disciplines use complex large data generating techniques such as
chromatography, mass spectroscopy and nuclear magnetic resonance.
These methods are not described further in this thesis.
An alternative approach to high throughput screening techniques such as
genomics and proteomics is to directly identify tumour cells in biological
samples such as blood (circulating tumour cells). This approach is discussed
in more detail in the introduction to Chapter 2 before concentrating on the
main subject of whole genome expression analysis in the following chapters.
All of these methods are useful individually and increasingly together now that
software allowing integration of data from multi-disciplinary techniques is
being developed. These allow deeper investigation of the various “hallmarks
of cancer” as outlined by Hanahan and Weinberg (Hanahan and Weinberg
2000). They described six key alterations in cell biology that are common to
most or all cancer cells which are 1) self sufficiency in growth signals, 2)
evading apoptosis, 3) insensitivity of anti-growth signals, 4) sustained
angiogenesis, 5) tissue invasiveness and metastasis and 6) limitless
replicative potential (Hanahan and Weinberg 2000).
Examples of these mechanisms of cancer biology in BTC are summarised in
various reviews (Fava, Marzioni et al. 2007; Blechacz and Gores 2008; Sirica,
Nathanson et al. 2008; Wise, Pilanthananond et al. 2008) and include:
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 Self sufficiency in growth signals and evading apoptosis.
IL6 has been widely associated with the pathogenesis of BTC. This in part
may be related to chronic biliary inflammation causing elevated levels of IL6
secreted from local inflammatory cells such as that seen in chronic Clonorchis
infestation, one of the major risk factors for intrahepatic CC. However,
cholangiocytes themselves also secrete IL6 acting in a paracrine loop.
Elevated levels of IL6 inhibit apoptosis via stimulation of MCL1 and STAT3
promoting malignant proliferation (Isomoto, Kobayashi et al. 2005).
 self sufficiency in growth signals
MAP2K2 and MAP2K1 belong to the MAP kinase kinase family and
phosphorylate and thus activate MAPK1/ERK2 and MAPK2/ERK3 stimulating
cell proliferation. The MAPK pathway is commonly upregulated in BTC and
KRAS mutations associated with increased MAPK activity is a common early
finding in CC. Inhibition of the MAPK pathways using siRNA inhibits the
growth of cholangiocarcinoma cell lines in vitro (Leelawat, Leelawat et al.
2006).
 evading apoptosis
Inactivating mutations in the tumour suppressor genes p16INK4a supporting
evasion of cell death are reported in BTC such as in patients with PSC and
PSC related CC. Other mechanisms include over-expression of the anti-
apoptotic MCL1 in CC (Wise, Pilanthananond et al. 2008).
 tissue invasiveness and metastasis
Elevated expression of various matrix metalloproteinases (MMP2, MMP7,
MMP9 and MT1-MP) that allow enhanced tissue invasiveness and abnormal
cell anchoring via mutated cell adhesion molecules such as E-cadherin are
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reported by DNA mutation analysis, mRNA expression profiling and tissue
levels by immunohistochemistry in BTC (Fava, Marzioni et al. 2007). Other
proteolytic enzymes that allow increased invasiveness such as PRSS1,
PRSS2 and aspartyl b-hydroxylase are also up-regulated in CC and inhibition
of the latter impairs the invasiveness of CC cell lines in vivo (Maeda, Sepe et
al. 2003; Nakanuma, Tajima et al. 2010).
 sustained angiogenesis
Increased expression of enhancers of angiogenesis such as VEGFA and
VEGFC are common in BTC (Fava, Marzioni et al. 2007).
 limitless replicative potential
BTC cells have elevated telomerase acitivity, which is also enhanced by
elevated levels of IL-6 commonly implicated in the biology of BTC as above
(Morales, Burdick et al. 1998; Yamagiwa, Meng et al. 2006).
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1.4 Preview of thesis
The following chapters describe work done in order to identify and investigate
potential novel biomarkers in BTC with a particular emphasis on gene
expression analysis. Chapter 2 introduces the concept of circulating tumour
cells and describes the measurement of circulating fragments of an epithelial
cell marker cytokeratin 19 (CYFRA 21-1), as an example of the approach to
the clinical application and testing of biomarkers with patient samples.
Chapter 3 is divided into two parts and investigates the suitability of formalin
fixed paraffin embedded (FFPE) tissue for gene expression studies. Part 1
examines the use of whole tissue sections and Part 2 examines the use of
laser capture microdissection of FFPE tissues. Results showed poor levels of
RNA isolated from such tissues, and with the rarity of the PSC related CC
samples, we elected to investigate the use, and demonstrate suitability of,
endoscopic biliary brushings for gene expression profiling (Chapter 4).
Chapter 5 provides methodology and a results summary for whole genome
RNA expression analysis of biliary brushings using microarray technology.
These results are then validated in Chapter 6 with alternative methods for
measurement of gene expression using quantitative real time polymerase
chain reaction (qPCR). The final results chapter (Chapter 7) investigates
whether a selection of genes identified in the earlier work are translated to
protein products which may be later tested as potential biomarkers in clinical
samples. The final section (Chapter 8) is a discussion of issues raised during
the project and potential future work.
64
1.5 Aims of this project
The central aim of this project was to identify novel biomarkers with which to
diagnose and predict prognosis of BTC, with a particular emphasis on
cholangiocarcinoma.
Specific aims were:
 To investigate whether measurement of circulating fragments of
cytokeratin 19 (CYFRA 21-1) may be a biomarker for BTC and to
assess the suitablitiy of our biobank for later validation studies.
 To investigate whether archived explanted liver tissue from patients
with PSC related CC and benign PSC disease may be used to identify
genes as biomarkers or risk factors for development of BTC in patients
with PSC.
 To investigate whether endoscopic biliary brushings may be used to
detect altered gene expression in BTC
 To investigate whether aberrantly expressed genes identified in RNA
expression studies are translated to altered protein expression in biliary
tissues of patients with BTC.
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Chapter 2.
2 Identification of circulating tumour
cells in blood and use of CYFRA 21-1
as a biomarker of biliary tract cancer.
2.1 Background
One approach to diagnosing BTC is to identify malignant cells in circulating
blood. Recent advances have allowed small numbers of circulating tumour
cells (CTCs) to be detected in blood or other body fluids such as urine, bile,
stool and pleural fluid in patients with malignant disease. However, these
methods are time consuming and technically difficult. For these reasons, they
were not yet widely available for research use when we began theses studies.
Another approach is to use tumour specific markers. However there are few
such markers and most are also produced to some degree in normal tissues
reducing their specificity. The tumour markers PSA, CEA and CA19-9 are up-
regulated in some cancers but are also identifiable at low levels in normal
tissues. Methods such as ELISA and PCR are often so sensitive that they
may result in false positive tests in absence of malignancy with a normal
threshold being difficult to define.
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Under normal circumstances, there are few, if any, identifiable circulating
epithelial cells in healthy individuals. Therefore, most assays for detecting
circulating tumour cells in blood are based on the identification of normal,
‘surrogate’ epithelial cell markers (eg EpCAM, CK19) rather than tumour
specific markers. Studies using such markers consistently demonstrate the
absence of circulating epithelial cells in healthy controls (Cristofanilli, Budd et
al. 2004; Fizazi, Morat et al. 2007; Nagrath, Sequist et al. 2007; Gervasoni,
Monasterio Munoz et al. 2008). These markers have the advantage that they
have a potential for population screening for multiple adenocarcinomas. The
disadvantages of this method are the potential for false positive results, the
lack of sensitivity in tumours of non epithelial cell origin, and the possibility
that positive results will only be found in metastatic or advanced, inoperable
cancers.
2.2 Methods used for detecting circulating
tumour cells
2.2.1 PCR based identification of epithelial specific
nucleic acids
These assays require the assumption that there is no epithelial cell specific
nucleic acid in circulating blood. The majority use RT-PCR to identify mRNA
for epithelial cell markers including various cytokeratins, mucins and CEA. To
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improve the sensitivity and specificity of such tests, protocols often employ
cell separation techniques to purify the samples prior to RT-PCR.
2.2.2 Cell separation using immuno-magnetic beads
Cell separation techniques are now commercially available from a number of
manufacturers (e.g. Dynabeads®). They are based either on positive
selection of the cells of interest using antibody coated magnetic beads, or by
‘cell depletion’, using beads to capture and remove contaminating cells (most
commonly leukocytes using the leukocyte common antigen CD45), leaving
the cells of interest in solution. Although these techniques are valuable to
provide a higher yield, improvements in RNA extraction techniques mean that
sufficient RNA can be extracted from as few as 5 cells.
This approach was used by Gervasoni et al (Gervasoni, Monasterio Munoz et
al. 2008). Ficoll based fractionation of blood was followed by removal of
leukocytes using CD45 immuno-magnetic beads, and then RT-PCR to identify
epithelial cell markers including CEA, CK18, CK19, CK20, GCC, EpCAM,
MUC1 and TERT. A similar method was used to measure circulating
telomerase activity using a PCR-ELISA assay in patients with cancer of the
prostate (Fizazi, Morat et al. 2007). The assay detected 79% of patients with
advanced prostate cancer (n=24), 79% with early localised disease (n=70)
and none of the healthy controls (n=22).
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2.2.3 Cell separation using fluorescence activated cell
sorting (FACS)
As techniques for identifying CTCs improve, these methods could potentially
be automated using FACS machines. The main limiting factor at present is the
efficiency of cell separation for complex clinical samples, such as blood.
2.2.4 ‘Blood on chip’ devices
The term ‘blood on chip’ device has been used to describe semi-automatic
systems developed to extract CTC’s from blood. One such sensitive system is
the EpCAM “CTC-chip” (Nagrath, Sequist et al. 2007). This uses a chamber
filled with micro-posts coated with anti-Ep-CAM antibodies and uses image
analysis software to identify trapped epithelial cells which can then be isolated
and analysed. The sensitivity and specificity of this system was reported to be
over 99% in 116 patients with adenocarcinomas of the colon, breast, prostate
and lung. The system was also sensitive in a subgroup of 7 patients with early
cancers. No CTCs were identified in any of the healthy controls (n=20).
Systems such as this show promise for the development of screening tests for
adenocarcinomas, the characterising of tumours to direct appropriate medical
therapy, and the isolation of CTCs for more detailed biological study.
2.2.5 Commercial CTC assays.
Although these were not available at the initiation of this project, commercial
assays such as the CellSearch™ assay (Quest Diagnostics) have recently
become available. These use a combination of the methods described above
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to isolate a purified sample of CTCs from peripheral blood. The CellSearch™
assay relies on sequential use of antibodies to EpCAM, CD45, and then a
combination of CK8, CK18 and CK19 antibodies to isolate the CTCs. This
assay has been applied to the investigation of other cancers. For example, in
breast cancer, it has shown that the identification of CTCs using this
technique predicted future metastatic disease and poorer overall survival in
patients clinically staged as having non-metastatic disease (Bidard, Mathiot et
al. 2009).
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2.3 Measurement of circulating CK19 fragments
(CYFRA 21-1) for the diagnosis and
prediction of prognosis in patients with
biliary tract cancer
2.3.1 Introduction
Of the CTC markers investigated in other cancers, the most suitable
candidate biomarker for use in BTC may be cytokeratin 19 (CK19), which is a
constituent of the intermediate filament proteins responsible for the structural
integrity of epithelial cells. CK19 is constitutively expressed by many epithelial
cells, is a highly sensitive cholangiocyte marker and is also commonly over-
expressed by biliary tract cancer cells (Maeda, Kajiyama et al. 1996). As with
other epithelial markers, CK19 is rarely detected in the blood of healthy
individuals. Measurement of circulating CK19 fragments have been shown to
be a biomarker for other malignancies including non small cell lung cancer
(Takada, Masuda et al. 1995; Brechot, Chevret et al. 1997), bladder cancer
(Andreadis, Touloupidis et al. 2005), breast cancer (Nakata, Takashima et al.
2004), and gastric cancer (Nakata, Chung et al. 1996). Circulating CK19
fragments have also been shown to be a marker of prognosis and of disease
recurrence after surgery in non small cell lung cancer (Brechot, Chevret et al.
1997; Pujol, Molinier et al. 2004). These studies used the CYFRA 21-1
immuno-assay which utilises antibodies directed against CK19 fragments,
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allowing detection of circulating fragments in blood, even after degradation of
the intact protein.
CYFRA 21-1 was first reported to be a marker of BTC in a report of 4 cases of
intrahepatic cholangiocarcinoma (Kashihara, Ohki et al. 1998). A more recent
study reported that CYFRA 21-1 had a sensitivity and specificity of 75% and
92% respectively for the diagnosis of CC and that a low CYFRA 21-1 (<2.7
ng/ml) was a strong predictor of disease free survival after attempted curative
surgical resection with 5 year survival rates of 76% v 25% in those with levels
below or above 2.7 ng/ml respectively (Uenishi, Yamazaki et al. 2008). These
studies were done in Japanses patients with intrahepatic cholangiocarcinoma,
a disease which is distinct from the extrahepatic cholangiocarcinoma and gall
bladder cancer seen more commonly in the Western world. No data has been
published in such patient populations.
The current study was designed to evaluate the accuracy of CYFRA 21-1 in
the diagnosis and prediction of outcome of biliary tract cancer and to assess
whether this method may have a role in screening for biliary tract cancer in
high risk patients such as those with PSC.
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2.3.2 Materials and Methods
2.3.2.1 Patient population and clinical samples
The study was conducted following ethical approval granted by the Joint
UCL/UCLH Ethics Committee (reference 06/Q0152/106). Blood samples
(n=124) were collected prospectively using Vacutainer tubes (BD, New
Jersey, USA) from patients with;
 benign biliary disease (n=58);
o PSC [n=19]
o papillary stenosis or sphincter of Oddi dysfunction [12]
o choledocholithiasis [7]
o stricture secondary to chronic pancreatitis [8]
o inflammatory stricture [2]
o autoimmune pancreatitis [7]
o healthy controls [3],
 Biliary tract cancer (n=66)
o BTC [n=60; cholangiocarcinoma (56), gallbladder cancer (4)]
o PSC-related cholangiocarcinoma [n=6]
Blood samples were separated by centrifugation at 2500rpm for 8 minutes
and stored at -800C until further analysis.
Baseline patient characteristics and routine blood tests including liver
biochemistry, blood count and inflammatory markers, were recorded at the
time that blood was taken for CYFRA 21-1 measurement. In 120 of the 124
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patients, CA19-9 was also measured. All patients in the cancer group had
cytological or histologic confirmation of malignancy consistent with biliary tract
cancer. PSC was diagnosed on the basis of well described clinical
characteristics, primarily based on cholangiographic findings, and where
possible, supportive evidence such as the presence of IBD or liver histology
consistent with the diagnosis (Chapman 1980). None of the patients in the
benign group had evidence of malignancy after a minimum of 6 months follow
up (median 12 months). Cancers were staged using the TNM and the
American Joint Committee on Cancer staging systems (American Joint
Committee on Cancer Staging, New York, Springer Verbay 2005). T1/T2
disease without evidence of nodal or metastatic spread was classified as
‘early’ disease (stage I/II). The remainder (stages III/IV) were classified as
‘advanced’ disease. Median follow up from the date of blood collection to the
date of death or the study end date was 12.9 months (range 7.2-70) in the
benign/PSC group and 6.7 months (range 0.3-40) in the BTC group. Survival
time was calculated from the date of blood sampling.
All patients in the benign group were alive at the end of the study period and
only one had surgery for a complex biliary stricture related to autoimmune
pancreatitis. Three patients died in the PSC group (two with advanced PSC,
one with cardiac disease) and a further three underwent liver transplantation
during the follow up.
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Table 5. Baseline patient characteristics for blood samples used in the CYFRA 21-1
analysis
Benign
disease
n=39
PSC
n=19
PSC/CC
n=6
BTC
n=60
Age
(years)
53
(25-80)
50
(20-75)
60
(25-73)
68
(34-91)
Gender
(M:F) 21:19 10:9 4:2 30:30
Bilirubin
mol/L)
14
(5-335)
17
(7-341)
81
(28-375)
43
(8-676)
CA19.9
(U/ml)
10.5
(0-686)
13.5
(0-3145)
473
(129-4,139)
316
(0-145,528)
2.3.2.2 Measurement of CYFRA 21-1 and CA19-9
Measurement of serum or plasma CK19 fragments was performed using the
CYFRA 21-1 ELISA kit (DRG International, Marburg, Germany) according to
the manufacturer’s instructions. The assay uses 2 mouse monoclonal
antibodies (KS19.1 and BM19.21) for the detection of CK19 fragments. 50l
of sample were used in duplicate on 96 well ELISA plates. Horseradish
peroxidase was used for the colour immunometric assay. Absorbance was
measured at 450nm with the mean concentrations per pair calculated using
linear correlation. Serum samples were used for measurement of CYFRA 21-
1 where possible [n=86]. In others [n=38], only EDTA plasma samples were
available. According to the manufacturer, EDTA plasma may give falsely
elevated CYFRA 21-1 results. In order to test the correlation between serum
and plasma results, we measured CYFRA-21-1 levels in paired serum and
plasma samples from 13 patients. Using both the Pearson correlation and
paired T test tests, plasma levels had a mean level 1.3 times the level of
serum CYFRA 21-1 (R2= 83.3, p=0.001) (Figure 3). Serum and corrected
plasma levels were used for data analysis. Bilirubin does not impact on
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measurement of CYFRA 21.1 levels (personal communication, DRG
Inernational, Marburg, Germany).
Figure 3. Correlation between serum and plasma CYFRA 21-1 using
paired samples from the same patients showing a higher plasma
CYFRA 21-1 requiring a correction factor of 1.3 for comparison with
serum levels
Analysis of CYFRA 21-1 levels in combination with CA19-9 was also made
using an optimal cut-off for CYFRA 21-1 of 1.5ng/ml as determined by the
ROC curve, and a CA19-9 level of 37 U/ml as the limit of normal range used
by our laboratory. Analysis of the combination of both elevated biomarkers
was made for benign and malignant disease groups. In line with published
data for CA19-9 and CYFRA 21-1, we also assessed the value of both
markers with higher cut-off levels as a predictor of prognosis.
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2.3.2.3 Statistical analysis
Statistical analysis was performed using SPSS software version 14.0.
Comparison of groups was assessed using the Kruskall Wallis and Chi square
tests. Survival data are presented using the Kaplan-Meier method with
comparison made using the log rank test. Statistical significance was set at a
p value of 0.05 for all tests. The area under the curve method was used to
assess the efficacy of the biomarkers and to determine a suitable cut-off level
for CYFRA 21.1 in order to calculate sensitivity and specificity.
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2.3.3 Results
Baseline patient characteristics are listed in Table 5. Patients with benign
disease had lower median CA19-9 and bilirubin levels, which were highest in
the PSC related CC group. CYFRA 21-1 and CA19-9 levels are shown in
Figure 4.
Figure 4. Median levels for CA19-9 and CYFRA 21-1 for the different patient groups
with 75th centiles shown by the bars. Both CA19-9 and CYFRA 21-1 had significantly
higher levels in BTC compared to benign controls (PSC and non PSC controls).
2.3.3.1 Efficacy of CA 19-9 and CYFRA 21-1 as tumour
markers for BTC.
To analyse the efficiency of CA 19-9 and CYFRA 21-1 as tumour markers for
BTC, comparisons were made between all patients with cancer, against all
patients with benign disease, including those patients with PSC. Using a cut-
off for CA 19-9 of ≥37 U/ml, sensitivity, specificity, PPV and NPV were 79%,
78%, 81%, and 75% respectively. These figures are in keeping with published
figures. The optimal cut-off for CYFRA 21-1, determined using the ROC curve
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method, was ≥1.5ng/ml (Figure 5). At this level, CYFRA 21-1 had a sensitivity,
specificity, PPV and NPV of 56%, 88%, 84% and 64% for the diagnosis of
BTC. Data were also calculated using higher cut-off figures for CA19-9
(129U/ml) and CYFRA 21-1 (3.0ng/ml) (Table 6).
When using serum samples alone (n=86), results for determining sensitivity
and specificity were similar (as was an optimal cut-off of 1.5ng/ml), but had a
lower statistical significance (sensitivity 53%, specificity 86%, AUC 68%,
p=0.004 v 0.001). Using a cutoff of ≥3 ng/ml with only serum samples, the
sensitivity was 25% and specificity 95%.
Figure 5. Receiver operating characteristics (ROC) curves for CA19-9 (AUC 84% [77-
91%]) and CYFRA 21-1 (AUC 73% [64-82%]).
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Table 6. Efficacy of CA19-9 and CYFRA 21-1 tumour markers in the diagnosis of BTC
CA 19-9
>37
CA 19-9
>129
CYFRA 21-1
>1.5
CYFRA 21-1
>3.0
CA19-9 >37
+
CYFRA 21-1
>1.5
CA19-9 >129
+
CYFRA 21-1
>3.0
Sensitivity 79 74 56 30 45 27
Specificity 78 95 88 97 96 100
PPV 81 94 84 91 94 100
NPV 75 76 64 55 59 53
2.3.3.2 Combination of CYFRA 21-1 and CA 19-9 in the
diagnosis of BTC.
In order to assess the role of these markers in combination, results were
grouped into those positive for CA 19-9 and CYFRA 21-1 (+/+) [n=32], those
positive for one or other marker (+/-) [n=43], and those negative for both (-/-)
[n=45]. To calculate sensitivity and specificity of positive (+/+) tests, the
results of +/- and +/- were pooled into one group. Thus the comparison was
between +/+ and combined +/- & -/-. Data from the lower and higher cut-off
figures (37U/ml & 129U/ml for CA19-9, and 1.5 ng/ml & 3.0 ng/ml for CYFRA
21-1) were grouped in the same way. The calculated sensitivity, specificity,
PPV and NPV are shown in Table 6. Of note, in only 2 patients with benign
disease were both markers positive using the lower cut-off values. None were
positive for both using the higher cut-off values.
80
2.3.3.3 CYFRA 21-1 as a marker of tumour stage and
prognosis in BTC.
Patients with advanced disease (stages III-IV) had significantly higher CYFRA
21-1 levels (median 2.42 ng/ml, range 0.49 -35) than those with early stage I
or II disease (1.03 ng/ml, range 0.32 to 5.59) (p=0.001, Mann Whitney U test).
Figure 6. CYFRA 21-1 is a marker of tumour stage. Patients with advanced
stage (III-IV) disease had higher CYFRA 21-1 levels than those with early stage
(I-II) disease. (CYFRA 21-1 ng/ml)
Using the Kaplan-Meier method (Figure 7), an elevated CYFRA 21-1 (but not
CA19-9) was an indicator of poor prognosis. For patients with levels above or
below 3ng/ml, the median survival was 2 and 10 months, respectively
(p=<0.001). Only 3% of patients with elevated circulating CYFRA 21-1 were
81
alive at 1 year and none at 2 or 3 years, compared with 42%, 22% and 10%
respectively in the low circulating CYFRA 21-1 group (Table 7). The
combination of CYFRA 21-1 (3.0 ng/ml) and CA 19-9 (129 IU/ml) was also a
strong predictor of prognosis with median survival for those with both markers
positive (+/+), one or other positive (+/-) or neither positive (-/-) of 2, 9 and 11
months respectively (p=<0.001 for both +/+ and +/- versus -/-). Lower levels of
CYFRA 21-1 (1.5ng/ml) and/or CA19-9 (37 IU/ml) were not significant
markers of prognosis.
Figure 7 Kaplan-Meier survival plots showing that CYFRA 21-1 with or without the
addition of CA19-9, is a prognostic indicator in patients with BTC. CA19-9 alone was
not a marker of prognosis.
Table 7 Survival of patients with BTC related to circulating levels of CYFRA 21-1 and
CA19-9 showing a strong association (p=<0.001 for each group) between elevated
CYFRA 21-1 levels and poor prognosis.
1 year
survival
2 year
survival
3 year
survival
Median
survival
(months)
>3 ng/ml (n=21) 3% 0 0 2
CYFRA 21-1
<3 ng/ml (n=45) 42% 22% 10% 10
+/+ (n=18) 5% 0% 0% 2
+/- (n=33) 30% 16% 5% 9
CYFRA 21-1 (>3)
+
CA19-9 (>129) -/- (n=15) 47% 12% 10% 11
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2.3.3.4 CYFRA 21-1 and CA19-9 in the surveillance of CC in
PSC.
A retrospective analysis of case notes of patients with PSC at UCH, showed
that in our series, all cases of CC occurred in areas of dominant strictures
(DS) Figure 8. See Abstract 1 (Figure 73) in Appendix for further details
(Chapman, Witmann et al. 2008; Tidswell, Chapman et al. 2009).
Figure 8. Number of cases of CC developing in patients with and
without dominant strictures (DS) in patients with PSC at UCH. Note that
CC were only diagnosed in patients shown to have dominant strictures
(13/66) with none seen in those without dominant strictures.
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The prognosis for patients with PSC and a dominant stricture is worse than
those without this finding, (12.8 years and 19.4 years respectively) even after
exclusion of those who developed CC. In those with superimposed CC,
survival was a median of 5 months (Figure 9).
Figure 9. Kaplan-Meier survival plots for patients with and without dominant strictures.
Note that patients with dominant strictures have a worse prognosis. Prognosis is
particularly poor in those developing CC (right graph).
In order to address whether CYFRA 21-1 and CA 19-9 are of value in
surveillance for CC in PSC, these subgroups were analysed separately to
other benign diseases or non PSC related BTC. The number of cases of PSC
(n=19) and PSC-related CC (n=6) were small, resulting in large standard
errors. However, CYFRA 21-1 (>3.0 ng/ml) had a sensitivity of 30% and
specificity of 97%. Using the combination of markers in PSC, the sensitivity
and specificity were 33% and 95% for the lower cut-offs, and 16% and 100%
for the higher cut-offs. In view of the small number of patients with PSC
related CC, data were also assessed comparing patients with benign PSC
disease against al patients with BTC (n=66) (Table 8).
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Table 8 Diagnostic utility of CYFRA 21-1 and CA 19-9 for patients with BTC. Data
shown are a comparison of patients with benign PSC against all patients with BTC.
CA 19-9
>37U/ml
CA 19-9
>129U/ml
CYFRA 21.1
>1.5 ng/ml
CYFRA 21-
1 >3.0
ng/ml
CYFRA >1.5
+
CA19-9>37
CYFRA >3.0
+
CA19-9>129
Sensitivity 79 73 56 30 51 27
Specificity 79 95 68 95 95 100
PPV 40 71 24 50 63 100
NPV 95 95 90 89 92 89
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2.3.4 Discussion
Despite advances in diagnostic techniques (Moreno Luna and Gores 2006;
Tischendorf, Kruger et al. 2006), BTC remains difficult to diagnose and treat
with overall 5 year survival rates of 5-10% (de Groen, Gores et al. 1999). The
majority of patients present with inoperable disease and have a median
survival of only 6-9 months (Farley, Weaver et al. 1995; Jarnagin, Fong et al.
2001). Even those undergoing surgery with curative intent have a high rate of
recurrence, in part related to late presentation, lack of reliable biomarkers and
difficulties in pre-operative staging with high R1/2 resection rates (Ito, Agni et
al. 2008). At present, there are no surveillance strategies proven to improve
early diagnosis or outcome in high risk patients such as those with PSC.
CA19-9 has a relatively good sensitivity and specificity for diagnosis of BTC
but higher thresholds for diagnosis (>129 U/ml) are associated with non-
resectable disease and poor surgical outcome (Levy, Lymp et al. 2005).
Better non-invasive diagnostic and prognostic biomarkers are clearly needed.
In this series, which is relatively large compared with others, we have
assessed the role of the tumour marker CYFRA 21-1 in patients with BTC.
Our data indicate that CYFRA 21-1 is a less sensitive but more specific
marker than CA 19-9 for the diagnosis of BTC (specificity 88% to 97%). The
combination of CYFRA 21-1 and CA19-9 had very high specificities (96% to
100%) and positive predictive values (94% to 100%) for the diagnosis of BTC,
but sensitivities were lower (27% to 45%) than for CA19-9 alone. These
results are similar to reported sensitivity and specificity rates using biliary
brush cytology which, despite the invasive nature of the procedure, remains
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the best modality for diagnosis of BTC. Our data suggest that elevated
CYFRA 21-1 or the combination of elevated CYFRA 21-1 and CA19-9 is
highly suggestive of malignancy and would therefore be valuable in deciding
on the need for more invasive investigations such as ERCP with biliary
brushings. It was very unusual for patients with benign disease to have both
markers above certain threshold values. No patient with benign disease had
both markers positive using the higher cut-off levels and only two (3.4%) were
positive using the lower cut-off levels. The NPV (53 to 84%) and low likelihood
of malignancy with the combination of both negative results would significantly
reduce the pre ERCP likelihood of identifying a malignant stricture.
In contrast to other series, our data did not support the role of CA19-9 in
predicting outcome of patients with BTC. However, CYFRA 21-1 was found to
be a strong predictor of prognosis with marked differences in survival in those
with low or high circulating levels. This is in keeping with published data
where CYFRA 21-1 predicted tumour recurrence and survival after attempted
curative surgery in patients with intrahepatic cholangiocarcinoma (Uenishi,
Yamazaki et al. 2008) and suggests that CYFRA 21-1 may be a powerful
preoperative predictor of R0 resection and surgical outcome in patients with
BTC. Also, CYFRA 21-1 may be a predictor for those undergoing surgery who
may benefit from neo-adjuvant or adjuvant chemotherapy complementary to
their surgical treatments.
Benign dominant biliary strictures of PSC are often difficult to differentiate
from malignant strictures of cholangiocarcinoma. The only practical biomarker
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for screening patients with PSC to date is CA19-9 which is reported to have a
positive predictive value of 56% using a high cut-off value of 129 U/ml, and
only detects advanced cases (Levy, Lymp et al. 2005). Lower cut-off levels of
CA19-9 such as 40IU/ml result in only a slightly increased sensitivity with
reduced specificity (57% and 84% respectively) (Charatcharoenwitthaya,
Enders et al. 2008). Our CA19-9 data demonstrated an improved sensitivity
(100%) but lower specificity (79%) for the diagnosis of cholangiocarcinoma in
patients with PSC using a similar cut-off of 37 U/ml. However, as with many
studies of patients with PSC, the number of patients included was small and
insufficient to make definite conclusions on the role of CA19-9 or CYFRA 21.1
for surveillance of patients with PSC for CC, although our data do suggest
that an elevated CYFRA 21-1 or CA 19-9 in patients with PSC is highly
suspicious of coexistent CC (specificity 97% for CYFRA 21-1 >3 ng/ml). To
have sufficient statistical power (85%), studies would require 38 patients with
PSC–related cholangiocarcinoma and as such would need multi-centre
collaboration.
Additional clinical tests such as CYFRA 21-1 incur additional costs. However,
the cost of each ELISA plate is similar to that of CA19-9 (approximately £280)
equating to less than £10 per sample, assuming 40 samples run in duplicate
per plate. The CYFRA 21-1 ELISA kit is quick and easy to use and can be
anaylsed in any basic laboratory with an ELISA plate reader.
The main limitation of CYFRA 21-1 and CA19-9 as tumour markers is that
both have significant false negative rates. In this series there were 11% and
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24% false negative rates using the combined lower and higher cut-off levels.
The sensitivity of CYFRA 21-1 was too low (30% to 56%) to be useful as a
screening test. In addition, the majority of our patients had advanced disease
(n=42 (63%) for stage II-IV BTC) which may further lower the value of
circulating CYFRA 21-1 for the diagnosis or screening for early disease and
requires further investigation. It is unclear whether the presence or number of
circulating tumour cells is related to tumour stage or metastatic potential.
Studies using other surrogate markers of circulating tumour cells rarely
identify circulating epithelial cells in healthy individuals but report the presence
of such cells in patients with early localised disease (Nagrath, Sequist et al.
2007). As with other cancers, it is likely that a combination of molecular
markers would improve sensitivity and specificity and this needs to be
addressed with larger prospective studies (Liu, Liao et al. 2008). In addition,
the use of more sensitive assays such as quantitative PCR may further
improve the sensitivity of measuring circulating epithelial markers in patients
with BTC or other adenocarcinomas.
One further potential counfounding factor is that patients with BTC often
undergo invasive procedures such as interventional ERCP or percutaneous
biliary drainage with brushing and/or stenting. Such procedures may result in
transient release of epithelial cells into the circulation as a result of local
trauma at sites of intervention. However, against this is that many of the blood
samples were taken in the days following such procedures and the rate of
false positive elevations of CYFRA 21-1 was very low in the benign groups
and half that of CA 19-9 (12% and 22% using the lower cut-off levels).
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With regards to the biology of BTC, the frequent finding of circulating
fragments of CK19 (CYFRA 21-1) suggest that circulating tumour cells in BTC
may be relatively common, a phenomenon that, as far as we are aware, has
not been reported to date. It is possible that the CK19 fragments represent
cellular material leaking into blood but it is more likely that they arise from
CTCs. These studies support further work in the isolation and characterisation
of CTC’s in BTC.
In conclusion, CYFRA 21-1 alone or in combination with CA 19-9, is a highly
specific biomarker for the diagnosis of BTC in patients with biliary disease.
We suggest that the finding of an elevated level should prompt thorough
evaluation for the presence of BTC.
90
Chapter 3.
3 Gene expression profiling using RNA
isolated from formalin fixed, paraffin
embedded tissues
3.1 Aim
To perform whole genome RNA expression profiling using surgical resection
specimens (PSC, PSC-related CC and sporadic CC) in order to identify novel
biomarkers of cholangiocarcinoma.
3.2 Background
Most surgical resection specimens are stored in the form of formalin fixed,
paraffin embedded (FFPE) tissues. This provides a potentially useful source
of valuable clinical material. The FFPE method is used clinically because it is
cheap, easy to perform and produces excellent quality slides for histological
assessment. Cholangiocarcinoma associated with primary sclerosing
cholangitis is rare and tissue is usually only stored in the form of FFPE
tissues. The main source of this tissue is the incidental or early
cholangiocarcinoma in the liver explant from patients with PSC undergoing
liver transplantation.
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Until recently, most RNA-based molecular biology techniques have required
microgram quantities of good quality intact RNA for reliable data acquisition.
This has meant that only fresh or snap frozen tissue was suitable and has
hampered study of the vast majority of samples stored as FFPE tissue.
Research over the last 10 years has demonstrated that successful extraction
of RNA from FFPE tissue is now possible. Details of the optimal methodology
for RNA isolation have been published (Lehmann and Kreipe 2001; Chung,
Braunschweig et al. 2006; Coudry, Meireles et al. 2007; Penland, Keku et al.
2007; Hoshida, Villanueva et al. 2008). Furthermore, these reports have
shown that, despite the high level of RNA degradation, this tissue source is
often suitable for use with whole genome RNA expression profiling using
microarray analysis. In order to perform such analyses, certain
methodological variations are required but results are comparable to those
obtained from paired fresh frozen samples (Coudry, Meireles et al. 2007).
Most earlier studies used RNA isolated from blocks or sections of whole
tumour or normal liver. This potentially complicates RNA expression data
because of the presence of non biliary epithelial tissue such as fibroblasts,
hepatocytes and leukocytes. Some studies have used laser capture
microdissection to specifically isolate the cells or tissue of interest. This
technique is however also difficult because of the isolation of very small
quantities of RNA, which then require RNA amplification before analysis. An
example of the use of this technique is shown by Coudry et al who used laser
dissected colonic epithelium from sections of surgical samples for microarray
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analysis. Using paired specimens from the same source processed both by
FFPE and snap freezing in liquid nitrogen, they showed that RNA isolated
from both types of tissue processing resulted in similar results with a strong
correlation of overall gene expression (Coudry, Meireles et al. 2007).
3.2.1 Degradation of RNA during FFPE processing
Despite obvious benefits for clinical use, FFPE processing causes significant
degradation of RNA which has previously hampered further investigation. The
main causes of RNA degradation in tissue samples are:
3.2.1.1 Time to fixation
As soon as tissue is resected, RNA degradation begins as a result of changes
in temperature, pH, ischaemia and mostly, intrinsic RNase activity (Masuda,
Ohnishi et al. 1999). It is generally acknowledged that tissues should be
processed immediately as significant RNA degradation occurs within 30
minutes ex vivo. Another time-related factor is the time taken for the fixative to
infiltrate the tissue. This is short with cytological or small biopsy samples but
can take many hours for large resection specimens or whole organ explants.
A study by Start et al demonstrated that in whole resected spleens,
penetration of formalin was only 2.4mm in 24 hours (Start, Cross et al. 1992).
In practice however, time of fixation for most tissues is about 1 hour for each
mm of tissue and most are fixed for 24-48 hours. In general, the slower the
fixation time, the poorer the RNA quantity and quality.
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3.2.1.2 RNase activity
RNA is constantly broken down in vivo by intrinsic RNase activity which is one
of the homeostatic methods for controlling RNA activity. Tissues vary
considerably in the amount of intrinsic RNase and this clearly has an impact
on the required speed of fixation for different tissue. Liver, biliary and
pancreatic tissue in particular have very high intrinsic RNase activity and
should be fixed or frozen immediately.
3.2.1.3 Formalin fixation
Formalin fixation causes modification of RNA by cross linking RNA to
proteins, causing strand breakage and linkage of monomethylol groups to
RNA bases. RNA degradation continues but to a much lesser extent when
tissues are stored embedded in paraffin. It is therefore recommended that
formalin fixed tissues should be embedded in paraffin within a few days of
collection. Alternative fixatives such as ethanol reduce RNA degradation but
are rarely used in clinical practice. One study of nucleic acid recovery from
FFPE tissues suggests that no nucleic acid is recoverable from tissue stored
in formalin for more than 1 week (Lehmann and Kreipe 2001). Of note, most
large resection specimen or organ explants are stored in formalin solution.
The electrophilic attack and monomethylol addition to RNA during formalin
fixation is most marked on adenine nucleotides. Therefore the polyA tail of
mRNA is likely to be highly modified and this can be taken into account at
later stages of RNA processing by avoiding oligo dT primers and using
random hexamer primers for RNA replication and cDNA synthesis.
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3.2.1.4 Heat damage during paraffin embedding
Degradation of RNA during the heating that occurs with paraffinisation almost
certainly occurs but the extent of this damage is unclear and has been little
studied. In contrast to the commonly held view that formalin is primarily
responsible for RNA fragmentation, work done at Ambion (Austin USA) and
independent laboratories, suggests that formalin induced cross linking itself
does not cause RNA fragmentation but that this occurs during the heating
process of paraffin embedding (Masuda, Ohnishi et al. 1999).
3.2.1.5 Degradation during long term storage
Once stored in paraffin, tissue and nucleic acids are far more stable than
samples stored in formalin. The rate of RNA degradation once embedded is
small but it is likely this becomes significant over many years (Ribeiro-Silva,
Zhang et al. 2007). A study specifically looking at RNA extraction from new
and old FFPE samples suggests that samples stored for 10 years have
significantly reduced quantities and quality of RNA (Ribeiro-Silva, Zhang et al.
2007).
The remainder of this chapter is separated into two parts. Part 1 examines the
use of whole sections of FFPE tissues for RNA expression in order to test
methodology. Part 2 describes the use of laser capture microdissection with a
view to isolating specific biliary tissues for RNA expression analysis.
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3.3 Part 1: RNA expression analysis using whole
sections of FFPE tissues.
3.3.1 Materials and Methods
3.3.1.1 Clinical samples and ethical approval
Clinical samples of PSC and PSC-related CC were identified via the liver
transplant database at the Royal Free Hospital. Six patients with PSC-related
cholangiocarcinoma were identified over a period of 15 years. FFPE samples
of sporadic cholangiocarcinoma taken at surgery were available at both the
UCL and Royal Free Hospital sites. Ethical approval for the research was
granted by the joint UCL/UCLH research ethics committee (ref 06/Q0152/106)
with additional site specific assessment and approval for the Royal Free
Hospital site.
As explained later, the above samples were not retrieved for use in this
project. Methodology was tested initially on other, less rare samples of
colorectal, small bowel, sporadic cholangiocarcinoma and pancreatic cancer.
FFPE tissue blocks were kindly provided by Ms Uzma Qureshi, Cancer
Research UK Targeting and Imaging Research Group, Royal Free Campus,
UCL Medical School). These samples were used to develop technique and
test methodology in laser capture micro-dissection, RNA isolation and
downstream analysis using quantitative real time polymerase chain reaction
(qPCR).
96
3.3.2 RNA isolation from FFPE tissues
In view of the difficulties in extracting RNA from FFPE tissues, many
researchers use commercially available RNA extraction kits designed for use
with FFPE tissues. Commonly used kits include the Paradise system
(Arcturus), RNeasy FFPE kit (Qiagen, Crawley, UK) and the RecoverAll kit
(Ambion, Warrington, UK). Kits such as PicoPure (Arcturus, Mountain View,
Ca, USA) have been developed for the extraction of picogram quantities of
RNA from even single cells but these are mostly applied to non FFPE tissue
samples. Similar combinations of reagents are used with similar steps in each
method. Deparaffinisation is carried out using Xylene or Histoclear. Protein
digestion is ordinarily performed using proteinase K or guanidine thiocyanate.
RNA is precipitated and extracted using ethanol and filter columns with further
clean up using DNA digestion. Depending on the digestion times, the RNA
isolation process usually takes one day but can be extended up to 6 days for
higher yields using prolonged deparaffinisation and protein digestion steps
(Chung, Braunschweig et al. 2006). Careful RNase free technique is crucial
throughout the entire process.
3.3.2.1 Methods for RNA isolation used for this work
A variety of kits and published methods for RNA isolation were used. These
were initially tested using two 10m sections of resected colon, pancreatic,
small bowel and/or cholangiocarcinoma tissue for each experiment performed
at least once on a minimum of 2 samples. Sections were approximately 1 year
old with a tissue diameter of approximately 20mm and should therefore have
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contained far more nucleic acid than would be present in small volumes of
micro-dissected tissue. These larger sections were used in order to test the
methodology for RNA isolation that would be used for later micro-dissected
samples.
The main methods tested were:
3.3.2.2 Optimum FFPE RNA extraction kit (Ambion)
Sections were deparaffinised using Histoclear for 15mins followed by
graduated ethanol washes (100% to 70% ethanol) and air dried before RNA
extraction as per the manufacturer’s instructions. In brief, sections were
digested using a proteinase K digestion solution for 3 hours at 370C followed
by isolation of RNA using the RNA extraction buffer, ethanol precipitation and
spin column separation. Following a DNase I digestion step for 30 minutes at
37oC, the RNA was dissolved in 10ul of RNase free water and stored at -
80oC.
3.3.2.3 Picopure RNA Isolation Kit (Arcturus)
Sections were deparaffinised using Histoclear for 15mins followed by
graduated ethanol washes (100% to 70% ethanol) and air dried before RNA
extraction as per the manufacturer’s instructions. Sections were digested
using the extraction buffer for 30 minutes at 42oC. The resultant cell extracts
were mixed with an equal volume of 70% ethanol and passed through a spin
column which captures the RNA. A DNase I digestion step was performed on
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the spin column before washing and elution of RNA in 11l of RNase free
water.
3.3.2.4 Modified acid-phenol, chloroform, isoamyl-alcohol
method
This technique follows the methods described by Chung et al as the most
effective method of isolating RNA from FFPE tissues (Chung, Braunschweig
et al. 2006). Protein digestion was done using 1ml Buffer RLT (Qiagen) with
10l -mercaptoethanol for 48 hours at 42oC. An equal volume (1ml) of acid-
phenol, chloroform, isoamyl-alcohol (ratio 25:24:1) at pH 4.5 was added. The
sample was mixed vigorously for 15 seconds and allowed to settle for 10
minutes before centrifuging at 13,000 rpm for 15 minutes at 4oC. RNA was
then precipitated using 100% isopropyl alcohol followed by centrifugation at
13,000 rpm for 8 minutes, a wash in 70% ethanol, air drying of the pellet after
removal of the supernatant and re-suspension in 20l of RNase free water for
analysis and storage.
3.3.2.5 RecoverAll Total Nucleic Acid Isolation Kit for FFPE
Tissues (Ambion)
Deparaffinisation was performed using Histoclear as above. Samples were
then processed as per the manufacturer’s instructions. In brief, tissues were
digested for 3 hours using a proteinase K based digestion buffer, nucleic acid
was separated using ethanol based precipitation and capture in a spin filter
column, a DNase I digestion step was performed, and lastly, RNA re-
suspension and elution in 10l RNase free water.
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Variations on the above methods were performed such as using alternative
deparaffinisation methods (e.g. xylene, prolonged deparaffinisation for up to
three days) and variable durations of proteinase digestion steps (3 hours to 3
days). Each method was usually performed twice in order to assess its ability
to isolate RNA.
3.3.2.6 Quantification of RNA recovered from FFPE sections
Studies comparing fresh, snap frozen and FFPE samples from the same
source samples suggest that it is possible to recover 80% of the total RNA
from frozen tissue and 30-50% from FFPE sections. The amount of RNA
extracted from tissue depends on a number of factors including length of
storage, volume of tissue, type of tissue, effectiveness of deparaffinisation
and tissue digestion, fixative etc. mRNA is considered to be about 3% of total
RNA. This has not been formally tested in FFPE extracted RNA but is
assumed to be a similar fraction.
Baba et al published work on microarray analysis of laser capture
microdissected (LCM) biliary epithelial cells from fresh alcohol fixed samples
from patients with primary biliary cirrhosis (Baba, Kobashi et al. 2006). They
demonstrated that micro-dissecting a mean of 945 cells gave a mean of 46g
total RNA after 2 rounds of RNA amplification. The starting amount of total
RNA extracted was not described but assuming a 1000 fold amplification (as
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per the manufacturer’s information), this suggests that as little as 50pg total
RNA was extracted from a mean of 945 LCM isolated cells.
Quantification of RNA can be performed using various methods but a simple,
reliable and commonly used method is to measure absorbance at 260nm
using a spectrophotometer. Our laboratory used the Nanodrop ND-1000
spectrophotometer (Labtech) which accurately measures RNA concentrations
in small volumes of solution (1l) at levels as low as 10ng/l. Using this
system, calculated quantities of total RNA isolated from two 10m FFPE
sections are shown in Table 9.
Table 9 Mean total RNA isolated from two 10m FFPE sections using a selection of
tested methods
Method Mean Total RNArecovered
Spectrometric
260/280 ratio Notes
Optimum FFPE kit 914ng 2.01 Good yield and 260/280ratio
RecoverAll FFPE kit 360ng 1.97
Good quantity, 260/280
ratio, and plots according
to Nanodrop data
PicoPure 180ng 1.47 Low yield and 260/280ratio
Acid-phenol-
chloroform 1986ng 1.86
Best yield and good
Nanodrop plots using same
tissues
3.3.2.7 Assessing the quality of RNA recovered from FFPE
sections
The quality of mRNA extracted may be assessed using a number of methods.
The most accurate method is the Agilent Bioanalyzer (see chapter 4) which
was not available for use at the time this work was done. We used the
following methods.
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3.3.2.8 Agarose gel separation
Traditionally, the quality of mRNA is inferred by assessing the quality of total
RNA which is made up primarily of 18s and 28S ribosomal RNA subunits
which separate as clear bands on 1% agarose gel electrophoresis. If the
bands are broken up and appear as a smear then it is assumed that the small
amount of mRNA in the sample is also degraded. Samples of RNA from
freshly cultured human embryonic kidney (HEK293) cells were used as a
control (Figure 10). Gel separation of FFPE RNA was performed in only a few
samples in view of the large quantity of RNA required for gel separation
(usually >400ng for clear images).
Figure 10 Agarose gel separation of RNA from freshly cultured
HEK293 cells showing clear 18S and 28S bands of intact RNA and a
faint smear of degraded RNA isolated from FFPE tissue. The
loading quantity of RNA was smaller in the FFPE lane (150ng total
RNA) than in the clear bands for 250,000 HEK293 cells seen in the
central lane (250ng total RNA).
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3.3.2.9 Nanodrop 260/280 ratio
A simple and commonly used assay to assess quality and purity of extracted
total RNA is to measure the 260/280 absorbance ratio using a Nanodrop ND-
1000 spectrophotometer. A figure of 1.80 to 2.10 is considered to be a marker
of good quality RNA (see Table 9 and Figure 11).
Figure 11 Examples of Nanodrop ND-1000 spectrophotometer plots of RNA peaks at
260nm. Plots show weak peak for RNA isolated using Optimum FFPE kit (A) and clear
peaks of RNA at 260nm isolated from FFPE tissues using the RecoverAll kit (B &C) and
the acid phenol chloroform method (D).
3.3.2.10 Functional analysis using PCR
A practical way of demonstrating the presence of satisfactory functional
mRNA is to synthesize cDNA and perform RT-PCR of commonly expressed
‘house keeping’ genes such as -actin and GAPDH. Because degradation
results in fragmented mRNA, the cDNA synthesis step is best performed
using random hexamer primers rather than poly dT primers which may result
in a reduced yield because of degradation of the poly A tail on which the poly
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dT primers depend. If it can be demonstrated that mRNA for reference ‘house
keeping’ genes has been extracted than it is assumed that all or most mRNA
has been extracted and is usable for downstream applications despite the
RNA being degraded.
cDNA synthesis was performed using the iScript Select cDNA synthesis kit
(BioRad). The cDNA synthesis reaction was done using 100 to 200ng of total
RNA template and primed using random primers as per the manufacturer’s
protocol. RT-PCR reactions were performed using primer pairs for GAPDH, -
actin and 18S RNA. Primer sequences and amplicon lengths are shown in
Table 10. PCR reactions were performed with a standard protocol of 5
minutes at 250C, 30 minutes at 420C and 5 minutes at 850C. PCR products
were separated on a 2% agarose gel stained with ethidium bromide using
10l PCR product and 1l loading buffer (Ambion). A DNA ladder
(Hyperladder II, Ambion) was used to estimate PCR product length for
confirmation of appropriate amplicons. Reverse transcriptase positive (RT+)
and negative (RT-) controls were used in each experiment.
Table 10 PCR primer sets used for analysis of RNA isolated from FFPE tissues
Primer Amplicon
length
Forward sequence
(5’ - 3’)
Reverse sequence
(5’ - 3’)
B-Actin 92 Undisclosed Eurogentec sequence Undisclosed Eurogentec sequence
18S RNA 99 432CGGCGACGACCCATTCGAAC451 530GAATCGAACCCTGATTCCCCGTC508
GAPDH 226 108GAAGGTGAAGGTCGGAGT125 333GAAGATGGTGATGGGATTTC314
CK19 79 514TACAGCCACTACTACACGACCATCC538 592GGACAATCCTGGAGTTCTCAATG570
EGFR 68 1813TGCGTCTCTTGCCGGAAT1830 1883GGCTCACCCTCCAGAAGGTT1863
CD45 102 1353GGAAGTGCTGCAATGTGTCATT1374 1454CTTGACATGCATACTATTATCTGATGTCA1426
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Further analysis was performed using real time quantitative PCR (qPCR).
cDNA synthesis was done using 100 or 200ng total RNA and the iScript
Select cDNA synthesis kit as above and qPCR was performed using the
SYBR Green method. All reactions were carried out in 25l reaction volumes
using x2 Power SYBRGreen master mix (Applied Biosystems), 0.5l of 10M
forward and reverse primers and 2.5l cDNA template (equivalent to 12.5ng
or 25ng input total RNA). All reactions were performed in duplicate using 96
well real time PCR plates in an Applied Biosystems 7500 Real Time PCR
machine (Applied Biosystems). qPCR thermal cycling conditions were
standardised as follows: 500C for 2 minutes, 950C for 10minutes followed by
40 repeat cycles of 950C for 15seconds and 600C for 1 minute.
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3.3.3 Results: Part 1
Appropriate gene-specific PCR products for the house keeping genes
GAPDH, 18S RNA and -actin were identified in approximately half the
samples analysed using RT-PCR. This confirmed the presence of mRNA for
highly expressed house keeping genes in at least some samples (Figure 12).
Interestingly, the primers for GAPDH, producing the largest PCR amplicon (or
PCR product length, ie the specific nucleotide sequence synthesized by the
primer set during the PCR reaction) (220bp compared to 99bp for 18S RNA
and 92bp for -actin), resulted in the weakest PCR signal (Figure 13). This
highlights that optimal identification and amplification for PCR quantification
was best achieved using primer sets with short PCR product lengths and that
amplicon lengths of 220bp were probably too long. Similar findings using
degraded RNA from FFPE have been published by others where amplification
of sequences as short as 130bp resulted in weaker PCR reactions (Antonov,
Goldstein et al. 2005; Coudry, Meireles et al. 2007).
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Figure 12 RT-PCR of commonly used highly expressed ‘house keeping’
genes using an RNA template extracted from FFPE sections. Note the
presence of clear PCR products for the 3 genes tested but a weaker
amplification for GAPDH which has a longer amplicon length of 220bp.
DNA ladders are shown on either side of the sample lanes.
In approximately half the experiments, no PCR products were detected
suggesting the absence of functional RNA from these samples. Negative
results were often obtained even when relatively high quantities of RNA were
measured using the Nanodrop spectrophotometer (e.g. using the acid-phenol-
chloroform method). The Nanodrop machine measures absorbance at 260nm
which may result in falsely elevated RNA quantification in the presence of
genomic DNA contamination from incomplete DNA separation or DNase
digestion steps.
Figure 13 RT-PCR using RNA isolated from 6 FFPE samples of colon and small bowel
(ReceoverAll FFPE kit), showing presence of functional RNA identified using GAPDH
and 18S RNA primers.
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When using qPCR, most samples had threshold cycle (Ct) values of over 38
or were undetectable (Figure 14). A high Ct of over 37 represents very low
levels of amplification that are considered negative. The only positive results
returned Ct values of 31 to 32 for most samples, which are very low
amplification thresholds for reference genes and less highly expressed genes
are unlikely to be identified. However, the reverse transcriptase (RT) negative
controls were also positive with similar Ct values suggesting DNA
contamination in the samples (Figure 14). These RNA samples were those
isolated from FFPE tissues using the modified acid phenol chloroform
technique suggesting larger quantities of RNA when assessed by Nanodrop
spectrophotometer. This again suggests that there was significant genomic
DNA contamination during the phase separation step using this technique and
results for this experiment should be considered negative. Therefore, although
some experiments identified small amounts of amplified cDNA, multiple
attempts failed to identify functional RNA isolated from FFPE sections.
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Figure 14 qPCR amplification plots for GAPDH using cDNA synthesized from RNA
extracted from FFPE sections of colon, pancreas and small bowel. Note all Ct values
(except one at 38) are over 40 demonstrating the absence of functional RNA. Control
RNA from TFK-1 cell line amplified appropriately with a Ct value of 25. No control RNA
was used in the experiment in the left plot.
Figure 15 qPCR amplification plots for GAPDH using cDNA synthesized from RNA
extracted from FFPE sections of colon and pancreas using the acid phenol
chloroform technique. Ct values for the samples were mostly 31-32. However, Ct
values were similar for the RT negative controls suggesting DNA contamination
and the results should therefore be considered negative.
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3.3.4 Conclusions- Part 1: RNA isolation using whole
sections of FFPE tissues
In conclusion, RNA extracted from FFPE sections is degraded as
demonstrated by smears on agarose gel electrophoresis. However, the purity
as measured by Nanodrop spectrophotometer suggests protein contamination
is small and RT-PCR analysis of cDNA prepared from FFPE total RNA
extractions demonstrates identifiable amplified cDNA in some samples when
looking at expression of highly expressed house keeping genes such as
GAPDH. A number of groups have demonstrated that using the latest
extraction kits, it is now possible to extract mRNA of good enough quality to
assess using microarray procedures. To confirm this they have compared
data using RNA extracted from fresh frozen and FFPE sections from the
same patients and obtained similar results in microarray studies. These
studies suggest that RNA extracted is potentially suitable for PCR in 30-50%
of FFPE sections (Chung, Braunschweig et al. 2006; Coudry, Meireles et al.
2007; Penland, Keku et al. 2007). Another important principal when using
RNA for downstream applications is that the fragmented mRNA is on average
about 200nt long so probes and primer sets should produce amplicon lengths
shorter than this. Larger amplicons of 300-400bp length are likely to give
falsely negative results.
Our data using agarose gel electrophoresis and PCR of cDNA from total RNA
extracted from FFPE sections of normal colon, pancreas, small bowel and
cholangiocarcinoma demonstrate the extraction of useful mRNA from whole
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FFPE sections. However, it is still possible that mRNA expressed at low levels
may not be measurable and this cannot easily be tested without complex and
expensive RNA amplification steps.
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3.4 Part 2: Laser capture micro-dissection of
FFPE tissues
Gene expression profiling is most appropriately performed using specific cell
or tissue types. In order to isolate RNA from biliary tissue, we aimed to
microdissect malignant biliary epithelium from patients with sporadic CC,
PSC-related CC and benign biliary epithelium from areas distant from the
tumour in the same patients.
3.4.1 General information
In order to limit further RNA degradation in the clinical samples, a clean
environment with regular changes of gloves, RNase free materials and RNase
free conditions using RNase digestion solutions (RNase Zap®, Ambion) were
used. Training and later use of the laser capture microdissection equipment
was carried out with the kind assistance of colleagues at the Cancer
Research UK laboratories, Lincolns Inn Fields, London (Dr Simon Leedham).
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3.4.2 Materials and Methods
3.4.2.1 Making tissue sections from FFPE blocks
The microtome was cleaned with an RNase Zap® solution and a clean blade
applied. The top sections cut were kept for H&E staining as the RNA is
usually markedly degraded in these sections. Sections were cut at both 5m
and 10m thicknesses in order to test optimal size for micro-dissection,
deparaffinisation and RNA yield. Sections were mounted on PALM®
MembraneSlides (PALM® Microlaser Technologies, US). Automated
deparaffinisation was achieved by immersing the slides in 90oC xylene for 15
minutes before serial 15 minute washes at room temperature in xylene x3,
100% ethanol, 95% ethanol, 75% ethanol and lastly phosphate buffered
saline (PBS) solution. Slides were air dried on a warm plate at 370C. Cut
sections were used within 4 hours or stored at -800C to reduce further RNA
degradation in the sections. The first cut section was stained using H&E for
optimal microscopic description. Further sections were stained using Methyl
green which allows basic microscopic identification of tissues for micro-
dissection without causing damage to nucleic acid that is known to occur
when using H&E.
3.4.2.2 Laser capture microdissection
The required tissue (initially benign and malignant colonic epithelium or
pancreatic acini) was dissected out using video assisted microscopy allowing
direct control of the laser dissection to the level of single cells. Approximately
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3 areas of benign or malignant epithelium were dissected out from each of 5
sequential slides per patient sample and pooled for RNA isolation.
Representative images are shown in Figure 16. Microdissected tissue was
immediately immersed in the extraction buffer containing proteinase K
(PicoPure kit) and processed as described below.
Figure 16 Representative images of laser capture microdissection
of pancreatic and cholangiocarcinoma sections showing the
reference slide stained with H&E (A and C) and the laser
microdissected slides stained with methyl green (B and D).
3.4.2.3 RNA extraction using the PicoPure kit (Arcturus)
The RNA extraction process was performed as per the PicoPure protocol
except for extending the initial step of tissue digestion in the extraction buffer.
The standard protocol suggests digestion for 30mins at 420C before
completing the extraction or storing at -800C for later extraction. FFPE tissues
are more difficult to process and a longer proteinase digestion step helps
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break down the formalin induced RNA-protein cross-linking, inhibits RNase
activity, further digest tissues and opens cell membranes to improve RNA
yields (Chung, Braunschweig et al. 2006). The sample was incubated in
extraction buffer at 42-500C for 24hours before continuing with the RNA
extraction as per the PicoPure protocol. Also of note, degraded RNA from
FFPE has a reduced affinity for purification columns in the extraction process
and some may have been lost during the purification process.
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3.4.3 Results Part 2
3.4.3.1 Quantification of total RNA recovered from
microdissected section of FFPE tissues
The amount of total RNA isolated from samples of LCM FFPE tissue as
assessed by absorbance at 260nm by Nanodrop spectrophotometer, was 10-
15ng. This is below the level of reliability for detection using these methods.
3.4.3.2 RT-PCR and qPCR using RNA isolated from
microdissected pancreas and cholangiocarcinoma
tissue
No identifiable bands of PCR products were seen using standard RT-PCR for
the house keeping genes GAPDH, TBP or -actin (results not shown). This
suggests either very low or negative levels of functional RNA isolated using
these methods. Quantitative real time PCR was used to demonstrate the
presence of small quantities of functional RNA. Ct values were 37 for most of
the RT+ samples and 39 or more for RT negative controls (Figure 17). These
suggest absence or extremely low levels of functional mRNA.
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Figure 17 qPCR amplification plots using RNA isolated from FFPE
tissues showing weak amplification of GAPDH cDNA (Ct 37). RT
negative controls were undetectable.
117
3.4.4 Conclusions; Part 2: Laser capture
microdissection.
The modified acid phenol chloroform isoamylalcohol method appeared to be
the most efficient method of isolating RNA as assessed by spectrophotometric
absorbance. However, functional analysis using PCR demonstrates significant
DNA contamination using this method resulting in overestimation of RNA
quantities.
The results suggest that small quantities of RNA may be isolated from whole
sections and LCM dissected FFPE tissues but are of insufficient quantity to be
useful without increasing the total starting quantity of RNA using more tissue
or an RNA amplification step. RNA amplification aims to increase the total
quantity of starting mRNA, usually by a 1000 fold from the starting quantity.
mRNA is relatively specifically selected for amplification by using the polyA tail
of mRNA as the template to start the nucleic acid replication using oligo dT
primers and T7 RNA polymerases. However, mRNA amplification methods
can introduce bias as mRNA is not degraded uniformly along the 3’ and 5’
ends with a greater degradation at the polyA tail end, on which the
amplification methods are based, being common in degraded RNA such as
that isolated from FFPE tissues. Also, with each step, the aRNA (amplified
RNA) product is slightly shorter than the ‘parent’ template so that bias can be
introduced between shorter and longer mRNA sequences if later PCR primer
sets used are not designed to recognise suitable areas of the aRNA product
near the polyA tail end.
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Sensitive assays such as qPCR for highly expressed genes failed to show
useful results of gene expression and therefore genes with lower levels of
expression would not be quantifiable using the types of samples available. An
RNA amplification step may provide sufficient levels for quantification and
qPCR but this was not attempted.
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3.5 Discussion: Isolation of RNA from FFPE
tissues
These and other data demonstrate that it is possible to isolate RNA from
FFPE tissues and that the RNA is degraded, but useful for downstream
application such as qPCR and microarray analysis. However, there are
considerable limitations which are discussed in turn.
The RNA is of small quantity and highly degraded and although may be useful
for further analysis with qPCR etc, primer and probe sets need to be well
designed with short PCR amplicon lengths to reduce bias in results. It would
seem unlikely that such RNA will be as reliable a template as RNA isolated
from fresh or frozen samples and therefore these tissues will remain the
sample types of choice for gene expression profiling where available.
Microdissection is a skilled and time consuming procedure and facilities are
not readily available to most laboratories. However, it remains the best way of
isolating specific cells or tissue types from clinical samples when investigating
many aspects of cell biology and where contamination with other tissues or
surrounding stroma is likely to significantly interfere with results.
The quantities of RNA isolated from micro dissected FFPE samples were too
small to be quantified using standard methodologies. It may be that we were
unable to recover any RNA in our samples but it is more likely that quantities
were too small to be detected. Such quantities are too small for routine
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protocols for whole genome RNA expression profiling using the microarray
platform and require RNA amplification. Had we performed an RNA
amplification step prior to cDNA synthesis and qPCR then we may have
demonstrated RNA expression of genes such as GAPDH. However, the
addition of an amplification step may introduce further bias which may have a
major impact on gene expression profiling.
The aim of this study using the FFPE tissues was to investigate the gene
expression profile of not just sporadic cholangiocarcinoma but also PSC-
related cholangiocarcinoma. As discussed above, it is likely that the very old
samples available for such work would have very little if any usable RNA
remaining within them, even if we were to use larger whole sections of tissue
which may not be representative of the malignant process. This is particularly
true when large organ explant specimens, such as livers, are stored in
formalin rather than paraffin embedding. We confirmed with the Department of
Pathology that most of the older explant specimens of interest were stored in
formalin and as such would have no significant functional RNA remaining.
Continuing with this approach to gene expression profiling for the identification
of novel biological pathways or biomarkers was likely to be a very high risk
approach with a high chance of failure. As such, we decided that this
approach was not a feasible way of reaching the overall project goal of
biomarker identification and should be abandoned in favour of using biliary
brush cutology and fresh surgical tissue samples.
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Chapter 4.
4 Suitability of RNA isolated from bile
and biliary brushings for gene
expression profiling
4.1 Introduction and background
In Chapter 3, we discussed and investigated the use of current methods in
molecular biology for gene expression profiling using degraded RNA isolated
from FFPE tissues. The aim of the work discussed in this chapter was to
assess the suitability of RNA isolated from samples of bile and biliary
brushings, for gene expression profiling.
Cytological examination of bile and biliary brushings taken at the time of
endoscopic retrograde cholangiopancreatography (ERCP) have the potential
to provide valuable information on the biology of benign and malignant biliary
diseases. These clinical samples may be useful in developing much needed
biomarkers of biliary tract cancer.
Until recently, the quantity and quality of RNA isolated from such material has
been insufficient for study. As already discussed, however, advances in RNA
isolation and gene expression techniques now allow small quantities of
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degraded RNA, such as that extracted from formalin fixed paraffin embedded
(FFPE) tissues, to be used successfully for other analytical techniques such
as quantitative real time PCR (qPCR) and microarray analysis (Lehmann and
Kreipe 2001; Cronin, Pho et al. 2004; Coudry, Meireles et al. 2007; Penland,
Keku et al. 2007; Linton, Hey et al. 2008). RNA prepared from paired fresh
frozen and FFPE tissue samples give comparable data so long as appropriate
methods are used (Penland, Keku et al. 2007; Linton, Hey et al. 2008).
These technical advances allow analysis of rare and archived pathology
samples as well as evaluation of degraded RNA from other sources such as
bile or biliary brushings. Reports have been published describing gene
expression profiling of biliary tissue using fresh frozen surgical resection
material (Hansel, Rahman et al. 2003; Obama, Ura et al. 2005; Jinawath,
Chamgramol et al. 2006), but there has been little published work using RNA
isolated from bile or biliary brushings (Feldmann, Nattermann et al. 2006;
Matull, Andreola et al. 2008). Reasons for this include the small quantity and
highly degraded nature of RNA isolated from such samples although there are
few published data on the quality of RNA isolated from these clinical samples.
Potential causes of RNA degradation in biliary samples include a direct effect
of bile or of the x-ray contrast agents used during ERCP procedures, both of
which have been shown to be cytotoxic to biliary epithelial cells in culture
(Benedetti, Alvaro et al. 1997; Ju, Kim et al. 2002). A further potential
confounding factor may be the presence of RNA isolated from leukocytes as a
result of biliary infection, particularly in those with bile duct obstruction. There
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are few published data on the quantity, the quality, or the primary source of
RNA in bile, or its suitability for further investigation such as RNA expression
analysis using microarray. Early work by our group suggests that there is very
little RNA in bile samples and that it is degraded, but despite thise, is useful
for downstream applications such as qPCR (Matull, Andreola et al. 2008).
Other groups have shown that degraded RNA isolated from other biological
samples, such as urine, is useful for qPCR and microarray experiments with
results comparable to RNA isolated from fresh frozen tumour tissue (Mengual,
Burset et al. 2006). This approach has been applied to analogous situations.
Thus, whole genome RNA expression profiling was successfully applied to
samples of bronchial brushings in patients with suspected lung cancer and to
urinary sediment in patients with bladder cancer (Mengual, Burset et al. 2006;
Spira, Beane et al. 2007).
The studies in lung cancer are particularly interesting (Spira, Beane et al.
2007). Work by this group demonstrated a field change in normal bronchial
epithelium of patients with a carcinoma of the lung at a distant site. Using a
panel of 80 differentially expressed genes identified by microarray (n=77 in
training set and 52 in validation set using Affymetrix U133A GeneChips),
patients with lung cancer could be detected from brushings of macroscopically
normal bronchial mucosa with a sensitivity and specificity of 80% and 84%
respectively. The addition of standard cytology of bronchial aspirates
increased the sensitivity to 95% (Spira, Beane et al. 2007). This methodology
may be transferable to the bile duct where the concept of a premalignant field
change has been proposed in conditions such as PSC (Fleming, Boberg et al.
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2001). In addition, a molecular signature of cancer or pre-cancer may be a
solution to the difficult problem of the low sensitivity of standard biliary brush
cytology, which is unlikely to improve using standard cytology methods.
In this chapter we investigate the suitability of bile and biliary brushings for
such an approach, describe the methodology for RNA isolation and
demonstrate that such samples provide useful RNA for further evaluation with
downstream applications such as qPCR and microarray analysis.
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4.2 Materials and methods
4.2.1 Clinical samples
Clinical samples were collected following written informed consent for ethically
approved research (06/Q0152/106). Samples of bile and biliary brushings
were taken at the time of clinically indicated diagnostic or therapeutic ERCP.
Bile was aspirated from a major bile duct using standard biliary catheters.
Biliary brushings were collected from macroscopically normal bile ducts
and/or benign or malignant biliary strictures using a wire guided, sheathed
endobiliary brush (Combocath Microinvasive, Boston Scientific, Notick, MA,
USA), and immediately snap frozen in liquid nitrogen or lysed in TRI Reagent
(Ambion, ). Samples were stored at -800C until further use.
Fresh bile for cell spiking experiments was collected from free draining
percutaneous biliary drains in patients with cholangiocarcinoma, or
gallbladder puncture in patients having undergone planned cholecystectomy.
The bile was filtered using sterile 0.45m Millex syringe filters (Millipore,
Watford, UK) in order to remove free floating cells in the donor bile. The bile
was then separated into 0.5ml aliquots ready for cell spiking.
4.2.2 Leukocyte control samples
For experiments investigating the relative quantities of epithelial and leukocyte
RNA, human circulating leukocytes were isolated from 20ml samples of
peripheral blood (ethical approval 06/Q0152/106). Fresh samples of blood
were mixed with an equal volume of RPMI culture medium. 20ml of the blood
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solution was gently pipetted onto 7ml of Lymphoprep (Fresnus Kabi Norge
AS, Axis Shield, Oslo, Norway) and centrifuged at 2100rpm for 20mins. The
buffy coat containing the leukocytes was then removed using a pipette and
spun down to a pellet and washed in PBS. The pellet was used for isolation of
purified RNA as described below.
4.2.3 BTC cell lines used for positive controls
Two biliary epithelial cell lines were used for spiking experiments and controls.
The first, TFK-1 (DSMZ, Germany), is a human extra-hepatic
cholangiocarcinoma cell line (Saijyo, Kudo et al. 1995). The second, H69, is a
human immortalised biliary epithelial cell line isolated from normal human
intra-hepatic biliary epithelium (Grubman, Perrone et al. 1994). Both were
cultured to confluent monolayer before use, as per published methods
(Grubman, Perrone et al. 1994; Saijyo, Kudo et al. 1995).
4.2.4 Culture of biliary epithelial cells in bile and X-ray
contrast agent.
In order to test whether the RNA degradation occurs in vivo as a result of
cytotoxicity from bile or X-ray contrast agent, or ex vivo during the RNA
isolation process, a series of control and cell spiking experiments were
performed. A concentrated cell suspension containing 250,000 cells was
spiked into 0.5ml aliquots of filtered bile or Iohexol x-ray contrast solution
(Omnipaque®, GE Healthcare) at 25% and 50% concentrations diluted in
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RPMI culture medium. Further aliquots of cells were transferred into an
Eppendorf tube and immediately lysed in TRI reagent (Ambion) to assess the
RNA integrity from cells at baseline. The spiked aliquots were incubated at
37oC for 15 minutes, 30 minutes, 1, 3, 6, and 24 hours. After the designated
incubation time, cells were lysed with TRI reagent and stored at -80oC until
RNA isolation as described bellow.
4.2.5 RNA isolation and purification
Biliary brushes were agitated in 1ml of TRI Reagent (Ambion) until most of the
visible biological material had been disrupted from the brush. Total RNA was
isolated using TRI Reagent according to the manufacturer’s instructions. Bile
appears to impair the efficiency of RNA extraction using TRI Reagent,
possibly because of the volumes of bile required and possibly by chemical
interaction interrupting the phase separation. We found the optimum volumes
for RNA isolation are 0.5ml of bile added to 1ml of TRI Reagent. Bile also
results in significant DNA contamination requiring a DNase digestion step that
was performed using 4U of TurboDNase (Ambion) for 30 minutes at 370C.
Total RNA was then further purified using a spin column technique (RNEasy
MinElute, Qiagen) and re-dissolved in 12l RNase free water as per the
manufacturer’s instructions. In addition to the brushings and bile samples,
plastic biliary stents removed at the time of ERCP were also used to isolate
cellular material in the early stages of testing the methodology.
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4.2.6 Evaluation of RNA quantity and quality
Estimation of total RNA quantity and quality was first performed using a
Nanodrop ND-1000 spectrophotometer (Labtech). 1.2ml of RNA solution was
used to reliably obtain readings from the spectrophotometer, leaving 10.8ml of
RNA solution remaining for further analysis. Readings were taken pre and
post DNase digestion and cleanup steps but were unreliable pre DNase
digestion because of the large quantity of contaminating DNA. Data recorded
included estimation of RNA concentration (ng/ml) by measuring absorbance
at 260nm, and 260/280 absorbance ratios as a measure of RNA quality and
purity. 260/280 ratios of 1.8 to 2.1 were considered to be markers of relatively
good quality and purity of RNA.
An Agilent 2100 Bioanalyzer was used after RNA clean up to further
accurately assess RNA quantity and quality. The Agilent RNA integrity
number (RIN) and electropherogram plots were used to document RNA
quality and calculate fragment size. The larger quantities of RNA isolated from
biliary epithelial cells cultured in bile or x-ray contrast was also assessed by
gel separation on a 1% Agarose gel before and after DNase digestion and
cleanup.
4.2.7 cDNA synthesis
Purified total RNA was reverse transcribed using the iScript Select cDNA
synthesis kit (Bio-Rad) as per the manufacturer’s protocol. Reactions were
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performed in 20l volumes using 150ng or 200ng total RNA and primed with
random hexamers in view of the fragmented nature of the RNA.
4.2.8 Quantitative real time PCR
PCR reactions were carried out in 25l volumes using the qPCR Master mix
plus dNTP kit (Eurogentec) with 2l of cDNA (equivalent to 15ng or 20ng
RNA) sample template per reaction. PCR reactions were performed in
duplicate using the SYBR Green detection method and an Applied
Biosystems 7500 Real Time PCR system (Applied Biosystems). Thermal
cycling conditions were set at 50oC for 2 minutes, 95oC for 10 minutes
followed by 40 repeats of 95oC for 15 seconds and 60oC for 1 minute.
Quantitative values for gene expression were calculated using the Ct
method normalizing to GAPDH (NM002046.3) as the reference gene. qPCR
measurement of GAPDH expression was also assessed using 4 different
primer sets producing PCR products of increasing lengths (87nt, 131nt, 220nt
and 405nt lengths).
When using clinical samples of bile and biliary brushings, expression of CK19
(NM 002276.3), EGFR (NM 005228.3) (markers for biliary epithelial cells) and
CD3 (NM 000733.2) and CD45 (NM 080922.1) (leukocyte markers), were
measured in order to ascertain the primary origin of the RNA. Expression of
MUC4 (AF058803) and MUC5AC (Z48314) were also measured in clinical
samples. Primer pairs used are listed in Table 11.
130
Table 11 Primer sets used for qPCR experiments
Primer Ampliconlength (bp)
Forward sequence
(5’ - 3’)
Reverse sequence
(5’ - 3’)
GAPDH 87 87 556TGCACCACCAACTGCTTAGC575 642GGCATGGACTGTGGTCATGAG621
GAPDH 131 131 156CACCAGGGCTGCTTTTAACTCTGGTA181 286CCTTGACGGTGCCATGGAATTTGC263
GAPDH 226 226 108GAAGGTGAAGGTCGGAGT125 333GAAGATGGTGATGGGATTTC314
GAPDH 406 406 625ATGACCACAGTCCATGCCATCA 646 1030GCTTGACAAAGTGGTCGTTGAG1009
CK19 79 514TACAGCCACTACTACACGACCATCC538 592GGACAATCCTGGAGTTCTCAATG570
EGFR 68 1813TGCGTCTCTTGCCGGAAT1830 1883GGCTCACCCTCCAGAAGGTT1863
CD3 88 161GGCAAGATGGTAATGAAGAAATGG184 249AGGGCATGTCAATATTACTGTGGTT225
CD45 102 1353GGAAGTGCTGCAATGTGTCATT1374 1454CTTGACATGCATACTATTATCTGATGTCA1426
MUC4 101 1499GCCCAAGCTACAGTGTGACTCA1520 1600ATGGTGCCGTTGTAATTTGTTGT1578
MUC5AC 102 273TCCACCATATACCGCCACAGA293 375TGGACGGACAGTCACTGTCAAC354
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4.3 Results
4.3.1 Quantity of RNA recovered from bile and biliary
brushings
The quantities of purified total RNA isolated from the clinical samples as
assessed by Nanodrop ND-1000 spectrophotometer were as follows;
 Bile (n=26);
o median total RNA 148 ng (range 0 – 535 ng).
o 260/280 ratio 2.17 (1.34 - 3.25).
 Biliary brushings (n=51);
o median RNA 759ng (range 44 - 2640ng).
o 260/280 ratio 2.04 (1.2 to 2.74).
Figure 18. Representative examples of Nanodrop ND-1000 spectrophotometer data of
RNA quantity and quality as assessed by 260/280 nm wavelength absorbtion ratios.
RNA quantity and quality are higher in the biliary brush samples than bile samples.
132
4.3.2 Quality of RNA recovered from bile and biliary
brushings.
RNA integrity as assessed by Agarose gel electrophoresis was mostly
investigated where larger quantities of RNA were available in the cell culture
spiking experiments in order not to lose valuable RNA from bile and biliary
brushings. In the few clinical samples assessed by gel electrophoresis, faint
smears of RNA were seen, suggesting the RNA to be highly degraded (Figure
19). Agilent Bioanalyzer plots of purified RNA from bile and biliary brushings
demonstrated highly degraded RNA with low RIN scores and short fragments
of RNA estimated to be primarily 100 to 600nt long (Figure 20 and Figure 21).
Median RIN scores were 2.4 (range 1 to 3.9) for bile and 2.4 (range 1 to 5.8)
for biliary brushings.
Figure 19. Agarose gel separation of RNA isolated from control TFK-1
cells (intact bands), samples of biliary brushings and biliary stent
(degraded) and faint smear from bile (degraded).
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Figure 20. Representative Agilent Bioanalyzer plots of RNA isolated
from A) control TFK cells [intact], B) TFK cells incubated in bile (6
hours) [minimal degradation], C) biliary brushings, [partly degraded],
and D) bile [highly degraded].
Figure 21. Examples of Agilent Bioanalyzer electropherograms showing
small size (100-500 nt) of the degraded RNA isolated from clinical
samples of bile and biliary brushings (lanes 2-7). The three
electropherograms on the right show clear peaks of 18S and 28S RNA
demonstrating intact RNA from controls samples (TFK-1 cells)
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Figure 22 Agilent Bioanalyzer plots of RNA isolated from biliary brush samples (n=38)
showing moderately (identifiable 18S and 28S peaks and RIN 3-6) and severely (no
identifiable 18S and 28S peaks and RIN <3) degraded total RNA.
4.3.3 Quality of RNA isolated from PBMC’s and BTC/biliary
epithelial cells (BEC) cultured in bile or x-ray contrast
agent
Purified RNA isolated from freshly cultured PBMC’s and BTC/BECs was high
quality intact RNA as assessed by both agarose gel electrophoresis and
Agilent Bioanalyzer (RIN scores >8, Figure 23 and Figure 24). This
demonstrates that the methodology for RNA isolation is suitable and not
responsible for the RNA degradation found in the clinical samples. Although
the quantity of RNA isolated from BECs cultured in whole bile was reduced,
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the quality of RNA extracted was excellent, even after 24hours culture in bile
(RIN 7.8 to 9.0). Similar findings were seen in BECs cultured in 25% and 50%
x-ray contrast (RIN 7.8 to 8.9) but with less marked effect on RNA quantity,
which was thought to be related to an effect of bile on the phase separation
using TRI Reagent. These data suggest that short term exposure to bile or x-
ray contrast agents are not responsible for the RNA degradation found in
clinical samples of bile or biliary brushings.
Figure 23. Agarose gel separation of RNA isolated from TFK-1 cells cultured in
filtered bile (top) and 50% Omnipaque (bottom) showing clear bands of intact RNA
up to at least 6 hours. Note the bands of DNA contamination seen near the starting
wells.
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Figure 24. Representative Agilent Bioanalyzer electropherograms for purified RNA
isolated from BTC cells cultured in bile and x-ray contrast agent. All samples were of
good quality, similar to the control samples with clear rRNA peaks and RIN scores
mostly >8, even when incubated in bile or x-ray contrast for up to 6 hours. The same
samples are shown as electrophoresis strips showing clear 18S and 28S bands of
intact RNA (bottom right).
4.3.4 qPCR analysis of degraded biliary RNA
To test whether the RNA isolated from clinical samples was reliable for gene
expression analysis by qPCR and to test the effect of PCR amplicon length,
GAPDH mRNA expression was assessed using 4 different sets of primers.
These were designed to amplify regions of the GAPDH transcript ranging from
87 to 406 base pairs in length. In the clinical samples the lowest Ct values
(i.e. greatest GAPDH mRNA expression) were consistently obtained when
using primers amplifying the shortest region (87bp) of the GAPDH transcript.
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However, the Ct values from the same samples rose significantly, in a
stepwise fashion, when primers generating larger amplicons were used
(Figure 25). This effect was primarily seen in highly degraded RNA from bile
with much less significant variation using partially degraded RNA for which
primer amplicons of up to 226bp length appear to be satisfactory. In contrast,
no shift in the Ct values was observed when assessing GAPDH mRNA
expression in control TFK-1 or H69 cells, regardless of the primer set used.
As described by others (Paska, Bogi et al. 2004), primers with larger
amplicons (e.g. 406bp), result in a significant rise in amplification thresholds
and are not suitable for qPCR using the SYBR Green method (Figure 25).
When assessing other genes of interest (CK19, EGFR, MUC4, MUC5AC and
CD45) in clinical samples (Figure 25), primers amplifying regions ≤100bp and
the Ct method can be used to assess relative gene expression (Livak and
Schmittgen 2001).
Figure 25. qPCR amplification plots (left) and Ct calculations of gene expression using
GAPDH primer pairs with increasing amplicon lengths. Note the separation in
amplification plots and larger Ct when using PCR primers sets with long amplicon
length with degraded RNA from bile, but not with intact control (TFK-1) RNA.
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4.3.5 Relative expression of epithelial and leukocyte RNA in
biliary brushings
Expression of CK19 and CD45 were measured as markers of epithelial and
leukocyte RNA respectively. TFK-1 cells (BTC cell line) and human PBMCs
were used as positive controls to assess the level of expression in pure
samples. Note that the Ct values were very high and close to GAPDH for
genes of interest in the control samples but very low (over 35) or negative in
the other cell type (Figure 26). For clinical samples, the Ct values compared
to the reference genes were used an estimate of the relative proportion of the
two types of RNA in the samples.
Figure 26. Confirmation of suitability of qPCR primer sets. Note that the Ct value for
CK19 in TFK-1 (BTC) cells and CD45 in PBMCs respectively are very low,
demonstrating high expression levels near to those of the house keeping gene
GAPDH. Conversely, levels of CD45 are very low (CT >35) and negative for CK19 in
PBMCs confirming specificity of the primer sets. Relative expression of CK19 was
higher than CD45 in stent samples but there is significant variation in both.
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The relative expression of epithelial RNA was consistently higher than that for
leukocyte RNA suggesting that the RNA isolated from bile or biliary brushings
is primarily of epithelial origin. This pattern of gene expression can be seen on
individual sample gene plots (Figure 27) and when grouped for calculation of
mean figures (Figure 28). Also of importance was that there was no
significant difference in relative expression of CK19 in benign versus
malignant samples (1.02, CI 0.98-1.06) suggesting that both have similar
quantities of epithelial RNA and should therefore be suitable for comparison
using the Ct method. Relative expression of CD45 (1.65, CI 1.48-1.83) was
slightly higher in malignant samples raising the possibility of bias in genes
expressed by leukocytes. However, as shown above, the relative quantities of
leukocyte RNA are much smaller (difference in Ct approximately 6, equating
to 64 fold higher epithelial RNA assuming that the respective markers of cell
type are equally highly expressed by the cells of interest) suggesting that a
slight difference in total leukocyte RNA is unlikely to significantly impact on
results in genes of interest.
Although not an accurate method for assessing relative quantities, one may
estimate this by comparing the DCt for each against the reference gene
(18S). This is not accurate as it assumes that i) 18S is equally expressed by
both cell types (likely true), ii) 1Ct accurately represents x2 fold change (likely
true) and iii) both CD45 and CK19 are equally highly expressed in their
respective cells (assumed but not quite true despite small Ct for each
showing both expressed at levels near to GAPDH in their respective cell
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type). However, based on these assumptions and using the Ct for CD45 (21)
and CK19 (14.8), in biliary brushings, there was approximately a 77 fold
greater ratio of epithelial to leukocyte RNA.
Figure 27. qPCR amplification plots for RNA isolated from biliary brushings showing a
higher relative expression of the epithelial cell marker (CK19) than leukocyte marker
(CD45). A similar pattern of epithelial and leukocyte RNA is seen in malignant and
benign disease. The two boxes represent data from two different experiments, one
using GAPDH (left) and the other 18S (right) as the reference genes.
Figure 28. Amplification plots for CD45 and CK19 showing mean Ct
calculated against the 18S reference gene. In both benign and malignant
samples, expression of CK19 is similarly higher than that for CD45. Also
the expression of CD45 varies considerably between samples.
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4.3.6 Real time qPCR using samples of bile and biliary
stents
Similar qPCR results were obtained using highly degraded RNA isolated from
bile. Gene expression was quantified for 18S, GAPDH, CK19 and CD45 using
the Ct method (Figure 30 and Figure 31).
The input quantity of RNA is calculated to be similar for all qPCR reactions
and so the expression of the reference gene (GAPDH or 18S) should be
similar. However, unlike the biliary brush samples, there was a large variation
in the Ct values for the reference genes when using samples of bile (Figure
29). This may be partly due to errors in spectrophotometric assessment of
calculations at very low concentrations and/or due to inefficient amplification
of PCR products with the highly degraded RNA in bile or genomic DNA
contamination.
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Figure 29. Despite equivalent starting quantity of RNA as measured by Nanodrop
spectrophotometer (150ng per cDNA synthesis) and equivalent calculated cDNA
loading (1l or 7.5ng equivalent RNA), there is considerable variation in Ct values for
GAPDH in the bile samples (arrow) but not in the brush samples. This suggests that
the RNA isolated from bile is either poorly quantifiable or the higher level of RNA
degradation in bile results in greater variability in gene expression, even when using
primer pairs with short amplicons (87bp for GAPDH). Alternatively, genomic DNA
contamination may result in inaccurate estimation of the starting concentration of
RNA. However, the Ct method may still be useful on the assumption that the effect
of RNA degradation is similar for other measured genes within a sample.
When using clinical samples of bile (n=12) and 18S as a reference gene, the
relative expression of CK19 mRNA was much higher (Ct 18.15) than that of
CD45 (Ct 24.68) showing a significantly higher contribution of epithelial RNA
than leukocyte RNA in bile (Figure 31). When comparing the relative
expression of epithelial and leukocyte RNA between benign (n= 7 [stones,
stent changes for chronic pancreatitis, SOD]) and malignant bile samples (n=5
CC), there was no difference in relative expression CK19 (Ct 1.06 [95% CI
0.89-1.26]) or CD45 (Ct 1.06 [95% CI 0.66-1.69]).
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RNA isolated from stents retrieved at ERCP had highly variable quantities of
total RNA. More importantly, stent samples varied considerably with regards
relative expression of CK19 and particularly CD45. Examples of data from two
stent samples are shown in Figure 26 (other data not shown). This suggests
that these samples are unlikely to be suitable for gene expression studies
unless larger numbers of samples are used in order to reduce the variation
seen between individual samples.
Figure 30. Representative qPCR plots for CK19 and CD45 as markers of relative
expression of epithelial and leukocyte RNA respectively in bile samples. Note that
in the BTC cell line (TFK-1) and PBMC controls, expression of the relevant markers
are high (near to the GAPDH reference gene) or negative as exprected. In the
clinical samples, the higher expression of CK19 suggests a greater contribution of
epithelial to leukocyte RNA in bile, but with a lesser difference than that found in
biliary brushings.
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Figure 31. Left: Relative expression of epithelial (CK19) and leukocyte (CD45) RNA
markers showing a greater proportion of epithelial cell RNA in bile. Right:
Representative qPCR amplification plots from benign and malignant bile samples
using the 18S reference gene showing that both have a much greater proportion of
epithelial to leukocyte RNA.
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Figure 32. Use of the Ct method to compare gene expression in different sample
types. qPCR plots are shown in the graphs and Ct values tabulated in bar charts
below. Note that CK19 in the TFK-1 cell line has a slightly lower expression than the
clinical samples despite being a pure cell line, suggesting an element of
dedifferentiation and loss of full CK19 expression. Also, CD45 expression varies more
than other genes tested.
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4.4 Discussion
RNA isolated from clinical samples of bile and biliary brushings is shown to be
highly degraded. However, application of methodology developed for similarly
degraded RNA isolated from FFPE tissues allows gene expression profiling
that has, as yet, rarely been applied to endoscopically obtained biliary
samples. The clinical importance is primarily related to the fact that biliary
samples obtained at ERCP are far more readily available than relatively rare
surgical resection specimens. In addition, profiling of biliary brush cytology is
likely to identify novel disease biomarkers in bile and/or blood that will assist
clinical investigation and treatment in the future.
The in vitro experiments demonstrate that the methodology for RNA isolation
is suitable and can provide high quality purified total RNA. In contrast to
published data in biliary epithelial cell lines (Benedetti 1997, Ju 2002), our
data suggest that the RNA degradation does not occur as a result of short
term direct cell exposure to potentially noxious bile or x-ray contrast agents.
These conditions appear to have little effect on the quality of RNA isolated
from biliary epithelial cells cultured for up to 24 hours. We did not quantify the
number of cells surviving in such environments and it is still possible that
significant cell death occurred in vitro. However, if this were the case we
would have expected to find significant amounts of degraded RNA, which was
not found. These data also suggest that the RNA degradation occurs in vivo
and as such is not amenable to methodological variations to prevent this.
Maximisation of data acquisition is therefore dependent on the use of
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appropriate cDNA synthesis, amplification and/or qPCR methods after
isolation of the RNA.
A potential source of significant ‘noise’ and false positive results in biliary
samples is the presence of leukocytes which are commonly found in patients
with biliary disease and biliary obstruction. Relative gene expression of
epithelial cell markers (CK19) and leukocyte markers (CD45) using the Ct
method suggest that the primary source of RNA in our samples was epithelial
in origin with a relative quantity many orders higher than that of leukocyte
RNA. We are therefore confident that we have representative RNA expression
data from our samples.
Our findings suggest that RNA isolated from bile and biliary brushings is
suitable for gene expression profiling. This provides a potential route for
development of new biomarkers for the diagnosis of malignant biliary
strictures, as well as further investigate the biology of biliary diseases such as
primary sclerosing cholangitis. Our aims are therefore to further explore gene
expression in benign and malignant biliary disease using these methods along
with whole genome RNA expression profiling using the microarray platform.
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Chapter 5.
5 Whole genome RNA expression
profiling of RNA isolated from biliary
brushings
5.1 Introduction
We have demonstrated that RNA isolated from bile and biliary brushings is
degraded and of relatively low quantity but can be used for gene expression
analysis using qPCR. Similar quantities and quality of RNA isolated from other
sources such as FFPE tissues, bronchial brushings and urine have been
shown to be useful for whole genome expression profiling using microarray
analysis (Lehmann and Kreipe 2001; Cronin, Pho et al. 2004; Mengual,
Burset et al. 2006; Coudry, Meireles et al. 2007; Penland, Keku et al. 2007;
Spira, Beane et al. 2007; Linton, Hey et al. 2008). One of these studies
showed that differential gene expression using microarray analysis of
bronchial brushings from macroscopically normal epithelium in the upper
bronchus, identified tumour at a distant site in the bronchial tree (Spira, Beane
et al. 2007). This suggests that a ‘field change’ of alterations in gene
expression exists and this phenomenon has also been proposed in the
unaffected liver of patients with PSC and distant cholangiocarcinoma (CC)
(Fleming, Boberg et al. 2001). A major problem with biliary brush cytology for
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the diagnosis of CC is the low sensitivity even when directly brushing
malignant strictures. The work by Spira et al in bronchial brushings and the
low sensitivity of biliary cytology provides an obvious rationale to evaluate this
approach in biliary brushings.
Microarrays are referred to by a number of different names by manufacturers
and in the literature (microarrays, DNA microarrays, RNA expression arrays,
gene expression arrays, oligonucleotide spotted arrays, gene chips etc). All
refer to products with similar techniques and aims. The principle of
microarrays is that a particular mRNA sequence will bind to a complementary
DNA template from which it was made, and binding to a cDNA oligonucleotide
can be quantitated, often using immuno-fluorescence. Microarrays have been
developed using standardised information on gene sequences and
nomenclatures from the Human Genome Project and public databases such
the National Center for Biotechnology Information (NCBI) databases. This has
allowed mRNA specific DNA oligonucleotides to be designed, synthesized
and spotted densely onto glass plates in the gene chips. The confusion in
nomenclature between RNA expression and DNA microarrays arises from the
fact that cDNA oligonucleotides complementary to mRNA are used to bind to
the oligonucleotide probes on the chips and hence identify gene expression.
Most commercially available microarray chips now include genes spanning
the entire genome as described by NCBI databases. The signal (e.g. colour
or immuno-fluorescence) released by bound cDNA can be measured as
relative abundance for each data point on the chip using a high resolution
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laser, and the vast amounts of data generated are analysed using software
designed for specific questions such as quantification of gene expression,
identification of DNA mutations or splice variants. Worldwide agreements on
publications using microarray data, set out as the microarray mark-up
language (MAML), require that all raw source files and experimental methods
are submitted for public use in one of the main microarray depositories such
as the Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/). In
time, this will provide an enormous resource for data analysis that will be
available for work such as biomarker development and improved
understanding of cell biology in health and disease. Microarray technology
has been successfully applied to the identification of biomarkers in other
cancers including pancreas, breast, prostate and lung cancers (Perou, Sorlie
et al. 2000; Dhanasekaran, Barrette et al. 2001; Garber, Troyanskaya et al.
2001; Iacobuzio-Donahue, Maitra et al. 2002).
Searches of databases reveal only very limited microarray data sets in BTC to
date, in line with the limited research in this field. Studies have been
performed using BTC cell lines and surgical resection specimens from partial
hepatectomy for cholangiocarcinoma (Obama, Ura et al. 2005). Cancer cell
lines provide useful data with regards to cancer biology and alteration in
cellular pathways in response to treatment interventions but do not
necessarily translate into clinical practice. Microarray analysis using surgical
resection specimens has been mainly performed using samples of
intrahepatic cholangiocarcinoma (Obama, Ura et al. 2005; Jinawath,
Chamgramol et al. 2006; Hass, Nehls et al. 2008). The same group published
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two of these papers investigating the expression profile of intra-hepatic CC
with or without evidence of liver fluke infection. They used laser capture
microdissection (LCM) to separate out biliary epithelial tissue and identified a
list of differentially expressed genes in intrahepatic CC. Although the addition
of LCM should improve the accuracy of gene expression profiling, these
cases do not necessarily represent the different pattern of extrahepatic CC
more commonly seen in the Western world.
A group in Germany published data on differential gene expression between
blocks (n=10) of fresh frozen intrahepatic CC compared to the surrounding
“normal’’ liver (Hass 2008). This study used the first generation of Affymetrix
U133A GeneChips and identified 552 differentially expressed genes in CC.
The most significant up-regulated gene in this study was osteopontin with a
fold change in cancer versus benign disease of 33 (p=<0.001). However, the
study was limited by the fact that adjacent liver tissue will greatly differ in
cellular content (predominantly mature hepatocytes) from that of CC
(predominantly adenocarcinoma and stromal cells), and these tissues are
therefore not directly comparable.
One paper has been published using fresh surgical samples of resected
extrahepatic BTC (Hansel, Rahman et al. 2003). This group used scrapings of
biliary epithelium resected at the time of Whipple’s procedures, whole surgical
resections of BTC (mostly gallbladder cancer) and BTC cell lines analysed
using the first generation of Affymetrix chips (HG U133A). Although these
samples are likely to be more representative than the intrahepatic tumour
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samples investigated by others, data are still confounded by the use of cell
lines, stromal tissue and predominance of gallbladder material, and hence are
not ideal for analysis. However, a list of 282 genes with greater than 3 fold
change in expression (up- or down-regulated) was generated, many of which
have previously been shown to be altered in BTC.
5.2 Aims
The main aim of the work presented in this chapter was to use whole genome
RNA expression profiling of RNA isolated from biliary brushings of benign and
malignant biliary disease for the identification of genes that may be potential
biomarkers for the diagnosis and prognosis of BTC.
Secondary aims were:
 To identify genes that may be important in the biology of BTC.
 To assess whether microarray of biliary brushings is feasible for
investigating gene expression in other biliary diseases hampered by
paucity of clinical material such as PSC.
 To assess whether there may be a role for expanding the work on
biliary brushings in order to identify multiple gene signatures in the form
of ‘diagnostic chips’ that may be useful in diagnosis and prognosis of
malignant biliary strictures.
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5.3 Materials and methods
5.3.1 Biliary brush samples
Brushings of biliary epithelium were obtained from macroscopically normal
bile duct wall, and benign and malignant strictures using a wire guided,
sheathed endobiliary brush (Boston Scientific, Notick, USA) at the time of
clinically indicated ERCP. Ethical approval was granted by the joint UCL/UCH
ethics committee for sample collection and research (ref 06/Q0152/106) with
separate site specific assessment at the Royal Free Hospital. Details of
methods for RNA isolation are described in Chapter 4.
Clinical samples used for the microarray analysis are described in Table 12.
Definitive diagnosis was reached in all by cytology or histology confirmatory of
cholangiocarcinoma. Those with sphincter of Oddi dysfunction (SOD) were
considered to have normal biliary epithelium and those with benign findings
had benign clinical history, benign cytology and no evidence of malignant
disease after at least 12 months follow up. In 5 out of the 10 cases, diagnostic
cytology was sent for pathological assessment at the same time a second
sample was taken for research. In the remaining 5 cases, a diagnosis was
already clear and no clinical cytological samples were obtained at the time
research samples were taken.
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Table 12 Summary of biliary brush samples used for microarray analysis
Sample Diagnosis TotalRNA
Agilent
RIN
Malignant
cytology
Biliary
sepsis Further comments
B1 Benign stricture(chronic pancreatitis) 1123 5.1 No No
Stent in situ at time of
ERCP
B2 Biliary SOD 150ng 4.3 Not done No
Normal ERCP with
elevated biliary
sphincter pressure
B3 Pancreatic SOD 1657ng 2.5 Not done No
Normal ERCP with
elevated pancreatic
sphincter pressure
B4 Benign stricture(chronic pancreatitis) 2840ng 1.8 No No
Stent in situ at time of
ERCP.
C5 Low CBD CC 270ng 5.8 Not done No Stent change
C6 Hilar CC 2290ng 2.9 Not done No
Elevated CRP (138)
but no other evidence
cholangitis
C7 Hilar CC 690ng 2.5 Not done No Stent change
C8 CBD CC 2400ng 2.0 Adenocarcinoma No Diagnostic ERCP
C9 Hilar CC 650ng 1.8
Suggestiv
e but not
diagnostic
Yes
Pus in biliary tree but
normal clinical
parameters
C10 Hilar CC 815ng 2.5 Adenocarcinoma No Diagnostic ERCP
The biliary brushings were immediately snap frozen in liquid nitrogen within a
few minutes of collection. The tip of the brush was cut off into a 2ml
Eppendorf tube using a wire cutter. The tube was then immersed and
transported in liquid nitrogen and transferred to a -800C freezer until further
processing.
5.3.2 RNA isolation and purification
Total RNA was isolated and purified as described in chapter 4. In brief, RNA
was extracted from the biliary brush samples using phase separation and
ethanol precipitation using TRI Reagent (Ambion) as per the manufacturer’s
protocol. The total RNA solution was then purified using DNase digestion (4U
TurboDNase, Ambion) and spin column filtration steps (RNEasy MinElute,
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Qiagen). Total RNA was stored in 12l volumes of RNase free water at -800C
until further use for the microarray experiments.
5.3.3 Whole genome RNA expression profiling using
Affymetrix U133 plus 2.0 GeneChips
The RNA amplification, labelling and hybridisation to the Affymetrix
GeneChips were performed as a paid microarray service by UCL Scientific
Support (Catherine King, Wolfson Institute for Biomedical Research, UCL).
5.3.3.1 Choice of microarray chips
Many commercially available microarray chips are now marketed. The choice
of chip depends on the information one aims to obtain and the local facilities
available. Each chip has strengths and weaknesses and the latest generation
are usually designed for specific purposes. For example, the Affymetrix
Human Exon Arrays have probes designed to detect each exon of a gene and
can therefore detect splice variants for specific genes. However, they require
larger starting quantities of RNA and are less efficient in detecting small
mRNA sequences with few exons.
The microarray chips used were chosen following a review of the literature on
RNA from FFPE samples and advice from the microarray service at UCL.
Different manufacturers use different size oligomer probes. Affymetrix uses
smaller 25mer probes and the Agilent systems use 60mer probes with no
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difference in accuracy for gene expression. In view of the degraded RNA and
the demonstration in earlier work (Chapter 4) that PCR amplicon size is
important for quantification of gene expression, it was felt that the Affymetrix
arrays were more likely to provide accurate results. When assessing overall
gene expression, a study comparing the main Affymetrix chips concluded that,
despite variation in probe level expression, there was little variation in gene
level expression of differentially expressed genes between chips (Robinson
2007).
The chip chosen was the Affymetrix Human U133 plus 2.0 GeneChip (Figure
33) which has been the most widely used chip to date. This chip has a smaller
probe level variance than other Affymetrix chips. Unlike the exon array, it
cannot detect splice variants for each gene and detects overall expression of
each gene using multiple 25mer probes per gene. The level of expression is
determined by the number of bound probes per gene.
Figure 33 Affymetrix GeneChip showing magnified areas of the
oligonucleotide spotted plate and bound immunofluorescence
tagged sample cDNA measured by the chip reader. (Collage of
images taken from Affymetrix.com
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5.3.3.2 Statistical aspects of sample numbers for microarray
experiments
Advice for experimental design was given by staff at the microarray service
(Dr Mike Hubank, Institute of Child Health) and the Bloomsbury Centre for
Bioinformatics (Dr Sonia Shah). In general, the larger the number of samples,
the more reliable the results and the more likely it is that small differences will
be identified. Our work centres on biomarker development rather than cell
biology and hence we were interested in identifying only larger differences
between groups. The advice was that the minimum sample size required for
application of statistical methods to gain meaningful results is 3 samples per
group. However, microarray experiments are expensive and clinical samples
are precious. Therefore we first undertook a pilot experiment using only 2
samples per group to assess feasibility of the work. These experiments
suggested good quality data and identified genes already implicated in BTC
so further supporting the technique. The variation in level of gene expression
was smaller in the benign group. We therefore concluded that the addition of
six further samples would likely be sufficient in order to detect genes with
large differential expression for biomarker development. In total, 6 samples
were taken from patients with malignant disease and 4 from patients with
benign biliary strictures.
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5.3.3.3 RNA amplification and labelling
In a deviation from standard protocol, we did not use the Affymetrix RNA
labelling kits prior to hybridisation to the Affymetrix chips and used alternative
kits more appropriate for the degraded nature of our RNA. Both the steps
described have been tested and approved by the manufacturer and others for
use on the Affymetrix microarray platform.
The WT-Ovation FFPE RNA Amplification system (Nugen, USA) uses a
mixture of random and oligo dT primers to synthesize amplified cDNA. Like
many systems, transcription is initiated at the 3’ end of the RNA using poly dT
primers but also uses the addition of random priming of the whole
transcriptome. This significantly improves amplification and cDNA synthesis
using short segments of degraded RNA, where degradation preferentially
occurs at the polyA end of RNA, and is a more efficient RNA amplification and
cDNA synthesis method for degraded RNA isolated from FFPE for microarray
studies. The cDNA synthesis step results in amplified levels of cDNA (up to
10g) complementary to mRNA sequences. The starting quantity of total
purified RNA used was 75ng. Link to the instruction manual:
http://www.nugeninc.com/tasks/sites/nugen/assets/File/user_guides/userguid
e_wt_ov_ffpe.pdf
cDNA labelling for hybridisation to the microarray chips was performed using
the FL-Ovation cDNA Biotin Module v2 (Nugen, USA) as per the
manufacturers instructions:
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(http://www.nugeninc.com/tasks/sites/nugen/assets/File/user_guides/userguid
e_fl_ov_biotin.pdf).
The process uses a thermal cycling fragmentation step to produce single
stranded fragments (50-100bp) of cDNA followed by enzymatic attachment of
a biotin labelled nucleotide to the cDNA. The biotin label is used for
quantification by the Affymetrix chip readers. Prior to this step, samples of
amplified cDNA were assessed using the Nanodrop ND-1000
spectrophotometer to quantify 5g of required input cDNA and to ensure
260/280 ratios were over 1.8.
5.3.3.4 Hybridisation to DNA microarray chips
Processing of GeneChips was performed as a paid service by the microarray
facility, Scientific Support, Wolfson Institute for Biomedical Research, UCL.
Each sample of biotin labelled cDNA was hybridised to single Affymetrix
human U133 plus 2.0 GeneChips and processed as per the manufacturer’s
instructions. GeneChip signal intensities were recorded using a GeneChip
Scanner 3000 (Affymetrix) and raw probe level data stored as standard
Affymetrix CEL (.cel) data files for data analysis.
5.3.4 Microarray analysis
Statistical analysis and assessment of quality control in our samples was
performed as a paid service by Dr Sonia Shah at the Bloomsbury Centre for
Bioinformatics.
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Prior to analysis of gene expression data, the raw data obtained from the CEL
data files requires a number of quality control and normalisation steps to
ensure that quantities and quality of data from each chip is similar and
comparable. Variability in biotin signal intensity can be normalised using
normalisation genes and in built chip signal controls so that each chip
provides comparable data. However, variation in quality of the data recovered
cannot be easily normalised and therefore, samples with significant quality
control variance from other samples must be removed from the pool before
data analysis. In general, consistency in quality of input RNA is more
important than the actual quality of RNA at baseline. Therefore, if we had
samples of good quality starting RNA, they would not be suitable for inclusion
with our mostly degraded samples. As shown above, none of the samples
were of good quality RNA and we chose samples with the least degraded
electropherogram plots.
Each gene has multiple probes with separate signals. Summarisation
combines the individual probe intensities to calculate single gene intensity
used to calculate gene expression. Background correction adjusts the value of
each probe signal to account for background hybridisation. The data were
normalised using the Affymetrix microarray suite (MAS5) algorithm. During
MAS5 background correction, the chip is divided into regions (default=16).
The lowest 2% of signals are used to compute the background for that region.
Each probe intensity is adjusted based upon a weighted average of each of
the background values. Perfect match (PM) probes are adjusted using
mismatched (MM) signals and the probe signals are then summarised into
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gene signals using the Tukey Biweight algorithm. The data were lastly
normalised by scaling all arrays to have the same mean intensity (Figure 34).
Figure 34 Histogram of individual GeneChip signal intensities before and after MAS5
normalisation showing very similar profile for all samples
5.3.5 Quality control
Quality control of the raw and normalised data was performed using the
following methods:
5.3.5.1 Box plots
The box plots (Figure 35) display the median, and upper and lower quartiles
of overall intensities for each sample. The whiskers show data 1.5x the inter-
quartile range. Figures outside this range (shown as dots) are considered
outliers and provide data on those samples with a higher variability in signal
intensity. One sample (RC) had significantly more outliers than the others and
was considered unusual, marking it for possible removal from data analysis.
162
Figure 35 Box plot of microarray signal intensities before and after normalisation
5.3.5.2 Histograms of PM versus MM probe signal intensities
Affymetrix GeneChips consist of a combination of mismatch (MM) and perfect
match (PM) probe sets. The MM probes measure the degree of non-specific
hybridisation while PM measure specific hybridisation. The cRNA should bind
the MM probes less strongly than to the PM probes and have a weaker
intensity signal than the PM probes. If the PM curve is not significantly
different from the MM curve, this implies a low signal to noise ratio. In such
cases it is often difficult to distinguish truly differentially expressed genes from
the noise. In our samples, the PM versus MM plots intensities differed as
expected but had some variation in distribution between plots (Figure 36).
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Figure 36 Histograms of PM (perfect match) versus MM (mismatch) probe signal
intensities showing similar strength and spread of signal intensities for benign (left)
and malignant (right) disease samples
5.3.5.3 RNA degradation plots
RNA degradation occurs preferentially at the 5' end of the molecule. Genes
and transcripts are represented on Affymetrix chips as a series of
oligonucleotide probes numbered 0-10, with probe 0 being the most 5'
sequence and probe 10 the most 3' sequence. RNA degradation plots show
expression as a function of 5'-3' position of probes. The plot in Figure 37
shows the average intensity of the probes classified by this order. Each line
corresponds to an array and the slope of its trend indicates potential RNA
degradation and/or inefficient labelling.
The most important factor when assessing quality is consistency, and so it
may be acceptable for all samples to be of poor quality as long as they were
similarly poor. One sample (RC) had an RNA degradation plot that was much
flatter than the others. This suggested either much better quality RNA
(unlikely) or very poor RNA with little hybridisation to any of the probes.
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Figure 37 RNA degradation plots for each GeneChip
sample showing slope of curve as a feature of
hybridisation to probes at different points along the length
of control genes.
5.3.5.4 SimpleAffy software
SimpleAffy was used as a second commonly used quality control step. The
main data analysis tests are as follows:
Number of genes called ‘present’
All samples were recorded as having over 50% call rates, considered to be
satisfactory even when using good quality RNA.
3’ to 5’ ratios
Unlike the multiple probe sets analysed in the RNA degradation plots above,
SimpleAffy assesses only β-actin and GAPDH, two relatively long genes. By
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comparing the intensity values from the 3’ probe set to the 5’ or mid-point
probe sets a 3’:5’ ratio can be calculated. A high ratio indicates significant
RNA degradation or a poor in vitro transcription step. GAPDH 3’:5’ ratios are
plotted as circles; ratios > 1 are coloured red (unacceptable). Β-actin 3’:5’
ratios are plotted as triangles. Being longer than GAPDH, unacceptable ratios
are > 3 and also coloured red. Acceptable ratios for both are coloured blue.
Many of our samples had high ratios, most notably sample RC (Figure 38).
Figure 38 SimpleAffy quality control using GAPDH and
beta-actin normalisation genes showing variability in
signal intensity
5.3.5.5 Correlation plots
The correlation plot is a map of the array-array Spearman rank correlation
coefficients. Self-self correlations run diagonally and by definition have a
correlation coefficient of 1.0. Data from similar tissues or treatments should
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have higher coefficients. The plot can be used to detect outliers. Sample RC
had very different gene expression values from the rest of the samples which
is reflected in the lower correlation to other samples (Figure 39).
Figure 39 Spearman correlation plots for each GeneChip showing marked variation in
one (5), moderate variation in one (3) and good correlation in the remaining samples.
5.3.5.6 Microarray data quality control; conclusions
Analysis of the raw and normalised data suggested a satisfactory level of
quality for all samples except one (RC), which had many parameters outside
those for the other samples. This sample was removed prior to further data
analysis. The remaining samples had evidence of RNA degradation but were
considered to have similar overall quality individually and between the benign
and malignant groups and were therefore suitable for comparison and further
data analysis.
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5.3.6 Statistical considerations
5.3.6.1 LIMMA analysis for calculation of fold change in gene
expression
Analysis of microarray data is performed using specially designed data
analysis software. Our data were analysed by Dr Sonia Shah, Bloomsbury
Centre for Bioinformatics, using the linear models (LIMMA) Bioconductor
software designed for gene expression analysis. The software is based on a
modified t-test and stabilises data for small sample numbers and allows for
the presence of biological and experimental variation. Bayesian statistics are
applied as a means of measuring the probability of an outcome (i.e. significant
fold change) with the prior assumption of a null hypothesis.
5.3.6.2 Correction for multiple comparison testing
Statistical significance for most experimental work is usually set at a level of
5%. When using very large numbers of comparisons, such as the thousands
used in microarray experiments, a significant number of false positive and
false negative results will inevitably occur. Statistical techniques have been
developed in order to reduce both type I and type II errors in analysis of
microarray experiments. The method used for correction for multiple
hypothesis testing in our work was the Benjamini-Hochberg (FDR) test using
a p value cut-off of 0.05. This means that only 5% of the resulting list of
differentially expressed genes are likely to be false positive results (i.e. 56
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genes) as opposed to 5% of the entire probe set of 47,000 genes i.e. 2350
genes.
5.3.7 Gene expression data parameters used for gene
listing
Genes that were absent in three or more samples per group were considered
absent and excluded from analysis. For cell biology data, a fold change of 1.5
is usually set as the cut-off for alteration in gene expression. In order to
attempt to identify biomarkers with a high capacity to differentiate benign from
malignant disease groups, we used a fold change cut-off of 2 or more
(measured as a log2 fold change in data files and gene expression plots). A
statistical cut-off was set at a p value of 0.05. The resulting list of up- and
down-regulated genes therefore only includes genes with a fold change of 2
or more with a p value of less than 0.05 after correction for multiple
hypothesis testing.
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5.4 Results: microarray gene expression data
In view of the size of the files and for ease of reference, results were recorded
in the form of an HTML document which was also converted to Microsoft
Excel format for searching of genes. The files and information contained
within are too large to be included but the number of up- and down-regulated
genes identified are summarised in Table 13.
Table 13 Summary of numbers of genes with significant up- or
down-regulation in microarray data
Expression pattern Number of genes identified
Down-regulated 1001
No significant change 34057
Up-regulated 1141
5.4.1.1 HTML documents of altered gene expression
The HTML format provides an easy format to access the large amount of data
in the results. In addition, the table of data includes other important and useful
information such as the Affymetrix probe identification, fold change, p value,
official gene symbol and name, gene functions and locations, chromosome
location and links to NCBI databases including GeneBank, LocusLink and
PubMed links for each gene. In addition, each gene listed has a link to the
graphical display of the gene expression levels for each sample in each group
so that the pattern and spread of gene expression can be viewed easily.
These graphs are known as gene plots and examples are shown in Figure 41.
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An image of the HTML format of a small section of the up-regulated genes is
shown in Figure 40.
Figure 40 HTML format of microarray data presentation showing a small section of the
table.
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5.4.2 Choice of candidate genes for further validation
using qPCR
Initial examination of the microarray data of up- and down-regulated genes
appeared to identify many genes with different functions, locations and from
different pathways and cell types. Selection of candidate markers requires
exhaustive searches of databases to understand the biological function and
plausibility of each gene to assist with decision making
Examination of the data appears to include a significant number of leukocyte
genes which raises the question that there may be significantly more
leukocyte contamination in the cancer samples compared to the benign
samples as a result of cholangitis in patients with complex biliary strictures.
However, further exploration of the function and expression of these genes
shows that they have usually already been shown to be expressed by other
tissues including epithelial cells (e.g. lymphoid enhance binding protein 1
[LEF1], transforming growth factor 1 [TGF-1], Interleukin receptor kinase 3
[IRKAM]). An important finding providing evidence against a leukocyte bias in
the cancer samples is the lack of leukocyte specific genes such as CD45,
leukocyte specific protein-1 (LSP1), leukosialin (CD43), CD18 (MHM23),
cathepsin G, leukocyte alkaline phosphatase (LAP), CD11 and CD166. These
genes are commonly used as leukocyte specific markers for cell sorting and
other work and do not appear in either the up- or down-regulated list of genes.
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Selection of a shortlist of genes was made using a number of criteria
discussed in turn:
5.4.2.1 Up- or down-regulated expression
Even though the down-regulation of genes is clearly important in cancer
biology, the main aim of the project was identification of biomarkers. It is
unlikely that down-regulated genes will directly code for easily measurable
proteins in blood or bile and so are less likely to be useful for biomarker
identification than up-regulated genes. Identification of altered protein
expression up- or down-stream from down-regulated genes would require
further complex data analysis of inter-related pathways with the possibility of
introduction of further error. We therefore chose to concentrate on up-
regulated genes for the shortlist.
5.4.2.2 Level of alteration in gene expression (fold change)
The higher the fold change between disease and controls, the more likely that
the protein product will have significant differences between groups. However,
it is also possible that genes may be up-regulated as a result of mutation in
that gene which may be non-coding or code for biologically inactive proteins
which may not be measurable using standard commercial assays such as
ELISA. Another factor affecting protein product is the half life of the protein so
that genes coding for proteins with a short half life may result in limited fold
change in the measurable protein product. Alternatively, some genes with
smaller fold change in expression may code for proteins with a long half life
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and result in considerable differences in protein levels between groups. The
cut-off for fold change used in our microarray data analysis was 2 which will
exclude many biologically important genes but was chosen to limit the number
of genes to manageable levels.
5.4.2.3 Level of statistical significance
Despite correction for multiple hypothesis testing being performed as part of
the microarray data analysis, some of the gene expression differences will not
be real alterations. Using a p value of 0.05 will still result in 5% of the genes
being falsely identified as different between groups. The stronger the
statistical significance in fold change, the more likely the difference is not
related to chance.
5.4.2.4 Overlap of gene expression between benign and
malignant groups
The gene expression plots generated by the microarray analysis software
(gene plots) provide a visual display of gene expression for each sample in
each group as well as displaying the mean level for each group. Some genes
have no overlap in expression between cancers and benign samples raising
the possibility that protein levels will similarly be altered in such a way that a
definite positive and negative result may be possible. Other genes have
significant differences between groups but each group may have a wide
variation in expression level and overlap with the other group. This is more
likely to result in wide spread and overlap in protein expression such as that
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seen with CA19-9. In addition to the overlap, small variations in expression
within a group are likely to be more reliable than those with a large variation in
expression.
Figure 41 Examples of gene expression plots derived from Affymetrix U133 Plus 2.0
microarray analysis of biliary RNA from patients with benign (n=4) and malignant (n=6)
disease, showing significantly different (p<0.05) expression of: A&B) two genes
already reported to be up-regulated in BTC (MYC & MUC4), and C&D) two potential
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novel biomarkers with no overlap between benign and malignant disease (CD9 &
HOXA10)
5.4.2.5 Genes already identified as biomarkers in other
cancers
It is possible that genes listed in our data have already been identified as
biomarkers in other cancers but not yet assessed in hepatobiliary disease.
Depending on their accuracy in other cancers, they may represent suitable
candidate genes for testing in BTC.
5.4.2.6 Biological plausibility
Many genes are immediately recognised as genes important in cancer biology
such as control of DNA replication, angiogenesis, cell motility etc. Others are
less obvious as genes of interest but literature and database searches often
identify clear cancer links generating further interest in these genes for
biomarker selection. In addition, genes coding for nuclear proteins are less
attractive for bile or serum protein biomarker work as they are less likely than
extracellular matrix proteins to be released from the cell into the clinical
samples of interest.
A tool used to make this aspect of the work simpler is software that groups
genes into functions, cellular location, cellular pathways etc. This allows
identification of genes encoding proteins that may be more likely to be
released into the circulation for biomarker use, e.g. extracellular matrix
proteins. The software used for this project was the GeneGo MetaCore
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software (GeneGo, USA) in use by colleagues at CRUK (Dr Charles
Swanton). The data listed in Figure 42 are lists of general cellular functions or
pathways most commonly altered in our microarray data without the specific
genes listed. This may be helpful in order to plan future translational in vitro
experiments using BTC cell lines to further investigate pathways of interest in
BTC. Table 14 below is an abbreviated list of specific genes upregulated in
BTC as identified by cellular location using this MetaCore software. We
concentrated on genes related to secretory pathways, extracellular matrix, cell
membranes and adhesion proteins in order to concentrate on genes or protein
products more likely to be idenitifable for biomarker development using
simpler biologic fluids such as serum or bile. The location of the protein
product of the genes of interest was one of the factors used to draw up the
later shortlist of genes for further testing by qPCR.
The MetaCore software also generates maps for cellular pathways of interest
with genes identified as being up- or down-regulated marked on the map.
Examples of the gene grouping and pathways generated for common cell
adhesion and EGFR signialling pathways are shown in Figures 42 . The cell
adhesion pathway was chosen for similar reasons as outlined above- i.e we
hypothesised that cell membrane or secreted proteins are more likely to be
identifiable in serum samples than intracellular proteins for biomarker
development. The EGFR pathway is shown as this pathway has previously
been reported as activated and potentially implicated in the pathogenesis of
BTC as well as being a potential pathway for therapeutic interventions using
EGFR inhibitors (Kiguchi, Ruffino et al. 2005; Wise, Pilanthananond et al.
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2008; Wang, Maass et al. 2009; Gruenberger, Schueller et al. 2010). Of
particular interest for future biological investigation might be whether multiple
genes with direct links to one another are identified as altered within the same
pathway rather than random, potentially unconected alterations within
pathways which may conceivable be due to chance alone. However, to
generate such information would likely require larger sample sizes and
addition of down-regulated genes in the same pathway maps as upregulation
of one gene may result in downregulation of genes downstream in the
pathway via other homeostatic mechanisms. Our pathway maps only show
upregulated genes (>2 fold change) with a view to potential biomarker work
but could in the future be revised and re-formated so show additional down-
regulate genes.
178
Figure 42 MetaCore software groupings of commonest pathways and gene locations of
up-regulated genes in BTC
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Figure 43 MetaCore software-generated EGFR and cell adhesion pathways with up-
regulated genes marked (white mark with red band)
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Table 14 Genes up-regulated in BTC categorised by cellular location (excludes nuclear
location)
ECM
proteinaceo
us ECM
Anchoring
collagen
Basement
membrane
Cell
surface
Extracellul
ar region 1
Extracellula
r region 2
Secretory
granule
membrane
COL27A1 COL27A1 COL16A1 Osteonectin PKHD1 HS6ST2 GALNT2 ICA69
Osteonectin Osteonectin Endostatin LAMC2 MFGE8 Gpr172b Endostatin Rab-27A
COL4A2 COL4A2 COL6A3 COL4A2 OATP-D MSP MXRA5
BPAG2 BPAG2 COL9A2 LAMA5 ITGAMPuromycin-sensitive aminopeptidaseNectin-4
LAMA5 LAMA5 CFDP1 IL17BR NAP-2 Oct-3/4
COL1A1 PGAR ACES CD28 Ephrin-A CD9
Endostatin CSPG4 (NG2) VEGF-A IRAK2 OSCAR Thrombospondin 1
VEGF-A COL1A1 Endostatin CSPG4 (NG2) IL18RAP SC1
LAMC2 TGM2 CD43 ITGAX CLMP Activin beta A
Oct-3/4 Endostatin Calreticulin Beta-2-M PGES
SC1 VEGF-A CX3CL1 COL1A1 COL9A2
COL9A2 COCH HNRPU (SAF-A) VEGF-A Activin
COL6A3 Calreticulin PLAUR (uPAR) KRTCAP2 PAPLN
Tapasin LAMC2 ACES Ephrin-A1 Tapasin
COL16A1 Oct-3/4 IL-2R gamma chain LONRF3 ACES
Mucin 5AC SC1 CD22 LIF CEACAM3
ACES COL6A3 ICAM1 LISCH7 PLAU (UPA)
Lumican COL9A2 CD43 Mucin 4papilin, proteoglycan-like sulfated glycoprotein
CFDP1 Mucin 4 PILRA LILRA5
CD43 Cyr61 Cyr61 Ppif
PAPLN COL16A1 Granzyme B
Mucin 5AC MAGGABA-A receptor epsilon subunit
COL16A1 DHRS13 PC7
Tapasin CFDP1 STS
ACES CARD5 Alpha-defensin
MMP-2 IRAKM MFGE8
CFDP1 C1orf56 Osteonectin
Lumican ATR/TEM8 COL27A1
papilin, proteoglycan-like sulfated glycoprotein SERPINA3 (ACT) IDS
CD43 FUT6 CEACAM1
P-cadherin IL17BR
Semaphorin 4C Fetuin-A
PAP39 Fibrosin
LAMA5 Alpha-defensin 3
PGAR C1r
Ceruloplasmin Neuromedin U
TNFAIP2 GRO-2
CSPG4 (NG2) CNIH3
GZMH SRPUL
ENA-78 Collagen IV
TGM2 LAMC2
NPEPPS SIAT4B
COCH Fc gamma RII alpha
Calreticulin NOTCH3
CRISPLD2 PDK1
CX3CL1 CD47
PLOD3 Lumican
PLAUR (uPAR) COPA
TRSC 1CLN2 (Tripeptidyl-peptidase I)
ITIH5 PCDHB16
COL6A3 CD22
CELSR1 CD43
Furin BPAG2
GLVR1 COL4A2
Mucin 5AC ATP6V0A2
CD109 Alpha-defensin 1
MMP-2 Activin A
Calgizzarin
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5.4.3 Shortlist of genes for further validation using
TaqMan arrays
The shortlist drawn up of candidate genes for validation using qPCR on the
TaqMan arrays (n=128) contained a selection of the 1,140 up-regulated and
1,001 down-regulated genes identified by microarray (Table 15). Examples of
reasons for inclusion are given in the following categories:
5.4.3.1 Ubiquitous constitutively expressed genes for
normalisation and quantification of qPCR data
The genes chosen for this use were Glyceraldehyde 3-phosphate
dehydrogenase [GAPDH], 18S ribosomal RNA, [18SRNA], -actin [ACTB]
and beta glucuronidase [GUSB].
5.4.3.2 Biomarkers already reported to be related to BTC
These included mucin 4 [MUC4], mucin 5AC [MUC5AC], myc oncogene [c-
MYC], minichromosome maintenance protein 4 [MCM4], mitogen-activated
kinase 1[MAPK1] and HOX genes.
5.4.3.3 Genes with very high increased fold change in cancers
These included paraneoplastic antigen A2 [PNMA2] (x39), matrix remodelling
associated 5 [MXRA5] (x24), inter alpha inhibitor 5 [ITIH5] (x20), serpin
182
peptidase inhibitor clade A [SERPINA3] (x40), collagen 171 [BPAG2] (x16)
and CD9 (x19).
5.4.3.4 Genes with no overlap expression in cancers compared
to benign as seen with the gene plot graphs
These included CD9, integrin B8 [ITGB8], vascular endothelial growth factor A
[VEGFA], carcinoembryonic antigen cell adhesion molecule 1 [CEACAM1],
inter alpha inhibitor 5 [ITIH5], platelet endothelial aggregation receptor 1
[PEAR1], aspartate beta hydroxylase [ASPHD1], homeobox A10 and B6
[HOXA10 & HOXB6] and craniofacial development protein1 [CFDP1].
5.4.3.5 Genes identified as tumour markers in other cancers
Examples include matrix remodelling associated 5 [MXRA5], paraneoplastic
antigen A2 [PNMA2] in colorectal cancer, [RAD51] in pancreatic cancer,
anthrax receptor toxin 1 [ANTXR1] in colorectal cancer, mitogen-activated
kinase 1 [MAPK1] in many adenocarcinomas, IL18 receptor accessory protein
[IL18RAP] in adenocarcinomas and carcinoembryonic antigen cell adhesion
molecule 1 [CEACAM1] in many other adenocarcinomas.
5.4.3.6 Genes related to tumour biology
Examples include the homeobox genes that control cell proliferation and
development, notch signalling genes, protein kinases [MAPK1, PRKCB1,
PTK2, TNFAIP2, CSPG4], minichromosome maintenance proteins [MCM4],
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angiogenesis [VEGFA], matrix remodelling genes [MXRA5, MMP2, CSPG4],
oncogenes [cMYC, KRAS, PVT1], and genes involved in cell adhesion and
motility [CEACAM1, ITGB8, MUC4, CD9] .
5.4.3.7 Down-regulated genes
Only a small number of genes were included in this group: mastermind like 3
[MAML3], Sel-1 suppressor of lin 12 [SEL1L], tumour suppressor homolog 3
[FAT3] and KRAS.
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Table 15. Genes identified in microarray data for consideration of further validation
using qPCR. Most genes in black were selected for further investigation; those in grey
were not further assessed. In the notes column, overlap in gene expression plots
refers to the results presented in the microarray gene plot graphs.
Gene Name FoldChange P Function Notes
Up-regulated genes
MUC4 Mucin 4 3.2 0.025 Glycoprotein
Extracellular space, reported in BTC, some
overlap in gene plots. TaqMan amplicon
length 55bp
MUC5AC Mucin 5AC 3.6 0.033 Glycoprotein Extracellular space, reported in BTC, someoverlap in gene plots
CD9 CD9 19 0.0001 Cell surfaceprotein
Cell adhesion & motility, no overlap in gene
expression plots. TaqMan amplicon 72
LUM Lumican 11 0.001 ECM protein
Collagen binding, visual perception, No
overlap in gene
expression plots. TaqMan amplicon 107
MAML2 Mastermind like -2 3.5 0.00085 Notch signalling
Notch signalling, nuclear, control of
transcription, no overlap in gene expression
plots. TaqMan amplicon 84
PMPFIB
P1
PTPRF intercting
protein binding protein
1
2.6 0.010 Cell adhesion
S100A4 interaction, tumour invasiveness,
axonal growth, little overlap in gene
expression plots
ITGB8 Integrin B8 2.7 0.0011 Cell adhesion Cell adhesion, no overlap in gene expressionplots. TaqMan amplicon 64
VEGFA Vascular endothelialgrowth factor A 2.5 0.001
VEGF, cell
adhesion
VEGF, cell adhesion, cancer, no overlap in
gene plots. TaqMan amplicon 63
PNMA2 Paraneoplasticantigen a2 39 0.002 Nucleus
Nuclear protein, function not clear. Found in
serum in testicular and neuronal cancer,
some overlap in gene plots. TaqMan
amplicon 60
CEACA
M1
Carcinoembryonic
antigen cell adhesion
molecule 1 (biliary
glycoprotein)
3.5 0.0025 Cell adhesion Cell adhesion, angiogenesis, cell motility. Nooverlap in gene plots. TaqMan amplicon 78
MXRA5 Matrix remodellingassociated 5 24 0.007 Cell adhesion
Extracellular binding, overlap in gene
expression plots, up regulated in colon
cancer, function unknown. TaqMan amplicon
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THBS1 Thrombospondin 1 4.6 0.0084 Cell motility, celladhesion
Cell adhesion, protein binding, TGF B
signalling, Little expression overlap,
HOXA10 Homeobox A10 24 0.00011
DNA
transcription
factor
Nuclear, DNA transcription, no overlap in
gene expression plots. TaqMan amplicon 52
HOXB6 Homeobox B6 20 0.00023
Development
and cell division
Nuclear transcription, no overlap in gene
plots TaqMan Amplicon 73
ITIH5 Inter alpha (globulin)inhibitor H5 20 0.0008
Hyaluronan
metabolism
Serine endopeptidase inhibitor activity, No
overlap in gene plots, ABI amplicon 67
PEAR1
Platelet endothelial
aggregation receptor
1
10.3 0.0017 Plateletaggregation
Membrane protein, No overlap in gene plots.
TaqMan amplicon 66
RAPGEF
3
Rap guanine
nucleotide exchange
factor 3
10.2 0.0024
Cell proliferation,
GTPase,
leukocyte
migration
Membrane protein, no overlap in gene plots
ASPHD1
Aspartate beta
hydroxylase domain
1
10 0.0033 Peptidyl aminocid modification
Endoplasmic reticulum, no overlap in gene
expression plots. TaqMan amplicon 62
TGFBI/1 TGF B inducedtranscript 1 12.3 0.003
Cell adhesion,
Cell
differentiation
Wnt signalling, cell adhesion, RNA
polymerase promoter, tight junctions, No
overlap in gene plots. TaqMan amplicon 70
TM4SF1
8
Transmembrane 4 L
six family member 18 10.9 0.0042
Membrane
protein
Membrane protein. Function unknown, little
overlap in gene plots. TaqMan amplicon 70
PVT1 PVT oncogenehomolog 11 0.0055
Function
unknown
Function unknown. Little overlap in gene
plots. TaqMan amplicon 111
LEF1 Lymphoid enhancerbinding factor 1 15 0.0069
Developmental
biology, RNA
polymerase II
promoter,
Wnt signalling, DNA binding, multiple cancer
reports, little overlap in gene plots. TaqMan
amplicon 60
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LILRA2 Leukocyte Ig likereceptor 2 11.5 0.0082
Antigen
response
Cell membrane, signal transduction, antigen
binding, little overlap in gene plots
PAPLN
Papilin, proteoglycan-
like sulphated
glycoprotein
2.8 0.020 Metallopeptidase Proteinacious ECM , overlap in gene plots
CFDP1 Craniofacialdevelopment protein 1 5.3 0.0005 Cell adhesion
Proteinacious ECM, anti-apoptosis, no
expression overlap. TaqMan amplicon 63
MMP-2 Matrixmetallopeptidase 2 2.6 0.020
Matrix
metallopeptidase
Proteinacious ECM, collagenase, some
overlap in gene plots. TaqMan amplicon 65
COL16A
1 Collagen 16 2.5 0.017 Cell adhesion Proteinacious ECM, overlap in gene plots
SPARC
Osteonectin
(Secreted protein,
acidic rich)
7.1 0.004 Kinase signalling
Proteinacious ECM, collagen binding, kinase
signalling, ossification, little overlap in gene
plots. TaqMan amplicon 76
Cyr61 Cystein richangiogenic inducer 61 3.2 0.03
Cell growth &
adhesion
Proteinacious ECM, cell proliferation, overlap
in gene plots
COL6A3 Collagen 6 a3 8.8 0.003 Cell adhesion Proteinacious ECM, cell communication, littleoverlap in gene plots
TCF19
(SC1)
Transcription factor
19 2.2 0.023
Transcription,
cell proliferation
Proteinacious ECM. significant overlap in
gene plots
POU5F1
(Oct-3/4)
POU class 5
homeobox 1 3.3 0.0018
Regulation of
transcription
Proteinacious ECM, no overlap in gene
expression plots, reports in cancers, Stem
cell marker? TaqMan amplicon 77
CALR Calreticulin 2 0.026 apoptosis
Proteinacious ECM, gene expression overlap
in gene plots Antigen presentation, control of
proliferation and apoptosis
COCH Coagulation factor C 6.1 0.012
Sensory
perception of
sound
Proteinacious ECM, function unknown, some
overlap in gene plots
TGM2 Transglutaminase 2 3 0.016 Cell adhesion,apoptosis
Proteinacious ECM, NF kappa B signalling,
blood vessel remodelling, some overlap in
gene plots
LAMC2 Laminin gamma 2 2.5 0.005 Cell adhesion
Proteinacious ECM , ECM signalling, cell
adhesion, development, no overlap in gene
plots. TaqMan amplicon 79
LAMA5 Laminin alpha 5 2.33 0.021 Cell adhesion,development
ECM communication and cell adhesion,
Proteinacious ECM, overlap in gene plots
COL18A
1 Endostatin 2.8 0.014
Anti-
angiogenesis,
cell adhesion
Endogenous inhibitor of angiogenesis. ,
development, Proteinacious ECM, overlap in
gene plots
ICA1 Islet cell autoantigen1 2.1 0.030 Golgi membrane Secretary granule, overlap in gene plots
RAB27A Ras oncogene family 2.5 0.019 RAS oncogene
GTPase activity, protein transport, Secretory
granule, little overlap in gene plots. TaqMan
amplicon 121
TAPBP Tapasin 2.14 0.037 Antigenprocessing,
Cell surface, retrograde endosome transport,
protein complex assembly, little ovelap in
gene plots
MFGE8 Milk fat globule EGFfactor 8 7.5 0.009 Cell adhesion Cell surface, some overlap in gene plots
PKHD1 Polycystic kidney andhepatic disease 1 2 00.025 Cell adhesion
Cell surface. No overlap in gene plots,
negative effects cell motility. Haemostasis
ITGAM Integrin alpha m,complement subunit 2.9 0.019
Cell adhesion,
cell motility
Cell surface, effects on actin cytoskeleton,
cell motility, some overlap in gene plots
ICAM1 Intercellular celladhesion molecule 1 3.6 0.037 Cell adhesion
Cell surface, cell adhesion, NK cell mediated
killing, trans endothelial cell migration, wide
overlap
CD22 8.2 0.02 Cell adhesion Cell surface, plasma membrane, no overlapexpression, mostly B lymphocytes
IL2RG IL-2R gamma chain 10 0.024 Cell membranesignalling
Cell surface, jak-stat signalling, immune
responses, wide overlap in expression
PLAUR
(uPAR)
Plasminogen activator
urokinase receptor 3.1 0.009
Cell motility,
complement and
coagulation
cascades
Cell surface, Cell motility, complement and
coagulation cascades, some spread within
groups in gene plots
CD28 CD28 3.3 0.038 T cell activation
Cell surface, T cell proliferation, anti-
apoptosis, cytokine synthesis, wide overlap
in expression plots
IL17RB IL17 receptor B 2.3 0.004 Cytokineresponse
Cell surface, cytokine to cytokine
interactions, activation of immunocytes, little
overlap in gene plots
IRAK2 IL1 receptor kinase 2 3.4 0.006 apoptosis Cell surface, kinase signalling, NFKB
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pathway, apoptosis, inflammatory response,
little overlap in gene plots
CSPG4
(NG2)
Chondroitin sulphate
proteoglycan 8.5 0.018 Angiogenesis
Cell surface, Angiogenesis, cell motility, cell
differentiation, development, tissue
remodelling, protein tyrosine kinase, Some
overlap in gene plots. TaqMan amplicon 113
ITGAX
Integrin alpha x
(complement
component)
4.8 0.002 Cell adhesion Cell surface, cell adhesion, integrin mediatedsignalling, No overlap in gene plots
CX3CL1 Chemokine ligand 1 5.4 0.022 Cell adhesion
Cell surface, leukocyte activation and
adhesion, cytokine receptor interactions,
some overlap in gene plots
HNRNP
U (SAF-
A)
Heterogeneous
ribonuclear protein 2.03 0.021
mRNA
processing
Cell surface, significant overlap in gene
expression plots
PRKCB1 Protein kinase C beta1 8.3 0.014
Protein kinase
phosphorylation
Protein kinase and VEGF signalling, EGFR
pathway, some overlap in gene plots.
TaqMan amplicon 68
PTK2 Protein tyrosinekinase 2 3 0.03
ERBB2 binding
and activation
Cell membrane, intracellular, EGFR, no
overlap in gene plots benign/CC. TaqMan
amplicon 68
cMYC Myc oncogene 2.7 0.028 Cell proliferation,cell cycle arrest,
Regulation of transcription, jak-stat signalling,
wnt signalling, TGFb signalling, cancers++,
some overlap of gene plots. TaqMan
amplicon 65
MFGE8 milk fat globulin EGFfactor 8 7.5 0.009 Cell adhesion
Cell adhesion, some overlap in gene
expression plots
LIF Leukaemia inhibitoryfactor 4.7 0.0012
Jak-stat
signalling
ECM, PK pathways, cell proliferation, no
overlap in gene plots, biomarker in other
cancers. TaqMan amplicon 66
UBE2D3
(MAG)
Ubiquitin-conjugating
enzyme E2D 3 2.1 0.026 Ubiquitin cycle
Ubiquitin mediated proteolysis, some
overlap in gene plots
Ephrin-
A1 Ephrin A1 2.4 0.03 Axon guidance
Cell membrane, Cell signalling, significant
overlap in gene plots
IRAKM Interleukin receptorkinase 3 5 0.009 apoptosis
Cytokine and chemokine signalling,
apoptosis, some overlap in gene plots
ANTXR1 Anthrax toxin receptor1 3.5 0.012
Membrane
receptor
Tumour specific endothelial marker in
colorectal cancer, some overlap in gene plots
SERPIN
A3 (ACT)
Serpin peptidase
inhibitor clade A 37.8 0.012
Acute phase
response
DNA binding, inflammation, regulation of lipid
metabolism, some overlap of gene plots.
TaqMan amplicon 70
HS6ST2 Heparin sulphatesulphotransferase 2 3.1 0.029
Heparin sulphate
biosynthesis
Cell membrane, significant overlap in gene
plots
Gpr172b G protein receptor172b 2.7 0.002
Membrane
receptor Cell membrane, no overlap in plots
PPBP
(NAP-2)
Pro-platelet basic
protein 9.3 0.010 Chemotaxis
Cell proliferation, ECM, some overlap in gene
plots
OSCAR Osteoclast associatedIg-like receptor 2.4 0.002
Plasma
membrane
receptor
Plasma membrane receptor, osteoclast
differentiation, presentation to dendritic cells,
no overlap in gene plots
IL18RAP IL18 receptoraccessory protein 6.6 0.0004
Cell membrane
receptor
Inflammatory response, no overlap in gene
plots, expressed in some epithelial cancers
ASAM
(CLMP)
Adipocyte specific
adhesion molecule 3.1 0.026
Tight junction
protein
Tight junction, significant overlap of gene
plots
B2M Beta-2-microglobulin 2.4 0.007 Membranereceptor
Antigen processing and presentation, little
overlap in gene plots
KRTCAP
2
Keratinocyte
associated protein 2 2.1 0.02
Cell membrane
protein
Oligosaccharyl transferase complex, some
overlap
CELSR1
Cadherin, EGF LAG
seven pass G type
receptor 1
5.2 0.004 Cell membraneprotein
G protein activity, cellular polarity, neural
tube closure, development, protein
dimerisation, no overlap in gene plots.
TaqMan amplicon 99
SPRY4 Sprouty homolog 4 3.5 0.004 Cell membrane Development, signal transduction, jak-statsignalling, some overlap in gene plots
CDH3 Cadherin 3 type 1,placental (p-cadherin) 6 0.012 Cell adhesion
Cell adhesion, some overlap in gene
expression plots
NPEPPS Aminopeptidasepuromycin sensitive 2.1 0.022 proteolysis
Aminopeptidase, metalloproteinase, some
overlap in gene expression plots
GZMH Granzyme H(cathepsin G like 2) 6.6 0.025 cytoplasm
Apoptosis, serine endopeptidase activity,
some overlap in gene plots.
TNFAIP2 TNF, alpha-inducedprotein-2 2.8 0.018
Extracellular
space
Angiogenesis, development, cell
differentiation, Little overlap in gene plots
ANGPTL Angiopoeitin like 4 4.2 0.033 Extracellular Angiogenesis, cell differentiation,
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4 space development, response to hypoxia, PPAR
pathway, some overlap in gene plots
PRPSAP
1
(PAP39)
Phosphatidyl
pyrophosphate
synthetase-
associated 1
2.3 0.019 Nuclear protein Nucleic acid metabolism/ synthesis, enzymeinhibitor, significant overlap in gene plots
PGES Prostaglandin Esynthase 5.3 0.028
Arachidonic acid
metabolism Significant expression overlap in gene plots
INHBA Activin beta A, inhibinbeta A 3.86 0.031 Cell proliferation
Cell proliferation and differentiation,
significant overlap in gene expression plots
SC1 Transcription factor19 2.22 0.020 Cell proliferation
Regulation of transcription from RNA, overlap
in gene plots
ATP6V0
A2
Lysosomal H
transporting subunit
V0 a2
10 0.0010 ATPase, protonpump
Membrane protein, Proton pump, epithelial
cell signalling, No overlap in gene expression
plots. TaqMan amplicon 58
PCDHB1
6 Protocadherin beta 16 2.4 0.016 Cell adhesion Cell adhesion, some overlap in gene plots
CLN2
(TPP1) Tripeptidyl-peptidase I 2 0.01 Tripeptidyl-peptidase I
S100A11 Calgizzarin 2.6 0.02
S100A11
calcium binding
protein
Signal transduction
SLC20A
1
(GLVR1)
Solute carrier family
20 (phosphate
transporter) member
1
2.4 0.019 Plasmamembrane
Phosphate metabolism, positive regulation of
I kappa B pathway, some overlap in gene
plots
FURIN
Furin (paired basic
amino acid cleaving
enzyme)
2.9 0.033 Plasmamembrane
Golgi peptise synthesis and transport, furin
activity, calcium binding, cell-cell signalling,
overlap in gen plots
PLOD3
Procollagen-lysine, 2-
oxoglutarate 5-
dioxygenase 3
2.7 0.009
Endoplasmic
reticulum,
protein
modification
ER protein modification, procollagen
alteration, metal ion binding, virtually no
overlap in gene plots
STS
Steroid sulfatase
(microsomal isozyme
S
2.1 0.020
Plasma
membrane,
Androgen and
oestrogen
metabolism
ER, microsomes, lipid, androgen, oestrogen
metabolism, calcium binding and hydrolase
activity, some overlap in gene plots
GZMB Granzyme B 2.3 0.03 cytoplasm
NK cell killing, proteolysis, apoptosis,
cleavage of lysine, some overlap in gene
plots
GABRE GABA-A receptorepsilon subunit 3.4 0.003 GABA signalling
GABA signalling, very little overlap in gene
plots
PCSK7 Proprotein convertasesubtilisin /kexin type 7 2.3 0.010 Cell membrane Proteolysis, ,golgi, no overlap
Ppif
Peptidylproolyl
isomerase F
(cyclophilin F)
2.6 0.010 mitochondria Protein folding, iosomerase activity, someoverlap in gene plots
CEACA
M3
Carcinoembryonic
antigen cell adhesion
molecule 3
3.1 0.029 Cell membrane Cell adhesion, signifiacant overlap
SEMA4C Semaphorin 4C 2 0.018 Cell membranereceptor
Cell differentiation, development, axon
guidance, no overlap in gene plots
COPA Coatomer proteincomplex subunit a 4.7 0.010
ER, Golgi,
protein folding
Protein folding, vesicles, ER, Golgi, some
overlap in gene plots
PDK1
Pyruvate
dehydrogenase
kinase 1
2 0.014 T cell receptorsignalling
Carbohydrate & glucose metabolism,
mitochondrial protein, little overlap in gene
plots
NOTCH3 Notch homolog 3 6 0.022
Plasma
membrane,
Notch signalling
Development, regulation of transcription, cell
differentiation, some overlap in gene plots.
TaqMan amplicon 87
CNIH3 Cornichon homolog 3 2 0.022 Intracellularsignalling
Membrane protein, some overlap in gene
plots
CXCL2
(GRO-2)
Chemokine (CXC
motif) ligand 2 or Gro
2 oncogene
4.7 0.028 chemotaxis
Chemokine cytokine interaction, g protein
signalling, extracellular space, some overlap
in gene plots
NMU Neuromedin U 3.6 0.024 Smooth musclecontraction
Extracellular space, neuropeptide signalling,
muscle contraction, some overlap in gene
plots
C1r
Complement
component 1 r
subcomponent
2.2 0.018 complement Complement and coagulation cascade, ECMmatrix, little overlap in gene plots
FBRS Fibrosin 2.4 0.039 ? ? significant overlap in gene plots
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IDS Iduroniate 2 sulfatase 2.3 0.02 Glycosaminoglycan degradation
Hunters syndrome, ER location, overlap in
gene plots
COL4A2 Collagen type IV,alpha 2 2.4 0.014 Cell adhesion
Proteinacious ECM, cell adhesion and
communication, ECM receptor interaction, no
overlap in gene plots
COL1A1 Collagen type 1 a1 7.2 0.00049 Cell adhesion
Proteinacious ECM, no overlap in gene plots.
TaqMan amplicon 66
COL9A2 Collagen type IX,alpha 2 2.1 0.025
Skeletal
development Some overlap in gene plots
COL16A
1 Collagen XVI alpha1 2.4 0.017 Cell adhesion
ECM protein, integrin signalling, overlap in
gene plots
BPAG2
(COL17A
1)
Collagen 17 a1 16 0.019 Cell adhesion
Proteinacious ECM, cell adhesion, cell
communication, wide variation in cancer
samples. TaqMan amplicon 64
COL27A
1 Collagen 27, alpha 1 2.2 0.024 Cell adhesion Proteinacious ECM, overlap in gene plots
CTNND1
Catenin (cadherin
associated protein)
delta 1
3.4 0.005
Transcription,
cell adhesion,
adherens
junction
Wnt signalling, cell-cell adhesion, regulation
of transcription, leukocyte trans endothelial
migration, almost no overlap in gene plots
MCM4
Minichromosome
maintenance complex
4
2.2 0.03 Control of DNAreplication
DNA replication, nuclear protein, overlap in
plots, identified in BTC cell line microarray
data also, TaqMan amplicon 90
MAPK1 Mitogen-activatedprotein kinase 1 2.35 0.010
MAPK signalling,
apoptosis, cell
cycle
MAPK signalling, apoptosis, cell cycle,
chemotaxis, response to DNA damage,
VEGF signalling, TGF signalling, reports in
cancer including CC, pancreas. No overlap in
gene plots. TaqMan amplicon 74
RAD51 RAD51 homolog 4.3 0.03 DNA repair Some overlap, data in pancreatic cancer.TaqMan amplicon 58
NCSTN Nicastrin 3.4 0.004 proteolysis Notch signalling, no overlap in gene plots.TaqMan amplicon 69
STAT1
Signal transducer and
activation of
transcription 1
2.5 0.002 DNAtranscription
JAK-STAT signalling, nuclear protein, no
overlap in gene plots. TaqMan amplicon
length 67
TRIB2 Tribbles homolog 2 4.3 0.001 MAPK
MAPK, protein phosphorylation, cytoplasm,
no overlap in gene plots. TaqMan amplicon
length 60
LYST Lysosomal traffickingregulator 3.7 0.003
Endosome
transport
Microtubule function, endosomes, cellular
defence responses, no overlap in gene plots.
Gene defect of Chediak Higashi disease
HDAC9 Histone deacetylasecomplex 9 2.3 0.019
DNA
transcription
DNA replication, development, inflammatory
response, some overlap in gene plots,
HDAC2 key in HCC
Down-regulated genes
FAT3 Tumour suppressorhomolog 3 -8.8 0.014 Cell adhesion Calcium binding, some overlap in gene plots
SEL1L Sel-1 suppressor oflin12 -7.5 0.011 Notch signalling
Membrane and ER protein, notch signalling,
wide spread in cancer but little overlap in
gene plots
KRAS KRAS -2.5 0.013 MAPK signalling
GTPase, development, NK cell killing,
cancer, some overlap in gene plots. TaqMan
amplicon 109
MAML3 Mastermind like 3 -8.5 0.007 Notch signalling Large variation on cancers on gene plots.TaqMan amplicon 104
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5.5 Conclusions
In this chapter we demonstrate that it is possible to gain useful whole genome
gene expression data from RNA isolated from biliary brushings. Evaluation of
the genes with significant fold change in gene expression identifies many of
the genes already noted to be altered in BTC as well as many that may be
useful for the identification of novel biomarkers for BTC. Confirmation of gene
expression profiles using an alternative method such as qPCR is required
prior to testing protein expression of the candidate genes.
Our data also justify further investigation using a larger sample size in order to
identify a gene signature diagnostic of cancer in biliary brushings or to use
similar methodology in order to investigate the biology of disease progression
and development of cholangiocarcinoma in patients with PSC.
5.6 Discussion
Despite the encouraging results from our microarray data, the possibility that
results represent a high level of false positivity remains. The first broad cause
is methodological. The degraded nature of the RNA, small samples size and
very large number of genes analysed has the potential for introducing
significant variation by chance alone. RNA degradation is outside of our
control. Sample size is dependent on availability of samples and cost, which
are the primary limiting factors. Statistical error is controlled for as best as
possible using statistical methods designed to reduce this error to minimal
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levels. Correction for small sample size and multiple hypothesis testing were
used in our methodology.
The second significant source of potential error is the presence of
confounding mRNA from other cell types including leukocytes, red cells and
fibroblasts. Other studies have compared surgical resection tissue to normal
liver which introduces significant bias in the predominance of hepatocytes in
the control arm and cancer cells and stromal tissue in the other. Our samples
were similar clinical samples from both malignant and benign groups and
should reduce this error by having more similar quantities of epithelial and
fibroblastic cells in each group. A major source of potential confounding
material is leukocytes in obstructed, non sterile bile ducts. Comparison of
cytology and clinical details (including evidence of overt cholangitis), does not
suggest a difference between benign and malignant groups. In addition,
leukocyte specific genes were not differentially expressed in either group
providing strong evidence against a significant leukocyte confounding effect.
Also, our experiments validating the RNA methodology in chapter 4 show that
RNA is predominantly epithelial cell in origin and that leukocytes have a
relatively small contribution to the overall mRNA pool. All samples must have
included RNA from non epithelial cell sources but the assumption is that
similar amounts of such RNA are found in both groups and the effect is
therefore cancelled out during data analysis.
Analysis of our data has shown a number of genes noted to be important in
cancer biology and in particular, the biology of BTC. This is also very
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encouraging and strongly suggests that the data is accurate. Many of these
genes are genes that are easily identifiable as having functions related to
cancer biology such as cell replication, adhesion and motility. However, such
genes are likely to be non specific for BTC although may be useful biomarkers
of cancers in general. It is also likely that the specificity of such genes will be
reduced by the presence of other actively replicating cells such as leukocytes
in infection or inflammatory disease. It may be that the most useful protein
biomarkers will be derived from unusual or unexpected proteins found to be
up-regulated and such genes should therefore be included in the search, even
if they appear bizarre. However, other, more predictable genes, may be useful
tests when combined as customised gene expression arrays and are
therefore included in the next stage of the project.
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Chapter 6.
6 Validation of gene expression profile
using real time quantitative PCR
6.1 Background
Microarray analysis generates huge amounts of data that are too large to be
analysed individually to screen for technical or reading errors. Also, the sheer
volume of data carries the potential for a significant number of false positive
results, even after correction for multiple hypothesis testing. As a result, using
a significance value of 5%, we would expect at least 57 of the 1140 up-
regulated genes to be related to chance and not a feature of BTC. False
positive results may be minimised by larger samples sizes and using a stricter
p value cut-off of <1% or 0.1%, but require further testing using alternative
methods of measuring gene expression.
Real time quantitative PCR (qPCR) is a well established technique used to
validate patterns of gene expression in microarray studies. The methods used
for qPCR are accurate and reliable and represent an alternative method to
microarray for quantification and validating gene expression. However, qPCR
has a number of disadvantages including:
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1. It is relatively time consuming to assess multiple genes in multiple
samples, despite advances in commercial kits and data analysis
software.
2. Relatively large quantities of input RNA are required. Each standard
qPCR reaction uses approximately 5-10ng of input RNA converted 1:1
to cDNA. When using duplicates and assessing multiple genes, low
RNA yield materials such as biliary brushings can only be assessed for
a limited number of genes (approximately 30 for our RNA samples).
3. Large numbers of separate experiments become costly.
4. Each PCR primer set used requires testing for specificity of target
mRNA, especially when using the SYBR Green method or using non
commercially available primer sequences.
5. Primer sets may amplify genomic DNA in addition to mRNA resulting
in an over-estimate of gene expression and inaccurate results. This
can be minimised by confirming absence of genomic DNA in the
samples using reverse transcriptase negative (RT-) controls that are
tested separately, or by using primer pairs designed to span two
separate exons and avoid non specific genomic intron DNA
amplification.
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6.1.1 Part 1: The use of TaqMan Arrays for multiple
gene qPCR
In order to overcome some of difficulties of individual gene qPCR, one can
use commercially available customised qPCR arrays that assess multiple
gene expression by Taq polymerase qPCR from a relatively small amount of
input cDNA mastermix. At present, the main available assay is the TaqMan
Array® (formerly TaqMan Low Density Array® [TLDA]) manufactured by
Applied Biosystems Inc (Austin, TX, USA). The use of qPCR arrays is a well
established technique for measurement of multiple gene expression for
purposes such as validation of microarray data (Canales, Luo et al. 2006).
Each TaqMan Array (figure 44) has 384 wells per card which can be
customised to include Taq polymerase qPCR primer sets for most genes of
interest. In addition to target genes to be measured, the assay requires at
least one (recommended 2 to 4) reference ‘house keeping’ genes (e.g.
GAPDH, 18S rRNA, ACTB) for normalisation. As described in chapter 4,
relative gene expression is calculated using the comparative threshold (Ct)
method.
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Figure 44. Format of the TaqMan Array (Applied Biosystems) used
for qPCR validation. The reservoir provides the cDNA substrate and
PCR mastermix that fill each of the 48 wells by centrifuging.
(Original image from Applied Biosystems)
We used customised TaqMan Array format 48 which included 3 reference
genes and 45 other genes for measurement of gene expression (Table 16).
As discussed in chapter 5, the genes for further assessment were chosen
using a variety of criteria including fold change, p value, biological plausibility,
qPCR amplicon length etc.
Table 16. Genes selected for further analysis using TaqMan Array qPCR.
List of genes for qPCR validation using TaqMan arrays
18S RNA ITGB8 CELSR1 CFDP1 ATP6V0A2 STAT1
GAPDH VEGFA NCSTN MMP-2 PRKCB1 NOTCH3
ACTB PNMA2 ASPHD1 COL6A3 PTK2 COL1A1
MUC4 CEACAM1 TGFBI/1 SPARC cMYC BPAG2
MUC5AC MXRA5 TM4SF18 TRIB2 SERPINA3 SEL1L
CD9 HOXA10 PVT1 LAMC2 LIF MCM4
LUM HOXB6 LEF1 RAB27A RAD51 MAPK1
MAML2 ITIH5 POU5F1 CSPG4 MAML3 KRAS
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6.2 Materials and methods
6.2.1 Clinical samples.
Clinical samples were collected at the time of ERCP as described in Chapter
4. A summary of patient details is shown in Tables 17 and 18.
Table 17. Summary of patient details for microarray sample set.
SOD- sphincter of Oddi dysfunction: CP- chronic pancreatitis
Sample Diagnosis Age Gender
B1 Papillary Stenosis 74 M
B2 SOD 55 F
B3 CBD Stricture (CP) 48 F
Benign
B4 CBD Stricture (CP) 58 M
Mean 59
M1 CC 50 M
M2 CC 64 M
M3 CC 79 F
M4 CC 59 M
Malignant
M5 CC 79 F
Mean 66
Table 18. Fresh sample set used for validation of gene expression using TaqMan Array.
Sample Diagnosis Age Gender
B5 PSC 35 M
B6 CBD Stricture and Stones 65 M
B7 IgG4 Disease 69 M
B8 SOD 38 F
Benign
B9 IgG4 Disease 47 M
Mean 53
M6 CC 79 M
M7 CC 63 M
M8 CC 60 F
M4 CC 59 M
M9 CC 71 F
Malignant
M10 CC 72 M
Mean 67
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6.2.2 RNA isolation, purification and cDNA synthesis.
RNA from the biliary brushings was isolated and purified as described in
chapter 4. cDNA was synthesized using the High Capacity RNA to cDNA
Synthesis Kit (Applied Biosystems Inc, Austin, TX, USA) as per the
manufacturers instructions. cDNA synthesis was performed in 20l volumes
from a template of 150ng total RNA using the reverse transcriptase enzyme
mix for 60mins at 37oC. Reverse transcriptase negative (RT-) controls were
made for the majority of samples where there was potential spare RNA in
order to test for genomic DNA contamination. cDNA samples were stored at -
20oC until further use.
6.2.3 Quantitative real time PCR.
Suitable specialist equipment was initially not available at UCL and so the
TaqMan Array qPCR assays were performed at Cancer Research UK,
Lincolns Inn Fields, by kind invitation and assistance of Dr Charles Swanton
and his PhD student, Alvin Lee. All reactions were carried out as per the
manufacturers instructions using 50l TaqMan Universal PCR Master Mix
(2X) (Applied Biosystems Inc, Austin, TX, USA) and 37.5ng cDNA made up
with water to a total volume of 100l in each fill reservoir. After application of
the mastermix into the fill reservoir, the cards were centrifuged twice for 1 min
each at 2200 rpm to evenly distribute the mastermix into each reaction
chamber. The card was sealed as per the manufacturers instructions and
transferred to a 7900HT Real Time PCR system (Applied Biosystems Inc,
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Austin, TX, USA). Thermal cycling conditions were set at 950C for 10 mins
followed by 40 repeats of 950C for 15s and 600C for 1min.
45 genes (Tables 16 and 19) were tested in duplicate using the same source
RNA used for the microarray analysis (n=9) as well as a second validation set
using RNA isolated from a fresh sample set (n=11). The qPCR cards also
included 3 reference genes (GAPDH, 18S and ACTB) for normalisation. Raw
threshold cycle (Ct) data were extracted using RQ Manager v1.2 software
(Applied Biosystems Inc, Austin, TX, USA). Relative quantification of gene
expression was calculated using the Ct method in Microsoft Excel after
pooling cancer versus benign samples with expression of genes in the benign
set normalised to 1 using 18S or GAPDH as the calibrator.
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Table 19. Layout and gene reference data for the customised TaqMan Array
format 48. Each column of the table represents the 2 columns of qPCR reaction
wells filled by each of the 8 fill reservoirs on the TaqMan Array cards.
POU5F1 Hs00999632_g1 GAPDH Hs00266705_g1
LAMC2 Hs01043711_m1 ACTB Hs00357333_g1
RAB27A Hs00608302_m1 MUC4 Hs00366414_m1
CSPG4 Hs00426981_m1 MUC5AC Hs01365616_m1
PRKCB1 Hs00176998_m1 CD9 Hs00233521_m1
PTK2 Hs00178587_m1 LUM Hs00158940_m1
MYC Hs99999003_m1 MAML2 Hs00418423_m1
LIF Hs00171455_m1 ITGB8 Hs01110394_m1
SERPINA3 Hs00153674_m1 VEGFA Hs99999070_m1
CELSR1 Hs00183906_m1 PNMA2 Hs00246721_s1
ATP6V0A2Hs00429389_m1 18S Hs99999901_s1
NOTCH3 Hs00166432_m1 CEACAM1 Hs00236077_m1
COL1A1 Hs00164004_m1 MXRA5 Hs00377849_m1
COL17A1 Hs00990073_m1 HOXA10 Hs00172012_m1
MCM4 Hs00381539_m1 HOXB6 Hs00255831_s1
MAPK1 Hs01046830_m1 ITIH5 Hs00228960_m1
RAD51 Hs00153418_m1 ASPHD1 Hs00736180_m1
NCSTN Hs00299716_m1 TGFB1 Hs00932734_m1
STAT1 Hs01014005_m1 TM4SF18 Hs00298933_m1
TRIB2 Hs00222224_m1 PVT1 Hs00413039_m1
KRAS Hs00364282_m1 LEF1 Hs00212390_m1
MAML3 Hs00298519_s1 CFDP1 Hs01041483_m1
PEAR1 Hs01378394_m1 MMP2 Hs01548727_m1
COL6A3 Hs00915120_m1 SPARC Hs00234160_m1
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6.3 Results
6.3.1 Testing of mRNA isolated from biliary brushings.
This was done as outlined in Chapter 4. In summary, RNA was quantified
using the NanoDrop ND-1000 Spectrophotometer and quality assessed by
Agilent Bioanalyzer. Prior to use on the TaqMan Array cards, samples were
assessed for contamination with genomic DNA and functional analysis of the
RNA was performed using single gene SYBR Green qPCR alongside reverse
transcriptase negative (RT-) controls using highly expressed genes such as
GAPDH or 18S. Samples were considered suitable if there was appropriate
amplification of the reference genes and CT values >35 in the RT- controls.
6.3.2 Failed TaqMan Array cards and exclusion of
samples with poor amplification thresholds
In the batch of 10 TaqMan Array cards, 5 failed to provide data due to
machine misalignment. The majority of these samples were repeated using
spare RNA converted to cDNA. Two samples (1 BTC, and 1 benign) were
excluded from the second fresh validation set in view of reference gene CT
values being much higher (i.e. lower cDNA input) than the other samples
resulting in most of the other genes of interest shifting to the right with lack of
amplification within the 40 cycles. These samples could therefore not be used
for meaningful results and were excluded from further data analysis.
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Figure 45. Example of gene expression from 2 samples not
demonstrating amplification within the 40 cycles with a right
shift in the amplification curves due to lower input levels of
cDNA. These 2 samples were excluded from further data
analysis.
6.3.3 Relative gene expression assessed by TaqMan
Array qPCR
Mean CT and mean Ct were used to calculate the relative gene expression
as described in Chapter 4. Examples of amplification plots and Ct values for
a selection of the genes are shown in figure 46.
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Figure 46. Examples of qPCR amplification plots for 9 of the 45 genes assessed by
TaqMan Array. Plots show grouped benign and cancer data normalised to 18S RNA for
the microarray validation set 1 and the fresh validation sample set with relative gene
expression shown by the mean Ct calculations.
Overall, the pattern of gene expression supported that identified by
microarray. Exact duplication of levels of fold change were unlikely and not
required for confirmation of the trend in gene expression. Concordance of
expression pattern was considered present if the fold change was ≥2 in both
the microarray and qPCR data.
6.3.4 Validation set 1 (same source RNA used for the
microarray experiments)
Up regulated genes analysed using the customised TaqMan Array qPCR
cards are shown in the results Table 20 and Figure 47. The pattern of gene
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expression was similar in both the microarray and qPCR data with 79%
(34/43) concordance of overall gene expression between the 2 platforms
when comparing up-regulated genes. Raw Ct data and Ct calculations of
relative gene expression are shown in the Appendix.
6.3.5 Validation set 2 (fresh RNA sample set)
Using the second, fresh validation set, 36 out of 43 up regulated genes
showed a similar pattern in gene expression (83% concordance). Levels of
fold change are shown in Table 20. Raw Ct data and Ct calculations of
relative gene expression are shown in the Appendix.
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Table 20. Results of gene expression assessed by microarray and TaqMan Array qPCR
showing mean fold change between malignant versus benign biliary brushings
Fold change
Gene
symbol
Gene ID Microarray
analysis
qPCR
validation
set 1
Second,
fresh qPCR
validation
set
ASPDH1 ASPHD1-Hs00736180_m1 10 1.7 3.6
ATP6VOA2 ATP6V0A2-Hs00429389_m1 10 1.1 3.1
CD9 CD9-Hs00233521_m1 19 2.2 4.0
CEACAM1 CEACAM1-Hs00236077_m1 3.5 2.1 3.1
CELSR1 CELSR1-Hs00183906_m1 5.2 7.2 7.3
CFDP1 CFDP1-Hs01041483_m1 5.3 1.1 1.7
COL17A1 COL17A1-Hs00990073_m1 16 10.9 4.9
COL1A1 COL1A1-Hs00164004_m1 7.2 21.6 3.4
COL6A3 COL6A3-Hs00915120_m1 8.8 26.7 2.3
CSPG4 CSPG4-Hs00426981_m1 8.5 19.5 1.6
HOXA10 HOXA10-Hs00172012_m1 24 67.0 35.8
HOXB6 HOXB6-Hs00255831_s1 20 5.0 10.2
ITGB8 ITGB8-Hs01110394_m1 2.7 4.0 2.6
ITIH5 ITIH5-Hs00228960_m1 20 12.4 1.5
LAMC2 LAMC2-Hs01043711_m1 2.5 2.8 3.3
LEF1 LEF1-Hs00212390_m1 15 7.1 4.9
LIF LIF-Hs00171455_m1 4.7 7.5 2.0
LUM LUM-Hs00158940_m1 11 3.7 1.1
MAML2 MAML2-Hs00418423_m1 3.5 3.9 1.4
MAPK1 MAPK1-Hs01046830_m1 2.35 1.6 2.2
MCM4 MCM4-Hs00381539_m1 2.2 1.5 2.5
MMP2 MMP2-Hs01548727_m1 2.6 11.0 2.3
MUC4 MUC4-Hs00366414_m1 3.2 29.4 15.5
MUC5AC MUC5AC-Hs01365616_m1 3.6 7.4 5.0
MXRA5 MXRA5-Hs00377849_m1 24 10.4 3.5
MYC MYC-Hs99999003_m1 2.7 6.0 11.5
NCSTN NCSTN-Hs00299716_m1 3.4 1.0 1.9
NOTCH3 NOTCH3-Hs00166432_m1 6 8.0 4.7
PEAR1 PEAR1-Hs01378394_m1 10.3 6.6 2.7
PNMA2 PNMA2-Hs00246721_s1 39 3.9 112
POU5F1 POU5F1-Hs00999632_g1 3.3 2.5 5.5
PRKCB1 PRKCB1-Hs00176998_m1 8.3 6.8 3.1
PTK2 PTK2-Hs00178587_m1 3 1.9 1.8
PVT1 PVT1-Hs00413039_m1 11 12.1 12.5
RAB27A RAB27A-Hs00608302_m1 2.5 2.7 2.7
RAD51 RAD51-Hs00153418_m1 4.3 3.0 4.2
SERPINA3 SERPINA3-Hs00153674_m1 37.8 46.7 4.4
SPARC SPARC-Hs00234160_m1 7.1 41.4 3.1
STAT1 STAT1-Hs01014005_m1 2.5 1.9 2.8
TGFBI TGFBI-Hs00932734_m1 12.3 3.3 2.5
TM4SF18 TM4SF18-Hs00298933_m1 10.9 0.9 5.3
TRIB2 TRIB2-Hs00222224_m1 4.3 3.4 3.1
VEGFA VEGFA-Hs99999070_m1 2.5 2.6 2.9
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Figure 47. Summary of gene expression data plotted as comparisons between
microarray, qPCR validation and fresh qPCR validation sets. The 3 graphs show the
same data in different formats to demonstrate the overall trends between different
sample sets
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6.4 Conclusions: Validation of gene expression
using TaqMan Array qPCR
Overall, the upregulation of gene expression identified by microarray was
confirmed using qPCR as an alternative method of measuring mRNA
expression. These data support further investigation at the protein level for
potential biomarkers in BTC. However, multiple gene qPCR by TaqMan Array
is still a relatively new and little used assay and therefore we chose to further
assess expression of selected genes by standard single gene qPCR.
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6.5 Part 2: Single gene qPCR validation of
mRNA expression.
6.6 Introduction
In order to further validate the gene expression pattern using an alternative
technique, we assessed the mRNA expression of a small number of genes by the
SYBR Green qPCR technique. The genes assessed were:
1. CD45 and CK19 markers were used to assess the relative quantities of
leukocyte and epithelial cell RNA in biliary brush samples.
2. CD9 and LUM – their expression was significantly upregulated in the
microarray data with no overlap in benign and malignant samples and
published data on suitable, tested primer sets were available.
3. MUC4 and MUC5AC – reliable and previously tested primer sets were
available in our laboratory. MUC4 was used as an internal control of up-
regulation in cancer as previously demonstrated (Matull, Andreola et al. 2008)
6.6.1 CD9
Cluster of Differentiation 9 (CD9, also known as MRP-1, MIC3, TSPAN29, P24, 5H9,
BA2, BTCC-1, DRAP27, and GIG2) is a member of the transmembrane 4 super
family. It is expressed by epithelial cells, endothelial cells, neurons and vascular
smooth muscle cells. CD9 expression is high in bone marrow derived progenitor cells
but low in activated lymphocytes and myeloid cells and is not expressed in resting T
or B lymphocytes (NCBI database information). Data from the Human Protein Atlas
(www.proteinatlas.org) show that CD9 is not present in normal cholangiocytes on
immunohistochemical staining. CD9 contributes to normal cell adhesion and motility,
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and up-regulation may play a role in invasiveness and metastasis of some cancers
including melanoma, prostate and cervical cancer, although its expression is reported
to be inversely correlated with poor prognosis in lung, pancreas and breast cancers
(Longo N 2001, Sauer G 2003, Miyake M, 1995 ). Mixed reports on CD9 expression
in cancer may relate to the observation that cells in contact with the basement
membrane, advancing tumour edges and areas of lymphovascular invasion have
elevated expression of CD9 (Sauer G 2003, Longo N 2001, whereas it may be
reduced in the centre of tumour masses. Elevated expression in BTC may relate to
the tendency of cholangiocarcinoma to infiltrate along bile ducts rather than form
mass lesions.
6.6.2 Lumican
Lumican (LUM, also known as LDC or SLRR2D) is a member of the small
leucine rich proteoglycan (SLRP) family. The protein is expressed in the
extracellular matrix of the pancreas, liver, skin, cornea, heart, placenta and
skeletal muscle but not in normal biliary epithelium or lymphoid tissue (data
from NCBI databases and the Human Protein Atlas). Lumican is involved in
modulation of collagen synthesis, tissue repair and control of cellular
proliferation and migration (Chakravarti S 2002). Studies in some cancers
including colonic and pancreatic cancer demonstrate elevated levels of
lumican in malignant disease (Lu YP 2002, Koninger J 2004). Our microarray
data suggest a significant upregulation of lumican in BTC (fold change 11)
and in view of its location as an extracellular matrix protein, it is plausible that
lumican fragments may be identified in the circulation as a tumour marker and
deserve further investigation in BTC.
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Figure 48. Microarray gene expression plots showing significant elevation of CD9
(mean fold change 19) and lumican (fold change 11) in BTC compared to benign biliary
disease.
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6.7 Materials and methods
6.7.1 Samples
Clinical samples of biliary brushings were those described in Chapter 4. The
same purified RNA samples were used as that used for the TaqMan Array
cards in order to provide a direct comparison of results. A summary of the 11
samples used is shown in Table 21.
Table 21. Samples used for further qPCR validation using the SYBR Green method.
Sample Diagnosis Age Gender
B5 PSC 35 M
B6 CBD Stricture and Stones 65 M
Benign B7 IgG4 Disease 69 M
B8 SOD 38 F
B9 IgG4 Disease 47 M
Mean 53
M6 CC 79 M
M7 CC 63 M
Malignant M8 CC 60 F
M4 CC 59 M
M9 CC 71 F
M10 CC 72 M
Mean 67
6.7.2 RNA isolation, purification and cDNA synthesis.
RNA from the biliary brushings was isolated and purified as described in
chapter 4. cDNA was synthesized using the High Capacity RNA to cDNA
Synthesis Kit (Applied Biosystems Inc, Austin, TX, USA) as per the
manufacturers instructions. cDNA synthesis was performed in 20l volumes
from a template of 150ng total RNA using the reverse transcriptase enzyme
mix for 60mins at 37oC. Reverse transcriptase negative (RT-) controls were
made for the majority of samples where there was potential spare RNA in
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order to test for genomic DNA contamination. cDNA samples were stored at -
20oC until further use.
6.7.3 SYBR Green qPCR
qPCR reactions were carried out in 25l reaction volumes in 96 well plates on
an Applied Biosystems 7500 Real Time PCR machine (Applied Biosystems
Inc, Austin, TX, USA). Experiments were performed in duplicate ordinarily
using cDNA input equivalent to 7.5ng RNA (range for some experiments 5ng-
10ng equivalent RNA converted to cDNA) with the addition of SYBR Green
qPCR Mastermix (x2) with low Rox (Eurogentec) and 0.5l each of 10M
forward and reverse primer pairs.
Primer pair sequences used for the SYBR Green qPCR reactions are shown
in Table 22. Primer sets were chosen based on short amplicon lengths (as
discussed in Chapter 4) as well as previous demonstration of suitability for
SYBR Green qPCR. Primer sets for CD9 and LUM were synthesized and
purchased from Eurogentec as per the sequences shown in the table.
Efficiency of amplification was assessed using a standard curve of increasing
concentrations of RNA isolated from human TFK-1 BTC cells in culture
(Figure 50).
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Table 22. qPCR primer sets used for SYBR Green qPCR analysis of gene expression in
biliary brush and bile samples.
Primer
Amplicon
length
(bp)
Forward sequence
(5’ - 3’)
Reverse sequence
(5’ - 3’) Reference
GAPDH 87
NM_002046 87 556TGCACCACCAACTGCTTAGC575 642GGCATGGACTGTGGTCATGAG621
(Wu, Lin et al.
2007)
18S RNA
NR_003286.2 99 331CGGCGACGACCCATTCGAAC350 429GAATCGAACCCTGATTCCCCGTC407
BIORAD
sequence
MUC4
AF058803 101 1499GCCCAAGCTACAGTGTGACTCA1520 1600ATGGTGCCGTTGTAATTTGTTGT1578
(Matull,
Andreola et al.
2008)
CD9
NM_001769.2 78 498CAACAAGCTGAAAACCAAGGA 518 576CAAACCACAGCAGTTCAACG 557
(Gandemer, Rio
et al. 2007)
LUM
NM_002345.3 97 489TCACCAAACTGTGCACCAGAA509 GGAGGCACCATTGGTACACTTT565
(Boheler,
Volkova et al.
2003)
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6.8 Results
6.8.1 Testing of qPCR primer sets
Prior to use with clinical samples, primer sets require testing to ensure
appropriate and specific amplification of PCR products. The primer sets for
GAPDH, 18S RNA and MUC4 had previously been tested within the group (Dr
Fausto Andreola) and shown to be suitable for qPCR using the SYBR Green
method. Examples of the single dissociation peaks are shown in Figure 49.
Figure 49. qPCR product dissociation plots showing single, specific peaks in
keeping with absence of non-specific gDNA amplification or primer
dimerisation.
Efficiency of primer sets was tested using a standard curve of increasing
amounts of input control (TFK-1 cell) RNA against the amplification threshold
(Ct). Results should show a direct correlation. As shown in Figure 50, both
the CD9 and LUM primer sets performed satisfactorily.
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Figure 50. Standard curves for CD9 and LUM primer sets to assess efficiency of PCR
amplification. Both primer sets produced satisfactory standard curves.
Specificity for mRNA amplification is tested most simply by evaluating the
dissociation plot after completion of the qPCR cycles. The CD9 dissociation
plot showed a single specific dissociation peak but the LUM dissociation plots
demonstrated non specific additional peak suggestive of primer dimerisation
that would affect the accuracy of the gene expression data.
Figure 51. SYBR Green qPCR dissociation plots showing a single specific peak for
CD9 but a second, non-specific peak of primer dimerisation using the LUM primer
set. (image from Rob Tidswell).
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Further experiments were performed using varying concentrations of forward
and reverse primers as well as MgCl2 which inhibits non-specific hydrogen
bonds and may prevent primer dimerisation. None of the conditions removed
the non specific peaks. These studies were performed by a supervised iBSc
student (Robert Tidswell). No further analysis of LUM expression by SYBR
Green qPCR was undertaken (data not shown).
6.8.2 Relative expression of CK19 and CD45 as
markers of epithelial and leukocyte RNA
respectively.
These data have already been presented in Chapter 4. In summary, there was no
significant difference in relative expression of CK19 or CD45 between benign and
malignant samples, although there was a trend towards higher CD45 expression in
malignant samples. Also, CK19 mRNA expression was much higher than CD45
mRNA demonstrating that epithelial cells represent the major source of RNA in the
biliary brush samples (Figure 52).
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Figure 52. qPCR amplification plots for the pan leukocyte marker CD45 and biliary
epithelial cell marker CK19 relative to the reference gene 18S, showing a much greater
proportion of epithelial than leukocyte RNA in biliary brushings. Also, there is no
significant difference in relative expression of each of the markers between benign and
malignant samples. There are much wider variations in leukocyte compared to
epithelial RNA quantities as shown by the wide spread in amplification curves and Ct
values for CD45 between different samples.
6.8.3 Expression of Lumican in biliary brushings
The lumican primer sets were considered unsuitable for reliable qPCR so
were not investigated further in clinical samples in significant numbers.
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6.8.4 Expression of CD9 in biliary brushings and bile
When assessed by SYBR Green qPCR, CD9 was shown to be upregulated in
cancer versus benign samples by 3 different experiments using biliary brush
RNA (n=6 to n=11 per experiment). In the largest experiment (n=11), CD9 had
a fold change of 2.8 [95% CI 2.6 to 3.0] in cancer versus benign. This level of
upregulation in smaller than that reported by microarray (fold change of 19)
but still demonstrates confirmation of upregulation at the mRNA level in the
malignant biliary brushings. Examples of individual sample qPCR plots are
shown in Figure 53.
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Figure 53. Representative qPCR amplification plots and Ct values for CD9 (middle
plot on each graph) and MUC4 (right hand plot on each graph) using GAPDH as the
reference gene. The Ct are on average smaller (i.e. higher expression) in cancer
versus benign samples for both CD9 and MUC4.
A small number of bile samples were used to assess the expression of CD9
relative to GAPDH. Numbers were too small (n=6) for definitive results but
suggest an upregulation of CD9 in bile from patients with BTC (Ct 4.14 in
219
cancer versus 6.08 in benign disease); the fold change was 3.8 in cancer
versus benign disease. Examples of CD9 qPCR plots are shown in Figure 54.
Figure 54. Examples of qPCR plots for CD9 expression in bile from patients with
benign and malignant biliary diseases. The mean Ct value is smaller in malignant
samples suggesting higher expression of CD9 in BTC.
6.8.5 Expression of MUC4 and MUC5AC in biliary
brushings
MUC4 was tested as an internal control as it has already been shown to be
upregulated at mRNA level in bile and protein level in tissue (Matull, Andreola
et al. 2008). As shown in Figure 55, there was a wide variation in MUC4
expression levels in both benign and malignant samples, a phenomenon that
was also noted in the microarray results.
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Figure 55. Plots demonstrating a high variability in MUC4 mRNA expression in biliary
brush samples by A) qPCR and B) microarray.
Validation using a further set of biliary brush samples by individual gene
qPCR using the SYBR Green detection method confirmed upregulation of
MUC4 (fold change 21.4 [95% CI 19.1 to 24.1], n=9). Up-regulation of MUC4
is shown above in Figure 53 and acts as a further internal control providing
further validity to the up-regulation of CD9 shown at the same time in the
same sample set.
MUC5AC was tested in only a very small sample set (n=4) insufficient for
proper data analysis. However, the qPCR amplification plots and Ct values
show that MUC5AC is highly expressed with Ct values only slightly higher
than GAPDH (Figure 56). The range of relative expression was 0.2 to 1.6 but
numbers were insufficient to calculate differences in benign and malignant
samples or make further conclusions.
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Figure 56. Expression of MUC5AC in biliary brush samples. Note expression levels
near to that of GAPDH (DCt 0.8 to 2.8) suggesting high expression in benign
(bottom right) and malignant (bottom left) biliary brushings.
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6.9 Conclusions
The main conclusions drawn from data presented in this chapter are:
 Where measured, gene expression in biliary brushings assessed by
qPCR, has a high concordance (79-83%) with that demonstrated by
microarray.
 Elevation of MUC4, previously shown to be upregulated in BTC, was
again identified as upregulated in our samples of biliary brushings,
acting as a type of internal positive control to support our results.
 These data support the validitity of the microarray data as
representative of gene expression in cells isolated from biliary
brushings
 The primary source of RNA in biliary brushings is from epithelial cells
with much more minor quantities from leukocytes. Therefore,
confounding from bile duct infections may be present but would be
small.
 These data provide support for further investigation of biliary strictures
by microarray and qPCR in greater numbers and also to investigate
other biliary diseases such as PSC and IgG4 disease.
 Elevated mRNA expression in genes of interest deserves further
investigation to assess the expression of the protein products as
potential biomarkers in BTC.
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6.10 Discussion
In this chapter we demonstrate that the majority of genes identified by
microarray analysis as upregulated in biliary brushings of BTC are also shown
to be up-regulated at the mRNA level by qPCR. The actual level of fold
change varies depending on the assay used but one cannot expect the data
to be exactly the same in all assays and when using relatively small numbers
of samples with large biological variations. If the sample size were increased,
then it is highly likely that overall variation would fall. The aims of these
studies were to identify novel biomarkers, primarily at the protein level. The
level of mRNA expression does not necessarily directly translate to the level
of protein expression. Reasons for variation between gene and protein
expression include post translational modification by microRNA and other
means, or non coding gene mutations in the genes of interest and a wide
variation in the half life of protein products. Therefore, precise levels of gene
expression are less important than confirming a definite trend in fold change
so that one can then study relevant protein expression levels directly. This will
be addressed in Chapter 7.
As described, these data support the use of global gene expression profiling
by microarray in biliary brushings. Some other biliary diseases such as PSC
and IgG4 disease, are difficult to study at the cellular and molecular level
because of a paucity of clinical materials and commonly an absence of
biopsiable tissues. The methods described so far, may therefore be well
suited to study such biliary diseases in more depth.
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Chapter 7.
7 Analysis of gene and protein
expression in biliary tissues
7.1 Introduction and aims
In Chapters 5 and 6 we identified some of the genes upregulated in biliary
brushings taken from patients with BTC. Cells brushed at the surface of
strictures at ERCP may include a mixture of cell types but are primarily
epithelial cells. These cells may be benign and/or malignant and may contain
a number of dead cells or cells undergoing apoptosis at the tumour edge
exposed to bile. Also, cells at the surface of tumours may have different cell
biology to those at the central zones, a phenomenon that is well recognised in
tumour biology. However, fresh frozen surgical tissues are still regarded as
the best tissues for further study with gene expression analysis and so
similarities between tissue and biliary brushings would provide further
supportive evidence for biliary brushings as clinical samples suitable for
translational work.
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In this chapter we aimed to assess;
1. whether a similar gene expression pattern is present in resected biliary
tract cancer tissue from patients undergoing attempted curative surgery
2. whether the upregulated gene expression is translated to upregulated
protein expression in biliary tissues in order to assess whether these
may become biomarkers in BTC.
This Chapter will be divided into two parts; the first addressing mRNA
expression analysis in the surgical tissues using methodology described in
Chapters 4 and 6; the second assessing protein expression in bile and
surgical tissue sections.
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7.2 Part 1. Analysis of relative mRNA expression
in resected biliary tract cancer tissues
7.3 Introduction
The biology of cells at the surface of tumours is somewhat different to those in
the necrotic and ischaemic central zones. Also, small and large
cholangiocytes at different locations in the biliary tree have different gene and
protein expression profiles, a phenomenon best described in animal studies
(Ueno, Alpini et al. 2003). Samples of superficial endoscopic biliary brushings
are not necessarily the same as samples of tissue taken from within the
tumour mass. However, fresh frozen tissue samples should contain good
quality RNA and represent the best (although not perfect) control for
comparison with the biliary brush data.
In this section, we describe analyses of gene expression in surgical resection
material carried out in order to compare with those found in the biliary brush
samples as shown in Chapters 5 and 6.
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7.4 Materials and Methods
In general, experimental methods used were the same as those used for the
biliary brush material described in Chapter 6.
7.4.1 Surgical resection tissue
Clinical samples were collected following written informed consent for ethically
approved research (NHNN Ethics Committee, reference 06/Q0152/106).
Surgical resection material was collected at the time of operation at University
College Hospital with the kind assistance of the surgeons Professor Massimo
Malago, Mr Charles Imber and Dr Steven Olde Damink. Once the relevant
area of liver, bile duct or tumour had been resected, the surgeon dissected
out a small area (approx 0.5-2cm3) of tissue that was then snap frozen in
liquid nitrogen and stored at -800C until further use. Pathological confirmation
of diagnosis in the main resected tissue specimen was confirmed for all cases
used. Tissues used for the TaqMan array qPCR are shown in Table 23. In
addition, a few other samples were collected and assessed (e.g. normal liver
from patients undergoing resection of colorectal metastasis and bile ducts
from patients undergoing Whipples procedures for pancreatic cancer) but
were generally not used for calculations of relative gene expression and these
data are not presented in the main data set.
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Table 23. Clinical details for surgical resection material used in the qPCR
experiments.
Sample Diagnosis
Benign1 Benign inflammatory / ischaemic CBD stricture
Benign2 Cystic duct at cholecystectomy for stones
Benign3 Benign inflammatory / ischaemic CBD stricture
Benign4 Cystic duct at cholecystectomy for stones
Benign5 Left hepatic duct at surgery for CRC liver metastasis
Benign6 Benign CBD stricture (IgG4 disease)
BTC1 Distal CBD cholangiocarcinoma
BTC2 Hilar cholangiocarcinoma
BTC3 Hilar cholangiocarcinoma
BTC4 Distal CBD cholangiocarcinoma
BTC5 Hilar cholangiocarcinoma
BTC6 Distal CBD cholangiocarcinoma
BTC7 Hilar cholangiocarcinoma
BTC8 Hilar cholangiocarcinoma
BTC9 Hilar cholangiocarcinoma
7.4.2 RNA isolation, purification and cDNA synthesis.
The surgical resection material was fragmented by crushing in a pestle and
mortar whilst frozen in liquid nitrogen or mechanically homogenised in TRI
reagent. RNA was isolated using TRI Reagent (Ambion) and further purified
by spin column purification (RNEasy Mini, Qiagen) as per the manufacturer’s
instructions and eluted in 20l of RNase free water. RNA concentrations and
quality were assessed by Nanodrop ND-1000 spectrophotometer (Labtech).
cDNA was synthesized using the High Capacity RNA to cDNA Synthesis Kit
(Applied Biosystems Inc, Austin, TX, USA) as per the manufacturers
instructions. cDNA synthesis was performed in 20l volumes from a template
of 300ng total RNA (double the quantity used for the biliary brush
experiments) using the reverse transcriptase enzyme mix for 60mins at 37oC.
Reverse transcriptase negative (RT-) controls were made in order to test for
genomic DNA contamination. cDNA samples were stored at -20oC until further
use.
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7.4.3 Single gene qPCR using the SYBR Green assay
qPCR reactions were carried out in 25l reaction volumes in 96 well plates on
an Applied Biosystems 7500 Real Time PCR machine (Applied Biosystems
Inc, Austin, TX, USA). Experiments were performed in duplicate ordinarily
using cDNA input equivalent to 7.5ng RNA (range for some experiments 5ng-
10ng equivalent RNA converted to cDNA) with the addition of SYBR Green
qPCR Mastermix (x2) with low Rox (Eurogentec) and 0.5l each of 10M
forward and reverse primer pairs.
Primer pair sequences for the SYBR Green qPCR reactions were the same
as those used in the biliary brush experiments (Table 24). The primary genes
assessed were;
 18S (NR_003286.2) and GAPDH (NM_002046) as reference genes
 CK19 (NM_002276.3) and CD45 (NM_080922.1) to assess relative
quantities of epithelial and leukocyte RNA in the tissue samples
 CD9 (NM_001769.2) for comparison with biliary brush and tissue
TaqMan Array qPCR results.
Table 24. Primer sets used for SYBR Green qPCR experiments in biliary tissues.
Gene &
GeneBank
accession number
Amplicon
length
(bp)
Forward sequence
(5’ - 3’)
Reverse sequence
(5’ - 3’)
GAPDH 87
NM_002046 87 556TGCACCACCAACTGCTTAGC575 642GGCATGGACTGTGGTCATGAG621
18S RNA
NR_003286.2 99 331CGGCGACGACCCATTCGAAC350 429GAATCGAACCCTGATTCCCCGTC407
CK19
NM_002276.3 79 514TACAGCCACTACTACACGACCATCC538 592GGACAATCCTGGAGTTCTCAATG570
CD45
NM_080922.1 102 1353GGAAGTGCTGCAATGTGTCATT1374 1454CTTGACATGCATACTATTATCTGATGTCA1426
CD9
NM_001769.2 78 498CAACAAGCTGAAAACCAAGGA 518 576CAAACCACAGCAGTTCAACG 557
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As described previously in Chapters 4 and 6, the comparative threshold
(Ct) method was used to calculate relative expression of the target gene
compared to the reference gene (usually 18S).
7.4.4 Custom designed TaqMan Array qPCR cards
In order to compare relative BTC gene expression in tissue with that of biliary
brushings, we used custom synthesized TaqMan Array qPCR cards with a
format similar to that used for the biliary brushings experiments in Chapter 6.
As before, cards were designed with a format of 48 genes per fill reservoir.
The gene IDs were similar to those used in the previous biliary brush
experiments with the difference being replacement of 2 genes with 2 new
gene primer-probe sets not used in the first set. A list of genes included in the
TaqMan Array cards is shown in Table 21.
The -actin control was removed in view of the fact that results were not
reproducible in the first set, a phenomenon that may be related to the primer-
probe set used or variation in cancer versus benign tissue. MAML3 was also
removed in view of the fact that the change in gene expression identified by
microarray was not found in either of the 2 qPCR validation sets, suggesting a
possible false positive result from the microarray data. These two genes were
replaced by two other genes on the original shortlist, VIM and MLL4. Vimentin
(VIM) is an intermediate filament protein of the cytoskeleton primarily
expressed in mesenchymal tissues and over-expression has been reported in
a number of other solid organ cancers (NCBI database information). Our
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microarray data reported a fold change of 3.4 (p=0.006) in malignant biliary
brushings. Despite its name, mixed lineage leukaemia 4 (MLL4) is
ubiquitously expressed by all tissues. The protein product is a histone
methyltransferase involved in epigenetic transcriptional activation and has
been shown to be up-regulated in other solid organ cancers (NCBI database
information). Our microarray data reported a fold change of 7.7 (p=<0.001) in
cancer versus benign biliary brushings. These 2 genes were added in place of
ACTB and MAML3.
Table 25. Genes included in the custom synthesized TaqMan Array qPCR cards used
for analysis of gene expression in biliary surgical resection material.
List of genes for qPCR validation using TaqMan arrays
18S RNA ITGB8 CELSR1 CFDP1 ATP6V0A2 STAT1
GAPDH VEGFA NCSTN MMP-2 PRKCB1 NOTCH3
MLL4 PNMA2 ASPHD1 COL6A3 PTK2 COL1A1
MUC4 CEACAM1 TGFBI/1 SPARC cMYC BPAG2
MUC5AC MXRA5 TM4SF18 TRIB2 SERPINA3 SEL1L
CD9 HOXA10 PVT1 LAMC2 LIF MCM4
LUM HOXB6 LEF1 RAB27A RAD51 MAPK1
MAML2 ITIH5 POU5F1 CSPG4 VIM KRAS
TaqMan® Array qPCR assays were performed at Cancer Research UK,
Lincolns Inn Fields, by kind invitation and assistance of Dr Charles Swanton
and his PhD student, Alvin Lee. All reactions were carried out as per the
manufacturers instructions using 50l TaqMan Universal PCR Master Mix
(2X) (Applied Biosystems Inc, Austin, TX, USA) and 75ng cDNA (double the
quantity used for the biliary brush experiments) made up to a total volume of
100l with water in each fill reservoir. After application of the cDNA mastermix
into the fill reservoir, the cards were centrifuged twice for 1 min each at 2200
rpm to evenly distribute the mastermix into each reaction chamber. The card
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was sealed as per the manufacturers instructions and transferred to a 7900HT
Real Time PCR system (Applied Biosystems Inc, Austin, TX, USA). Thermal
cycling conditions were set at 950C for 10 mins followed by 40 repeats of 950C
for 15s and 600C for 1min.
45 genes (Table 25) were tested in duplicate using RNA isolated from the
surgical resection material (n=15). The qPCR cards also included 2 reference
genes (18S and GAPDH) for normalisation. Raw threshold cycle (Ct) data
was extracted using RQ Manager v1.2 software (Applied Biosystems Inc,
Austin, TX, USA). Relative quantification of gene expression was calculated
using the Ct method in Microsoft Excel after pooling cancer versus benign
samples with expression of genes in the benign set normalised to 1 using 18S
or GAPDH as the calibrator.
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7.5 Results
7.5.1 RNA concentrations and quality.
As expected, RNA from fresh frozen resection specimens was of much higher
quality and quantity than that isolated from biliary brushings. Examples of
spectrophotometric analyses of purified RNA are shown in Figure 57.
Figure 57. Examples of the Nanodrop ND-1000 spectrophotometer results for RNA
isolated from fresh snap frozen surgical resection material. The table on the left shows
high concentrations and good quality RNA as assessed by absorbance at 260nm and
260/280 ratios near 2.0. One sample in this batch (MF) had no identifiable RNA which
was likely lost during purification and was discarded and RNA isolation repeated. The
graph on the right shows an example of a clean peak at 260nm as expected for pure
nucleic acid.
The RT negative controls did demonstrate some amplification by qPCR but
these were at threshold levels approximately x20 higher for the very highly
expressed 18S or at Ct values over 35 for GAPDH, CD45 and CK19 (Figure
46). These levels are considered to be insignificant or negative and
demonstrate a lack of significant genomic DNA contamination in the purified
RNA from the surgical resection material.
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Figure 58. Reverse transcriptase negative controls for cDNA used in the qPCR
experiments. Samples primed for 18S rRNA showed amplification from Ct 27 to >40
compared to approximately Ct 8 for RT positive samples (not shown). All samples for
CD45 and CK19 had Ct value ≥35. These results are considered to be negative
demonstrating either a lack of significant genomic DNA contamination in the source
RNA and/or appropriate mRNA specific amplification of the primer sets used. Single
peak dissociation plots demonstrate specific qPCR amplification and lack of non-
specific signal caused by primer dimerisation.
7.5.2 Relative expression of epithelial and leukocyte
RNA in surgical resection material
As per the experiments using RNA isolated from biliary brushings, we used
the epithelial and pan-leukocyte markers CK19 and CD45 respectively, in
order to assess the relative expression of epithelial and leukocyte RNA in
benign and malignant tissue samples (n=14).
235
Expression of CK19 was similar in both groups with a fold change of 0.89
(95% CI 0.87 – 0.92) in cancer versus benign suggesting similar, or slightly
lower but comparable, relative quantities of epithelial cells in malignant
compared to benign samples.
Figure 59. Examples of SYBR Green qPCR amplification plots for epithelial and
leukocyte markers in benign and malignant biliary surgical resection tissues. Note
similar Ct values for CK19 and CD45 in benign and malignant groups but that CD45 has
significantly higher Ct values than CK19 suggesting lower levels of leukocyte than
epithelial RNA.
When comparing relative expression of leukocyte RNA using CD45, there
were similar contributions of leukocyte RNA in both benign and malignant
samples (DCt 17.4 and 17.9 respectively). However, when comparing the
relative contribution of leukocyte RNA in brushes and tissues, there was a
much higher contribution of leukocyte RNA in surgical resection material (DCt
17.4) compared to ERCP biliary brushings (DCt 21.1) suggesting that biliary
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brushings are a purer source of epithelial cells than surgical resection material
(Figure 59).
Figure 60. qPCR plots demonstrating differences in relative quantities of epithelial and
leukocyte RNA from biliary tissues and biliary brushes. Note the mean Ct for CK19 is
slightly lower in the brush samples suggesting slightly higher relative quantities of
epithelial RNA in brushes than tissues. Similarly, the Ct values for CD45 were much
higher in biliary brushes (21.1 v 17.4) suggesting much fewer leukocytes in biliary
brush samples.
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7.5.3 Analysis of multiple gene expression in BTC
surgical resection material by TaqMan Array
qPCR
46 genes were assessed using 2 reference genes (GAPDH and 18S rRNA)
for calculation of comparative gene expression by the Ct method. Relative
expression of each gene was calculated using Microsoft Excel (data shown in
the Appendix). The results are presented in Table 26 with comparison to fold
change in the biliary brush samples as calculated by microarray and qPCR.
Examples of the qPCR plots are shown in Figure 61 in order to demonstrate
the spread of amplification thresholds for the individual samples.
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Figure 61. qPCR plots for benign and malignant biliary tissues. The pooled plots on the
left of each graph are the 18S reference gene and the amplification plots for genes of
interest are shown on the right hand side of each graph to show the range of cycle
thresholds. Note that for HOXA10 and MUC4, some of the samples had no amplication
(arrows) (ie no expression) and all of these were benign.
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Table 26. Comparison of relative gene expression in cancer between biliary brushings
and biliary tissue. N/A denotes genes not assessed in the TaqMan array cards for the
biliary brushings or biliary tissue batches.
Mean fold change (cancer versus benign) using
RNA isolated from biliary brushings
Mean fold change
using RNA isolated
from biliary Tissue
Gene Microarray qPCR qPCRvalidation set qPCR Tissue
18S 1 1.0 1.0 1
GAPDH 1 1.0 1.9 0.9
ACTB 1 2.0 2.3 N/A
MUC4 3.2 29.4 15.5 4.1
MUC5AC 3.6 7.4 5.1 1.2
CD9 19 2.2 4.0 1.5
NOTCH3 6 8.0 4.7 1.7
ASPHD1 10 1.7 3.6 1.0
ATP6V0A2 10 1.1 3.1 1.0
CEACAM1 3.5 2.1 3.1 0.6
CELSR1 5.2 7.2 7.3 1.6
CFDP1 5.3 1.1 1.7 0.5
COL17A1 16 10.9 4.9 15.6
COL1A1 7.2 21.6 3.4 2.5
COL6A3 8.8 26.7 2.3 1.6
CSPG4 8.5 19.5 1.6 1.3
HOXA10 24 67.0 35.8 6.2
HOXB6 20 5.0 10.2 1.5
ITGB8 2.7 4.0 2.6 2.0
ITIH5 20 12.4 1.5 0.3
KRAS -2.5 1.1 1.5 0.8
LAMC2 2.5 2.8 3.3 1.4
LEF1 15 7.1 4.9 1.6
LIF 4.7 7.5 2.0 3.1
LUM 11 3.7 1.1 0.6
MAML2 3.5 3.9 1.4 0.8
MAML3 -8.5 -1.3 3.7 N/A
MAPK1 2.35 1.6 2.2 0.8
MCM4 2.2 1.5 2.5 1
MMP2 2.6 11.0 2.3 0.9
MXRA5 24 10.4 3.4 1.5
MYC 2.7 6.0 11.5 0.9
NCSTN 3.4 1.0 1.9 0.8
PEAR1 10.3 6.6 2.7 0.8
PNMA2 39 3.9 112.3 0.9
POU5F1 3.3 2.5 5.5 1.4
PRKCB1 8.3 6.8 3.1 0.5
PTK2 3 1.9 1.8 0.8
PVT1 11 12.1 12.6 5.2
RAB27A 2.5 2.7 2.7 0.6
RAD51 4.3 3.0 4.2 1.5
SERPINA3 37.8 46.7 4.4 0.1
SPARC 7.1 41.4 3.1 1.1
STAT1 2.5 1.9 2.8 0.8
TGFBI 12.3 3.3 2.5 1.2
TM4SF18 10.9 0.9 5.3 0.6
TRIB2 4.3 3.4 3.1 1.0
VEGFA 2.5 2.6 2.9 1.0
MLL4 7.7 N/A N/A 0.9
VIM 2.0 N/A N/A 0.8
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When compared to the original biliary brush qPCR data, the results of
TaqMan Array qPCR in tissue had a much lower concordance than may have
been expected. For the biliary brush samples, the pattern of gene expression
was similar in both the microarray and qPCR data with 79% (34/43)
concordance of overall gene expression between the 2 platforms when
comparing up-regulated genes. The relative gene expression (fold change)
varied but the trend was considered similar if over 2 in both the microarray
and qPCR data. Using the second, fresh validation set, 36 out of 43
upregulated genes showed a similar pattern in gene expression (83%
concordance).
In the tissue samples, using the same criteria (cut-off of ≥2) for upregulated
genes, the concordance between biliary brush and tissue mRNA expression
was much lower at 16% (7/43). Genes that were consistently elevated
between microarray and qPCR of biliary brush samples with similar elevated
expression in the tissue samples were MUC4, COL17A1, COL1A1, HOXA10,
ITGB8, LIF, and PVT1. Other genes were not considered significantly
upregulated in the tissue samples and others appeared downregulated in
tissue despite upregulation being shown in the biliary brush samples
(CEACAM1, PRKCB1, RAB27A, SERPINA3, and TM4SF18).
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7.5.4 Relative expression of CD9 assessed by single
gene SYBR Green qPCR
Samples used for single gene qPCR were the same as those used for the
TaqMan Array qPCR except for the loss of one of the benign samples due to
insufficient RNA/cDNA remaining (benign n=5, BTC n=9). The Ct method
was used to calculate the expression of each gene relative to the reference
gene (usually 18S rRNA). The relative expression of CD9 was higher in
cancer versus benign samples (fold change 2.38 [95 % CI 2.24-2.53], Figure
62) despite the slightly lower epithelial content suggesting an underestimate
of fold change in cancer.
Figure 62. SYBR Green qPCR using RNA isolated from fresh frozen surgical resection
material. The similar Ct values for CK19 in the benign and malignant samples suggest
similar quantities of epithelial tissue but the lower Ct values demonstrate higher CD9
levels in cancer samples.
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For one patient undergoing a resection of colorectal liver metastasis, we had
separate samples of a portion of normal liver as well as the dissected left
main bile duct. RNA was isolated from both tissues and analysed separately
to assess relative expression of CK19 and CD9 (Figure 63). As might be
expected, CK19 mRNA expression was higher in the dissected bile duct
tissue than in the liver section (Ct 15.9 and 18.1 respectively). The
expression of CD9 mRNA however was higher in the normal liver than in
biliary tissue (14.7 and 17.0 respectively).
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Figure 63 Relative expression of CK19 and CD9 in a sample of normal
resected liver compared to normal left main bile duct showing higher
expression of CK19 and lower expression of CD9 in biliary tissues
compared to normal liver.
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7.6 Conclusions: analysis of mRNA expression
in biliary surgical resection material.
These data demonstrate that measurement of mRNA expression can be done
by multiple gene qPCR as supported by the up-regulation of MUC4 as
previously described in BTC. However, despite the better quality RNA, the
relative expression of epithelial and leukocyte RNA suggest that complex,
homogenised whole fragments of biliary tissues are less suitable for analysis
of epithelial cell gene expression than those obtained from ERCP biliary
brushings. The high stromal component of BTC tissue is well recognised and
examples of the mix of cell types in BTC tissue is shown in the
immunohistochemistry figures later in this chapter. Possibly for these and
other reasons, when compared with gene expression in ERCP biliary
brushings, elevated mRNA expression in surgical resection material had a
concordance of only 16%. However, a selection of genes with consistently
elevated mRNA expression in all sample sets have been identified and
deserve further investigation. These include PVT1, HOXA10, COL17A1 and
POU5F1 (oct 3/4).
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7.7 Part 2. Analysis of protein expression of
genes identified as elevated in biliary
brushings.
7.8 Introduction
We have demonstrated elevated expression of a number of genes in biliary
brushings and surgical resection material. However, elevation of gene
expression may not always translate to elevated protein expression due to
non coding gene mutations in the genes of interest, post translational
modification of mRNA by microRNA and other means, or rapid degradation of
protein products. Some proteins may be identifiable in serum but would more
likely be present in bile or biliary cancer tissue. The most commonly used
methods for investigation of protein expression are Western blot, ELISA and
immunohistochemistry.
Western blot uses radio- or chemiluminescent-labeled antibodies directed
towards epitopes on the proteins of interest in order to semi-quantitatively
assess levels of protein expression in tissues. There are a number of
limitations with this method, which is difficult to apply to complex and highly
variable biological fluids such as bile. Quantification of protein expression by
Western blot is also very limited and is primarily used to demonstrate
presence or absence of protein. Protein expression analysis in biological
fluids by enzyme linked immunosorbance assay (ELISA) is generally much
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simpler to perform, more reproducible and is quantitative. However, ELISA
kits and/or ELISA tested antibodies were not available for many of the
proteins of interest leaving Western blot as the primary method for protein
identification in our clinical samples.
Immunohistochemistry is a standard and reliable method for assessing protein
expression in tissue and was chosen as the primary method for further
investigation. Immunocytochemistry of biliary brush cytology specimen may
provide a more direct comparison of the biliary brush gene expression data
but cytological samples usually provided only 1-4 suitable slides and were not
practical for confirmation of multiple protein expression. Bile is simpler to
collect but is a complex biological fluid and much less simple to obtain reliable
measurement of protein expression. Also, bile is often diluted to variable
amounts by x-ray contrast agents used at ERCP, and there are no clear
reference protein standards with consituents of bile varying in health and
disease and in different anatomical locations within the biliary tree. The level
of common protein standards such as albumin and cellular protein standards
such as B-actin vary with disease and the cellularity of bile.
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7.9 Part A: Analysis of protein expression in
bile.
If elevated gene expression in epithelial cells in the lumen of bile ducts is
translated to elevated protein expression, then bile is likely to be the body fluid
with the most potential for having associated elevated protein levels in biliary
diseases such as BTC. As we showed previously with MUC4 (Matull,
Andreola et al. 2008), measurement of protein expression in bile can be
performed by Western blot using suitable conditions and antibodies. We
aimed to assess the expression of a number of proteins not previously
analysed in bile.
7.10 Materials and methods
7.10.1 Western Blotting
7.10.1.1 Clinical samples
Samples of bile obtained at the time of ERCP or from percutaneous external
biliary drains were used for measurement of protein by Western blot. Samples
were obtained followiing ethical approval (NHNN ethics committee, ref
06/Q0152/106) and informed patient consent. All bile samples were stored at -
800C. Total protein isolated from human BTC cells lines (TFK-1 and HUCCT)
was used for positive controls. For some experiments, bile was filtered using
MicroCon YM-100 Centrifugal Filter Devices (Millipore) to remove large,
complex biliary glycoproteins that may have interfered with the gel separation
and/or antibody binding.
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7.10.1.2 Gel electrophoresis separation of bile proteins.
Bile is a highly heterogeneous biological fluid and samples had often been
diluted by x-ray contrast agent used at the time of ERCP. Therefore, total
protein in bile was measured using a standard bicinchoninic acid (BCA)
method in order to calculate the volume of bile required to obtain a total
protein quantity of 30μg suitable for Western blot analysis. Protein
concentration was measured in 96 well plates using the MicroBCA Protein
Assay Kit (Pierce Protein Research Products, Rockford, IL, USA) with a
standard curve of bovine serum albumin and an ELISA plate reader used to
calculate protein levels. Bile samples were made up to a total volume of 25μl
with water and 1.25μl of 1M Sample Reducing Agent (1M DTT, Invitrogen,
Paisley, UK) followed by heating to 700C for 10mins for denaturing of proteins.
Gel electrophoresis separation was carried out at 200V using 4-12%
NuPAGE® Bis-Tris gels (Invitrogen) in 1% NuPAGE MOPS SDS Running
Buffer (Invitrogen) alongside 10μl of SeeBlue® Plus 2 Pre-stained Protein
Standard ladder (Invitrogen).
7.10.1.3 Western Blotting protocol.
A summary of the steps used for a standard protocol for Western blotting
were as follows:
1. Gel electrophoresis separated proteins were transferred to Invitrolon
PVDF Filter paper sandwiches (Invitrogen) using an iBlot® Dry Blotting
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System (Invitrogen) as per the manufacturers instructions. Membranes
were then:
2. stained with Ponceau red to ensure adequate protein transfer and
washed with distilled water.
3. blocked using 0.5x Western Blocking Reagent (Roche) for 1 hour and
incubated at 40C overnight with 10ml of primary antibody solution,
usually at a dilution of 1:1000 in 0.5x Western Blocking Reagent in
TRIS buffered saline with Tween (TBS.T).
4. washed x2 with TBS.T (0.1% concentration Tween) followed by x2
washes with 0.5x Western Blocking Reagent in TBS-T (10 mins each).
5. incubated with 10ml of secondary antibody solution for 1 hour at room
temperature at a dilution of 1:5000
6. washed x2 with TBS-T followed by x2 washes with 0.5x Western
Blocking Reagent in TBS.T (10mins each).
7. incubated with 5ml chemoluminescence substrate (SuperSignal® West
Pico, mouse or goat horseradish peroxidise kits, Thermo Scientific) for
5 minutes.
8. exposed onto plain photographic film for 1, 2, 5, 15 and 30 mins until
visible bands were seen on developing the film.
Western blot experiements were done with the assistance of Robert Tidswell
(iBSc student) and guidance of Dr Virginie Cerec and Dr Fausto Andreola.
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7.10.1.4 Antibodies used for Western blots
Primary antibodies
1. -tubulin, mouse anti-human IgG monoclonal antibody (Upstate, #05-
829, clone DMIA) was used as a reference protein, as the small 55kDa
protein product is ubiquitously expressed in the cytoskeleton of all
cells.
2. Notch3, rabbit anti-human IgG (Cell Signalling, #2889) recognising full
length 270 KDa and extracellular 90 KDa fragments of the notch3
protein. Notch 3 was chosen for Western blot as reliable tested
antibodies were available in the laboratory and the gene was reported
to be 4.7 to 8 fold up-regulated in malignant biliary brushings by qPCR
and microarray. There was a lesser up-regulation of mRNA (1.7) in the
BTC tissue samples.
Secondary antibodies
1. Affinity purified horse anti-mouse, horseradish peroxidise linked
antibody (#7076, Cell Signalling Technology)
2. Affinity purified goat anti-rabbit, horseradish peroxidise linked antibody
(#7074, Cell Signalling Technology)
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7.11 Results
7.11.1 Measurement of -tubulin protein levels in bile.
Calculated total protein levels in bile were highly variable with a large range from
0.8g/ml to 20g/ml. (Example, Table 27).
Table 27 Examples of total protein calculations for bile by
ELISA using a standard curve of bovine serum albumin.
Note the highly variable protein concentration likely related
to presence of confounding factors such as cholangitis,
biliary obstruction and source of bile (eg gallbladder, ERCP,
or internal/external drainage tube).
SAMPLE ID CrudeConcentration g/ml
Control; saliva 7268.8
Bile 33 4824.4
Bile 19 874.78
Bile 14 19360
Bile 28 5097
Bile 29 16541.6
Bile 29 supernatant 3612.2
Bile 21 34006
Bile 26 4511.2
Bile 16 4268.8
Bile 46 16844.8
Bile 60 3733.4
Filtered bile 34 1425.4
Pure bile 34 4268
Filtered bile 50 959.92
Pure bile 50 2940
On Western blot, no 51KDa protein bands were seen in any of the bile samples for
up to 30mins exposure despite clear bands being visible in the TFK cell protein
extracts (Figure 65). These results may be explained by:
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1. Total protein measurements in bile include a large proportion of extracellular
and secreted biliary proteins not found in the TFK-1 cells and there may have
been a relatively small amount of cellular protein material that was insufficient
to produce visible a-tubulin bands in the Western blot gel.
2. Complex biliary glycoprotein fragments separated in the gel may inhibit
protein transfer or binding of antibody to the -tubulin protein on the
membrane.
3. The large complex biliary glycoproteins will not likely separate out on the 4-
12% gels used and the smaller -tubulin protein may have been trapped
within the complex biliary glycoproteins producing the bands seen near the
position of the loading wells (Figure 65).
Figure 64. Western blot of bile samples using antibodies directed against a 51KDa
alpha-tubulin protein showing clear bands in the TFK-1 controls (black arrow, smaller
fragments are also idenfied by the antibody) but bands of variable intensity in the large
molecular weight areas in the bile samples (dashed arrow) suggesting evidence of
impaired gel electrophoresis in the bile samples.
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When repeated with filtered and unfiltered bile from the same patients, results
showed mixed levels of staining suggesting highly variable and unreliable
protein filtration or transfer with possible reasons outlined above.
When using known and predictable quantities of cellular protein as a pure
extract or spiked into bile, the size of the bands was markedly reduced in the
protein spiked in bile, suggesting impaired gel electrophoresis, transfer or
antibody binding as described above (Figure 66).
Figure 65. Results of Western blot for -tubulin in bile samples with
or without filtering of large molecular weight proteins. Note that
with the BTC cell line controls, cells spiked in bile resulted in a
significant reduction in the blot size suggesting that bile impairs the
process and applicability of Western blot analysis.
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7.11.2 Measurement of notch3 protein in bile
When notch3 protein expression assessed by Western blot was performed
using bile samples, no visible bands of notch3 protein were found suggesting
an absence of notch3 protein or methodological problems as outlined above
for -tubulin (data not shown).
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7.12 Conclusions: Western blot analysis of
protein expression in bile.
As cholangiocytes line the lumen of bile ducts and these are the primary
source of RNA providing data on gene expression in the biliary brushings, bile
would appear to be a good potential source of tissue for analysis of protein
expression and development of diagnostic tests.
Despite previously published works describing alterations in biliary proteins in
disease (Matull, Andreola et al. 2008), these results suggest that Western blot
is not a reliable method for investigating the presence of proteins of interest in
bile. Total protein levels in bile are highly variable and the composition of
protein types (e.g. cellular proteins, extra-cellular glycoproteins,
immunoglobulins etc) is also highly variable and not easily to quantitate. In
view of this and the variable cellularity of bile, there is no definitive reference
protein standard for use with bile samples making quantification by Western
blot difficult. In addition, other than the dilutional effects of x-ray contrast
agents in bile, it is unclear how these agents may interfere with the
methodology of Western blot. Our data also suggest major interference in the
assay by components of bile which may include the large complex
glycoproteins. Previously published work used a higher degree of bile
filtration with long (many hours) centrifugation times through small pore filter
columns to exclude larger biliary proteins. It is unclear whether this process
efficiently separates small proteins or protein fragments of interest and so
quantification of proteins in the filtrate may also be unreliable.
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In view of the methodological difficulties and lack of reliable quantification
using these methods, protein expression would be better assessed in bile
using alternative methods such ELISA or assessed in tissue sections using
immunohistochemistry. The lack of commercially available ELISA kits for our
proteins of interest supported the use of immunohistochemistry as the most
suitable next step in analysis of protein expression.
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7.13 Part B: Assessment of protein expression in
biliary tissues using immunohistochemistry.
7.14 Introduction
Immunohistochemistry (IHC) is a standard method for assessing protein
expression in histology sections of tissue specimens. It is used both in
research and for clinical assessment of patient samples. The methods require
standardised protocols for each tissue type with different conditions for
antigen unmasking and retrieval, antibody binding and staining.
In order to further assess protein expression of a selection of genes of
interest, we aimed to use IHC to assess distribution and levels of staining of
some of these proteins. One gene that appears to be highly upregulated in
BTC (PVT1) is not translated to protein so cannot be further assessed by this
method. Its mechanisms of action are unclear but include the coding of micro
RNA sequences that alter mRNA expression of other genes.
7.15 Materials and methods
7.15.1 Samples
Tissue blocks stored at the UCL Department of Pathology from patients who
had undergone surgery for benign and malignant disease were identified from
clinical databases. Ethical approval for use of the tissue was granted as
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described previously (06/Q0152/106). Cutting of blocks and
immunohistochemistry work was performed as a paid service by UCL
Advanced Diagnostics (Philippa Munson, R&D Manager) as UCL regulations
do not allow tissue blocks of clinical samples to be released from the
Department of Pathology. A summary of the clinical samples used for
immunohistochemistry is shown in Table 28.
Table 28. Summary of patient details of sections used for immunohistochemistry
Sample Diagnosis Age Gender
B1 CBD (Choledochal cyst) 74 F
B2 GB (Chronic cholecystitis) 63 F
B3 GB (Chronic cholecystitis) 44 M
B4 GB (Chronic cholecystitis) 30 F
B5 GB (Chronic cholecystitis) 39 F
B6 GB (Chronic cholecystitis) 15 F
B7 Gb (Chronic cholecystitis) 43 F
B8 Cystic duct (Chronic cholecystitis) 40 F
B9 GB(Chronic cholecystitis) 52 F
B10 GB (Chronic cholecystitis) 57 M
B11 CBD (Chronic pancreatitis) 50 M
B12 (Chronic cholecystitis) 67 M
Benign
Mean 48
C1 Tumour mass (CC) 55 M
C2 Tumour mass (GBCa) 63 F
C3 Tumour mass (CC) 65 M
C4 Tumour mass (CC) 59 M
C5 Tumour mass (CC) 75 F
C6 Tumour mass (CC) 53 M
C7 Tumour mass (CC) 69 M
C8 Tumour mass (CC) 49 M
C9 Tumour mass (CC) 55 M
C10 Tumour mass (GBCa) 78 M
C11 Tumour mass (CC) 61 M
BTC
C12 Tumour mass (CC) 56 F
Mean 62
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7.15.2 Selection of proteins for analysis by
immunohistochemistry.
The proteins for further analysis were partly selected prior to completion of the
tissue mRNA expression analysis. Criteria used to select proteins of interest
included;
1. Genes consistently up-regulated in different validation sets
2. Proteins with antibodies suitable for IHC using FFPE tissues
(determined by either manufacturer datasheets or other published work
providing details on suitable methods).
3. Proteins already identified as biomarkers in other cancers
4. Proteins expressed in extracellular compartments or those that may be
secreted into body fluids (bile or blood).
Some candidate proteins did not fulfil sufficient of the criteria above and were
not further assessed by IHC. Proteins selected for analysis by IHC and details
of suitable antibodies used are shown in Table 29.
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Table 29. Summary of proteins assessed and antbodies used for
immunohistochemistry
Protein Antibodies Positive control References
Goat anti-human HOXA10
polyclonal IgG.
#SC-17159, Santa Cruz
Biotechnology
Endometrium,
colon (Sarno, Kliman et al. 2005)
HOXA10 Rabbit anti-human HOXA10
polyclonal IgG.
#LS-C30941, Lifespan
Biosciences
Endometrium,
colon
Manufacturer approved for
FFPE tissues
POU5F1
(Oct3/4)
NCL-L-OCT-3/4,
Novocastra Laboratories,
Burlington, Canada)
seminoma In routine clinical use by theUCL pathology lab
#sc-68098 (C-19), Santa
Cruz Neuronal cells (Leja, Essaghir et al. 2009)
PNMA2 Rabbit anti-human IgG
#HPA001936, (Atlas
Antibodies (Sigma))
Neuronal cells Manufacturer approved forFFPE tissues
SERPINA
3 (AACT)
Mouse anti-human
SERPINA3 monoclonal IgG
M02 (clone 1C10)
# H00000012-M02, Abnova
Colon, skin Manufacturer approved forFFPE tissues
CD9
Monoclonal IgG mouse
anti-human CD9.
#NCL-CD9, Novocastra
Laboratories, Burlington,
Canada)
Mammary
fibroadenoma
(Coudry, Meireles et al.
2007)
COL17A1
Mouse anti-human
COL17A1 monoclonal IgG,
#NC16A-3, (ab79878),
Abcam
skin Manufacturer approved forFFPE tissues
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7.15.3 Immunohistochemistry methods
This work was performed as a paid service by UCL Advanced Diagnostics
using the BondTM Automated Immunohistochemistry & In-Situ Hybridisation
System. Tissue stored as FFPE blocks were serially cut to 10m sections for
IHC. One section was stained with Haematoxylin and Eosin (H&E) for later
assessment of tissue sections by a histopathologist.
Tissue sections were mostly processed with similar steps apart from minor
differences in incubation times, enzymes and secondary antibodies etc. A
summary of the steps for IHC is as follows;
1. Deparaffinisation using x3 washes in BondTM Dewax Solution at 700C
followed by x3 washes in ethanol and x3 washes in BondTM Wash
Solution.
2. Antigen retrieval by incubation with BondTM ER Solution 1 or 2 for 10
for 30mins at room temperature, 350C or 1000C followed by washes in
ER Solution and BondTM Wash Solution.
3. Addition of peroxide block for 5 mins followed by x3 washes with
BondTM Wash Solution.
4. Incubation of primary antibody followed by x3 washes.
5. Incubation with the secondary antibody for 8 mins followed by x3
washes.
6. Incubations with polymer followed by x3 washes and DAB biotin
substrate followed by x3 washes.
7. Staining with haematoxylin followed by x3 washes.
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Variations from the main protocol outlined are described for each antibody
below in line with published methodology or advice of the manufacturers.
7.15.3.1 CD9
Antigen retrieval was performed using BondTM ER Solution 1 for 30mins at
1000C. The primary antibody (mouse monoclonal IgG1, NCL-CD9,
Novocastra Laboratories, Burlington, Canada) was used at a dilution of 1/400.
7.15.3.2 POU5F1 (oct 3/4)
Antigen retrieval was performed using BondTM ER Solution 2 for 20mins at
350C. The primary antibody (mouse monoclonal IgG1, NCL-L-Oct3/4, clone
N1NK, Leica Microsystems) was used at a dilution of 1/100.
7.15.3.3 PNMA2
Antigen retrieval was performed BondTM ER Solution 2 for 30mins at 350C.
The primary antibody (rabbit polyclonal, HPA001936, (Atlas Antibodies) was
used at a dilution of 1/500.
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7.15.3.4 SERPINA3
Antigen retrieval was performed using Enzyme 1 for 10mins at 370C. The
primary antibody (mouse monoclonal IgG2, H00000012-M02, Abnova) was
used at a dilution of 1/400.
7.15.3.5 HOXA10
Antigen retrieval was attempted using Enzyme 1 and BondTM ER Solutions 1
and 2 for 10, 20 and 30mins. The primary antibody (LS-C30941, Lifespan
Biosciences and SC-17159, Santa Cruz Biotechnology) was used at
concentrations of 1/20 to 1/400 and longer incubation times. Different
secondary antibodies were also tried. None of the protocols gave positive
staining in even the positive endometrial tissue controls and so no suitable
slides were obtained for further histopathological assessment.
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7.16 Immunohistochemistry
7.16.1 Histopathological analysis of the immunohistochemistry
slides.
Stained tissue sections were assessed and scored by a histopathologist, Dr
Maesha Deheragoda, UCL. A standard scoring system was used to score
both intensity and number of epithelial cells stained (Figure 66). The number
of epithelial cells stained positive was scored as an estimate of the
percentage of the total number of cells.
Figure 66. Table of criteria used for scoring of
immunohistochemistry of BTC and benign tissue
sections.
Level of staining
0 None
1 low intensity
2 moderate intensity
3 high intensity
Comparison of results between benign and malignant groups was performed
using a two tailed t-test.
7.16.2 Concordance with previous analysis of protein
expression shown by other groups.
The protein expression pattern for genes of interest was searched in the
literature and via the Human Protein Atlas database. No similar data were
found in the published literature but four of the proteins of interest were
reported in liver and BTC in the Human Protein Atlas database (Figure 67)
(proteinatlas.org). These suggest negative or weak staining for HOXA10, CD9
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and PNMA2 in normal liver and biliary epithelium and up-regulation in BTC.
SERPINA3 was strongly expressed in both normal liver and BTC.
Figure 67. Examples of immunohistochemistry staining published by the Human
Protein Atlas showing staining levels in normal liver (top row) and cholangiocarcinoma
tissue (bottom row) for 4 of our proteins of interest. Note the increased staining in
cholangiocarcinoma specimen but also heavy staining of SERPINA3 in normal liver.
There were no data on either POU5F1 or COL17A1 available in the Human Protein Atlas
database (proteinatlas.org).
266
7.17 Results: Immunohistochemistry
Results for the individual scoring and evaluation of differences between
benign and malignant groups are shown in Table 30. Note that one of the
benign samples is blank as it was not scored due to a lack of epithelial tissue
in the histology slides.
CD9, SERPINA3 and PNMA2 were all significantly elevated at the protein
level in malignant versus benign biliary epithelial tissues. Significant
differences were seen both in the intensity of staining and percentage of
epithelial cells staining positive (Table 30). Examples of the immunostaining
for these proteins are shown in Figure 68, Figure 69, Figure 70 and Figure 71.
Despite evidence of mRNA upregulation in BTC, POU5F1 immunostaining
was negative in all benign and cancer specimens. The positive control slides
did however stain positive and the antibody was regularly used by the UCL
Advanced Diagnostics laboratory suggesting that the immunohistochemistry
results were valid and that POU5F1 (oct3/4) is not heavily expressed in biliary
epithelium. HOXA10 was not assessed due to difficulties in finding suitable
conditions for positive staining with the antibody. Work with HOXA10 and
COL17A1 is ongoing. However, in support of our data, there is a single
example of HOXA10 immunostaining staining in CC on the Human Protein
Atlas online databse (proteinatlas.org) showing strong staining in CC but not
in benign liver or biliary epithelium (Figure 67). There are no data available for
COL17A1.
267
Table 30. Results of immunohistochemistry showing scoring for CD9, POU5F1,
SERPINA3 and PNMA2
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Figure 68. Examples of H&E and CD9 immunostaining for benign and malignant biliary
tissues. Note the strongly positive epithelial staining for CD9 in cancer (arrows) not
seen in the benign sample.
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Figure 69. Examples of SERPINA3 immunostaining in benign (A&B, no staining) and
malignant (C&D, strong epithelial staining) biliary tissues.
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Figure 70. Examples of PNMA2 immunostaining showing negative or weak staining in
benign disease (A&B) and moderate staining of epithelium in BTC (C&D).
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Figure 71. Examples of immunostaining for POU5F1 (oct-3/4). All
benign and malignant samples were negative for immunostaining.
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7.18 Conclusions: Analysis of protein expression
by immunohistochemistry of biliary tissues.
The results of the immunohistochemistry support the hypothesis that
upregulation of mRNA expression in genes of interest identified by biliary
brushings +/- surgical resection material, is often translated to up-regulated
protein expression in tissue sections. Out of the 4 proteins assessed to date,
3 were significantly up-regulated and the fourth showed no staining in any
samples, raising the question of methodological problems with antigen
exposure in the biliary tissue sections.
Although there were clear differences between the overall levels of staining
and numbers of cells staining positive for CD9, SERPINA3 and PNMA2, none
had sensitivity or specificity high enough to be diagnostic markers by
immunohistochemistry. For example, using data for CD9, 10/12 cancer
samples (83%) were positive for any staining and 2/11 (18%) were positive in
the benign group, reducing its specificity. If one uses a stronger level of
staining (≥2) as the cut-off, only 5/12 (42%) were positive in the cancer
tissues and 1/11 (9%) were still positive in the benign tissues. Equally, of the
cancer tissues, there was a wide range in the number of cells staining positive
(5-70%), with up to 30% weak or moderate staining in the two benign samples
staining positive for CD9. The data presented and numbers tested were
insufficient to evaluate whether protein expression may be useful
prognostically.
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Despite the lack of high sensitivity or specificity by immunohistochemistry, the
results support further evaluation of some of the proteins of interest in other
clinical samples such as bile or blood using more quantifiable methodology
such as ELISA.
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7.19 Discussion: investigation of gene and
protein expression in biliary surgical
resection material.
These studies of mRNA expression in biliary tissues raise a number of
interesting results. Analysis and confirmation of elevated MUC4, previously
shown by our group to be upregulated in BTC, acted as an internal control
supporting the validity of the results. Despite a strong correlation of mRNA
expression in the second biliary brush validation set, the correlation was less
strong in the biliary tissues, with a concordance of only 14%.
The lower concordance of upregulated mRNA expression in tissues compared
to the ERCP biliary brushings may have a number of explanations. Firstly, we
have shown that the relative abundance of epithelial and leukocyte RNA in the
two types of tissues is different with the most striking difference being the
higher quantity of leukocyte RNA in the tissue samples  in keeping with
macroscopic assessment of biliary tissues where surgical resection material
from patients with complex strictures and/or those who have biliary stents in
situ, have much greater numbers of inflammatory cells than biliary brushings.
These data suggest that brushings may be a purer source of epithelial RNA
for experimental or clinical use.
When using ubiquitously expressed reference genes such as 18S or GAPDH,
an alteration in the ratio of different sources of RNA may impact on the
275
relative expression of genes related to epithelial cell function or disease. One
potential method of reducing this bias would be to use a standardised
reference gene of epithelial cell origin. CK19 and some other cytokeratins are
good biliary epithelial cell markers and are expressed at levels near to those
of ‘house keeping’ reference genes such as GAPDH. Therefore, these could
be used as reference genes for calculation of relative mRNA expression in the
genes of interest. However, most of these genes are altered to some extent in
disease states, including CK19 which has previously been shown to be
upregulated in BTC (Maeda, Kajiyama et al. 1996), and would therefore also
not be an ideal reference gene.
Another potential factor that we have not evaluated to date is the high stromal
component and fibrotic nature of BTC tissues. These result in difficulties in
breaking up the tissue during the initial steps of RNA isolation and may impair
release of epithelial cells and the contained RNA. In addition, there may be a
relatively high contribution of RNA from other stromal cellular components
such as fibroblasts. These mesenchymal cells do not express CD45 used as
our main marker of cells from haematogenous cell lineages. The number of
fibroblastic cells is thought to be relatively low in comparison to epithelial cells
and leukocytes but require further evaluation using fibroblast markers in biliary
tissues.
One way of overcoming this problem would be to use laser capture
microdissection of biliary tissues to isolate a purer pool of epithelial cells,
although this introduces additional technical challenges.
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An alternative explanation for the differences in gene expression between
biliary brushings and tissues is that cells at the centre of the tumour mass
(isolated from the tissue sections) have a different biology and gene
expression to those isolated from brushings at the tumour surface and leading
edge. This phenomenon of heterogeneity within cancers is well recognised
and recently specifically investigated with regards different genetic clonal
compositions within different areas of the same breast cancer mass from
individual patients (Navin, Krasnitz et al. 2010). Also, biliary brushings isolate
cells from the bile duct surface which are in contact with bile. It is highly likely
that gene expression in the different areas of the tumour is different
depending on the function of the genes of interest. This phenomenon may in
fact also support the use of biliary brushings as a more suitable source of
material for biomarker development as cells at the bile duct surface or leading
edges may be more likely to secrete protein biomarkers into more practical
clinical samples such as bile and serum.
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Chapter 8.
8 Conclusions, discussion and future
directions
8.1 Summary of main conclusions
1. Measurement of serum CK19 fragments (CYFRA 21-1) is shown to be
a diagnostic and prognostic marker of BTC with accuracy similar to that
of the current best biomarker, CA 19-9.
2. Measurement of serum CK19 fragments (CYFRA 21-1) as a surrogate
marker of tumour cell fragments in the blood supports the concept that
circulating tumour cells may be common in the blood of patients with
BTC.
3. Although technically possible, mRNA expression profiling of archived
samples of PSC related CC is currently not plausible, primarily due to
the rarity of the samples and the very high (or complete) degradation of
RNA caused by the methods used for storage. Alternative, RNA
preserving methods of storage would optimise prospective sample
collection for future studies.
4. RNA isolated from bile and biliary brushings obtained at ERCP is of low
quantity and highly degraded but is suitable for gene expression
analysis if appropriate techniques are used.
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5. Whole genome mRNA expression profiling of biliary brushings is
feasible and potentially provides a relatively simple and reliable method
of assessing gene expression in biliary disease.
6. A selection of protein products of genes identified by the microarray
and qPCR studies are shown to be upregulated in cancer tissues by
immunohistochemistry, supporting the validity of the gene expression
data.
7. Genes aberrantly expressed in BTC can be identified using brushings
of biliary strictures. A selection of the genes identified in this thesis
(e.g. PVT1, HOXA10, COL17A1) show promise as genes of interest in
the biology or as biomarkers of BTC and warrant further investigation.
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8.2 Discussion
Biliary tract cancer remains difficult to diagnose in many patients. Patients
with BTC have a poor prognosis, in part related to difficulties and delays in
diagnosis and most patients present at an advanced stage with five year
survival rates of less than 5%. Diagnostic difficulties are related to the lack of
reliable tumour markers, radiological similarities with benign disease such as
PSC and IgG4 disease, low tissue diagnosis rates because of the low
sensitivity of biliary brushings (18% to 69%, Table 1) and the absence of
mass lesions that can be biopsied in many patients. Some surgical series
report a high prevalence of benign disease (up to 17%) in patients undergoing
resection for presumed CC, highlighting the need for accurate diagnosis in
order to plan appropriate treatments (Erdogan, Kloek et al. 2008). High tissue
diagnosis rates can be achieved (Abstract 2, Figure 74 (Mills, Chapman et al.
2009)) but there remains a need for improved biomarkers for BTC.
In Chapter 2, we demonstrate that a simple ELISA test measuring circulating
fragments of CK19 (CYFRA 21-1) from epithelial cells, has a higher specificity
(88% to 97%) but lower sensivity (30% to 56%) than serum CA 19-9, for the
diagnosis of BTC. A major problem with all biomarkers is that until the
specificity of the test reaches that of a cytologic or pathologic confirmation (ie
usually 95% to 100%), it is difficult to recommend to patients high risk or
potentially toxic treatments such as surgery or chemotherapy. Although the
CYFRA 21-1 test has specificity approaching these figures, it is increasingly
recognised that single biomarkers are unlikely to achieve such high
specificities and be useful for diagnosis unless developed as part of multiple
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biomarker tests that incorporate assays of different biological pathways or
cellular components (Gervasoni, Monasterio Munoz et al. 2008). The
diagnostic accuracy of CYFRA 21-1 can be improved (sensitivity 27% to 51%,
specificity 95% to 100%) to levels similar to that of biliary brush cytology
(sensitivity 18-69%, specificity 90-100%) by combination with CA 19-9, which
recognises a different protein group in the form of extra-cellular mucins. The
possibility of further improving diagnostic accuracy by addition of other biliary
and/or epithelial markers remains but has not been tested.
The advantages of serum ELISA tests such as CYFRA 21-1, are that they are
simple to perform, relatively cheap (approximately £10 per sample) and,
unlike tissue diagnosis, are non invasive requiring only a sample of blood.
Therefore, they have the potential to be effective and efficient tests for
surveillance of high risk patients such as those with PSC. In order to address
the use of CYFRA 21-1 in screening and diagnosis of BTC in patients with
PSC, a large prospective multi-centre study is required which is feasible only
as part of other collaborative studies of patients with PSC.
In Chapter 2, we also demonstrate that CYFRA 21-1 is a strong predictor of
poor prognosis for patients with BTC (median survival 2 months v 10 months
for levels ≥ & ≤ 3ng/ml respectively). These results are superior to that of CA
19-9, used by some as an indicator of advanced disease and non-resectability
(Levy, Lymp et al. 2005). In our series, CA 19-9 was not a significant predictor
of prognosis. The issue of whether CYFRA 21-1 in addition to staging by
imaging modalities may be a marker of potentially curative surgery could not
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be assessed with the small number of surgical cases in our samples store but
deserves further consideration.
Another approach to biomarker development is to develop multiple gene
signature assays using data pooled from gene expression studies for the
disease of interest. Spira et al used this approach to identify microarray gene
signatures in lung cancer (Spira, Beane et al. 2007). In this study, mRNA
expression profiling of bronchial brushings from patients (all smokers) with
and without lung cancer, could detect the presence of a cancer using an 80
gene signature with a sensitivity of 80% and specificity of 84%. Importantly,
this disease identification was made by brushing macroscopically normal
bronchial mucosa in patients with cancer elsewhere in the bronchial tree.
Multiple gene assays are likely to be far more accurate for diagnosis of
disease than measuring single gene or protein expression. As utilised and
demonstrated in Chapter 6, assays are now available that can reliably
measure multiple gene expression using small amounts of mRNA. Such
assays can easily be customised to assess genes and/or splice variants of
interest and are becoming simpler and cheaper to use. They therefore lend
themselves to further evaluation as diagnostic or prognostic gene expression
assays.
An initially unexpected finding of our work was the level of RNA degradation
found in the biliary brush samples. However, using methodology developed
for use with similarly degraded RNA from FFPE tissues, we were able to show
that reliable data can be extracted from samples of biliary brushings. This, to
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our knowledge, has been little studied in the past and is a particular strength
of this thesis. We also showed that, in contrast to earlier studies reporting that
both bile and x-ray contrast agents are cytotoxic to biliary epithelial cells
(Benedetti, Alvaro et al. 1997; Ju, Kim et al. 2002), the degradation does not
appear to be related to short term exposure of cells to bile or x-ray contrast.
Also the degradation occurs in vivo and is thus not amenable to
methodological changes to prevent it.
We have shown that whole genome mRNA expression profiling using
microarray, supported by qPCR, can be done using biliary brushings.
Moreover, our data on relative expression of epithelial (CK19) and leukocyte
(CD45) markers in biliary brushings and surgical resection tissue suggest that
biliary brushings are a more reliable source of epithelial cells than tissue. This
is in line with microscopic findings at cytologic or histologic assessment of
biliary brushings and resection tissues which tend to have a greater number of
inflammatory cell infiltrates in the complex strictures of patients undergoing
surgery. Also, samples of biliary brushings are more clinically relevant
samples for biomarker work as ERCP is amongst the earliest tests done in
most patients with indeterminate strictures and is less hazardous than
percutaneous biopsy or surgery.
Our work is one of the first thorough evaluations of the suitability of biliary
brushings for gene expression studies. As such, data presented in this thesis
support the use of these methodologies for further, large-scale studies in
patients with indeterminate biliary strictures. Also, these methods could be
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applied to other biliary diseases that have historically been very difficult to
study, such as PSC, PBC and IgG4 disease. One of the major problems in the
past has been the lack of biliary epithelial cells for study as they are not
amenable to sampling by biopsy and are difficult to isolate by laser capture
microdissection (LCM) in the minority of cases that undergo surgery. To date,
we are aware of only a few studies where specific analysis of biliary epithelial
cells has been undertaken following LCM of surgical resection tissues in PSC
and PBC (Taniai, Higuchi et al. 2002; Baba, Kobashi et al. 2006). However,
with the development of more direct and sophisticated ERCP techniques,
including cholangioscopy, it is likely that directed biopsies of intraluminal
pathologies would provide a similar or even better source of material for work
similar to that described in this thesis.
PSC can be a difficult condition to manage and patients have a high risk of
developing cholangiocarcinoma. This is a topic of particular interest to us and
developing an understanding of the biology and biomarkers for use in this
clinical setting were initially major aims of these studies. We investigated the
feasibility of using archived FFPE tissues from patients with PSC and PSC-
related CC to achieve these aims. However, as described in Chapter 3,
despite methodology now being available to perform such studies, the clinical
materials were too few and were unsuitable for further analysis using gene
expression studies.
The phenomenon of a dysplastic ‘field change’ and the hypothesis of
precancerous dysplastic change in conditions such as PSC (Fleming, Boberg
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et al. 2001), led to our decision to transfer work to the biliary tree and
investigate gene expression in biliary brushings which commonly have no
malignant cells, even when directly brushing malignant strictures. Recent data
assessing explants of 100 PSC patients who underwent liver transplantation
reported that dysplasia is seen in bile ducts of 83% of those with coexistent
CC and 36% of those without CC (Lewis, Talwalkar et al. 2010). This high
prevalence remained when recording only high grade dysplasia which was
seen in 72% and 32% in those with and without co-existent CC in the explant.
Assessing gene expression and DNA mutational analysis in biliary samples
from patients with PSC is difficult because of the complexities of isolating
biliary tissues. One approach is to use laser capture microdisseaction of liver
transplant explants, but these tissues are not common and represent
advanced disease. Methods described in this thesis provide a technique for
sampling and evaluation of this problem in patients with PSC before or during
evaluation for liver transplantation. We support such studies in the form of
prospective sample collection of biliary brushings from patients with PSC and
other biliary diseases, who undergo ERCP.
Cholangitis in patients with biliary strictures or stents remains a potential
problem for gene expression profiling of biliary samples. A potential
confounding effect of infection in patients with complex malignant strictures
cannot be excluded but we demonstrate two important points that suggest
that any such confounding effect is small. The first is that the relative
quantities of epithelial and leukocyte RNA is such that differential leukocyte
expression between groups is likely to be minimised by the abundance of
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epithelial RNA which probably accounts for approximately 50 times more RNA
than leukocyte RNA. Secondly, the microarray data failed to show differential
expression of genes commonly used as leukocyte specific markers such as
CD45, leukocyte specific protein-1 (LSP1), leukosialin (CD43), CD18
(MHM23), cathepsin G, leukocyte alkaline phosphatase (LAP), CD11 and
CD166. We are therefore confident that the potential confounding effect from
leukocytes remains small.
Another potential source of error in our data is the relatively small sample
sizes. This is particularly true for the large data sets obtained from the
microarray experiments. However, such samples are precious and costs for
microarray analyses are high. Therefore, feasibility studies, such as these
presented in this thesis must be performed before large prospective studies
could be planned. Following bioinformatics advice, appropriate statistical
methodologies were applied to minimise bias and reporting errors, although
these cannot be removed completely with the small sample sizes used in our
microarray work. The validity of the results with regards sample size errors
was also supported by the high concordance between the biliary brush
validation sets as well as the finding of up-regulated protein products by
immunohistochemistry of tissue sections. This work continues with
assessment of HOXA10 and COL17A1, both of which were found to be highly
upregulated in all of the sample sets.
The lower concordance between the biliary brush and tissue gene expression
data may at first appear disappointing. However, as discussed, these two
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clinical samples are quite different and one could not expect the expression
pattern to be exactly the same. The higher ratio of leukocyte and stromal
material in tissue sections is clearly a problem in these samples. Also, the
biology of cells in the centre of masses (used for the tissue work) is somewhat
different to that of the cells lining the bile duct isolated by biliary brushings.
Both have advantages and disadvantages. The surface epithelial cells in bile
ducts are those most likely to be relevant for investigation of potential protein
products released into the bile which may be a good source of material for
biomarker work using ELISA, but, as discussed in Chapter 7, less suitable for
Western blot.
The relative quantities of fibroblasts in benign and malignant samples have
not been assessed in our work. However, based on cytologic and histologic
assessment, this is likely to be small in samples of biliary brushings but may
be more significant in tissues sections of BTC, which are known to have
relatively high proportions of stromal material (Okamura, Yoshida et al. 2005).
Fibroblastic and stromal tissue activity may be important in both
understanding the biology of cancer and in biomarker development. Studies in
other malignancies, such as breast and colon cancer, first demonstrated
alterations in stromal cell numbers and functions in cancer biology (Allinen,
Beroukhim et al. 2004; Nakagawa, Liyanarachchi et al. 2004). More recent
work in pancreatic and biliary tract cancer suggest that fibroblast activity and
gene expression becomes altered and may play a role in disease progression
(Hwang, Moore et al. 2008; Chuaysri, Thuwajit et al. 2009; Utispan, Thuwajit
et al. 2010).
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Another potential validation step, which may also be a possible clinical
diagnostic test, is for immunocytochemistry to assess protein expression in
the biliary brushings, samples which closely match the samples used for the
gene expression studies. A major obstacle for this however is the paucity of
the material obtained from biliary brushings, which is usually sufficient for
smearing only 2 to 4 slides, and hence insufficient for research work without
additional sampling of strictures with a second or third brush of bile ducts.
In summary, the data presented in this thesis describe the methodology for
gene expression studies in biliary brushings, data on gene expression in BTC,
and evidence to support this methodology and the validity of the results. Such
methods should be suitable for investigation of other biliary diseases.
8.3 Plans for further experiments
Further experiments are required in order to investigate the biology of genes
of interest but in particular to test the hypothesis that some of these genes
may serve as useful biomarkers in BTC. These were not completed as part of
this thesis but represent areas of planned and ongoing research by our group.
8.3.1 BTC cell lines
Some of the genes identified thus far have not been previously reported as
biomarkers or investigated with regards the biology of BTC and/or other
cancers. A better understanding of the biology of BTC and cancers in general
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is likely to lead to the development of new cancer therapies and such work
firstly requires investigation in vitro using suitable cell lines such as the TFK-1
and HUCCT BTC cell lines available in our group.
From the shortlist of over-expressed genes further assessed in this thesis,
PVT1 is particularly interesting with regards the biology of BTC. PVT1 (also
known as MYC activator) is a non protein-coding gene that was initially
identified as associated with lymphoma where chromosomal translocations
result in PVT1 becoming sited near to and co-amplified with the MYC
oncogene. It is thought to play a role in the normal MYC pathway via
microRNAs encoded within it (Beck-Engeser, Lum et al. 2008). Its location on
chromosome 8q24, a locus commonly amplified in other solid organ cancers,
led to the investigation of PVT1 in breast and ovarian cancer cell lines where
it was shown that RNA silencing of PVT1 results in apoptosis of cancer cell
lines, a phenomenon that was not seen with silencing of MYC (Guan, Kuo et
al. 2007). BTC is a relatively chemotherapy resistant cancer and elucidation of
mechanisms responsible for sensitising cells to chemotherapy +/- other
treatments such as PDT, may result in the generation of new therapies in
BTC. Using techniques and conditions already set up by the group, we aim to
assess the effect of RNA silencing PVT1 in BTC cell lines and assess the
response to addition of other treatments such as EGFR blockade and PDT.
Similarly, HOXA10 may be important in the biology of BTC. The HOX genes
are particularly important in embryogenesis but become less active in normal
adult physiology. HOXA10 is strongly expressed in a number of tissues during
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development but is mostly only weakly expressed in normal adult tissues
apart from endometrial cells in the proliferative mid-secretory phase of the
menstrual cycle. The primary drive for activation in normal physiology is
thought to be related to female sex hormones. HOX genes are not expressed
in normal ovarian surface epithelium but some (including HOXA10) are
expressed in some ovarian cancers (Cheng, Liu et al. 2005). In haemopoietic
cell lines, induction of HOXA10 over-expression leads to increased
proliferation of haemopoietic cell lines and transformation to cells with stem
cell like properties, including self renewal (Magnusson, Brun et al. 2007). A
recent report also demonstrates up-regulation of HOXA10 as a marker of oral
squamous cell cancer (Yamatoji, Kasamatsu et al. 2010).
We aim to assess the expression of HOXA10 (and possibly other HOX genes
such as HOXB6 shown to be upregulated in BTC by our and other data) in
BTC cell lines. If shown to be up-regulated, we would again use RNA
silencing to assess the effect on cell survival, with or without the addition of
other therapies such as chemotherapy, EGFR blockade and PDT.
8.3.2 Measurement of COL17A1 or COL17A1 fragments
in bile and serum
Collagen 171 (COL17A1) is an atypical collagen in that it is a membrane
bound protein rather than a component of the extra-cellular matrix. It forms
part of the hemidesmosomes and is involved in cell adhesion to the basement
membrane. It has a secreted,180kD, extra-cellular domain (also known as
290
BP180, ectodomain or LAD-1) releasing soluble collagen fragments into
surrounding tissues. To date, reports of abnormalities of COL17A1 function
are limited to the benign skin condition epidermolysis bullosa and there are no
published reports of altered COL17A1 in cancers.
Our data show that COL17A1 is highly and consistently up-regulated in all the
sample sets tested (microarray x16, qPCR validation of brushings x11, qPCR
with fresh set brushings x5, qPCR tissue x16). These data are in line with a
small study (n=17) demonstrating higher levels of type IV collagen in
embryologically related pancreatic adenocarcinoma (Ohlund, Lundin et al.
2009). This study used an ELISA assay to measure plasma type IV collagen
and showed significantly higher levels in cancer and a strong association
between elevated levels and poor prognosis. Similar results for another
collagen (collagen XXIII) have been reported in prostate cancer where
elevated levels were associated with both diagnosis and poor prognosis
(Banyard, Bao et al. 2007).
The striking pattern of mRNA up-regulation and the potential that the extra-
cellular domains may be secreted into bile or serum, support further
investigation of the hypothesis that COL17A1 may be a biomarker for BTC.
We aim to study this possibility by assessment of protein levels in tissue using
immunohistochemistry, and in bile and serum using antibodies directed
against the extra-cellular domain of the protein by Western blot and ELISA
assays. Commercial kits are currently not available but antibodies directed
against the extra-cellular portion have been described (Schacke et al 1998).
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Thus, it should be possible to develop an ELISA assay in order to measure
protein levels and test as a diagnostic and/or prognostic marker. Similarly, it
may be useful to investigate the protein expression of other collagens
(COL1A1 and COL6A3) also shown by our data to be consistently up-
regulated in BTC.
8.3.3 Analysis of further genes identified in the
microarray data set of BTC biliary brushings.
The original data set obtained from the microarray analysis of the biliary
brushings contained a list of over 2000 genes reported to be upregulated in
BTC. Many of these have only a small level of fold change or statistical
significance but a number of genes remain of interest for further investigation
in BTC. Plans are in place to investigate some of these genes using the
methods outlined in this project. Examples include MLL4 (myeloid-lymphoid
leukaemia 4, also known as TRX2, MLL2) which was originally identified as
amplified in leukaemia but subsequently shown to be a commonly amplified
locus (19q13.1) in solid organ tumours including some pancreatic cancers
(Huntsman, Chin et al. 1999). Our data uaing biliary brushings suggest that
MLL4 is upregulated in BTC (fold change 7.7, p<0.001) and data in
proteinatlas.org suggest weak or negative staining in normal bile ducts but
positive staining (>75%, moderate) in CC. Based on our microarray data,
biological function and/or proteinatlas.org data, other genes deserving further
investigation include THBS1, TSP1, PPFIBP1, RAPGEF3, ADAMTSL4,
CAMK1G, IFITM2, MED12 and NGFRAP1.
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8.3.4 Identification and analysis of circulating tumour
cells in BTC
CYFRA 21-1 is a component of the intracellular cytoskeletal protein CK19,
present in all epithelial cells. Due to the fact that epithelial cells ordinarily are
not present in the blood of healthy individuals or those wth benign diseases,
CK19 and/or CYFRA 21-1 may act as surrogate markers for cancer cells in
blood. Our data assessing the role of CYFRA21-1 in BTC demonstrate that it
is a relatively good biomarker for BTC (Chapter 2). Sensitivity and specificity
were 30% to 56% and 88% to 97%, respectively  figures similar to those for
the biomarker CA19-9, which is currently in widespread clinical use. However,
these data also support the hypothesis that there may be significant numbers
of circulating tumour cells in the blood of patients with BTC, a phenomenon
that has been little investigated and deserves further investigation.
One explanation for the high prevalence of circulating CYFRA 21-1 may be
that our cohort included mostly patients with advanced disease. However,
similar findings were reported in a pre-operative surgical cohort of Japanese
patients with early stage disease (Uenishi, Yamazaki et al. 2008). Another
finding of both our work and that of Uenishi et al was that CYFRA 21-1 is a
strong predictor of poor prognosis, and may play a role in the pre-operative
assessment of resectability. This may be related to CYFRA 21-1 acting as a
marker for the presence of circulating tumour cells in those with a poorer
outcome.
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These early findings support the plan for further experiments to assess
circulating tumour cells in BTC. Sensitive, automated technology is now
available that can isolate CTCs from peripheral blood and we plan to use
these assays in a patient cohort with benign and malignant biliary disease.
The current best example of CTC capture technology is the CellSearch assay
(Veridex LLC, Raritan, NJ, USA) which has now been in use for over 5 years.
The assay relies on magnetic particles coated with a selection of epithelial
(EpCAM, CK8, CK18 & Ck19) and leukocyte (CD45) markers that can be
used to separate cells from whole blood. Reports consistently show high
recovery rates of cancer cells spiked into healthy blood and negative or very
low rates (<1% of samples) of circulating epithelial cells in healthy or benign
diseases. For example, a large early study of 964 patients with different
cancers and 344 healthy or benign disease controls demonstrated a very high
recovery rate (85%-122%) of cancer cells (range 4-1200 cells) spiked into
7.5mls of healthy blood, with no CTCs found in healthy controls and only 1
low level of CTC found in 1 of 199 disease controls (Allard, Matera et al.
2004). The same study reported CTCs in 36% of all the 964 assorted
adenocarcinomas which also included identifiable CTCs in 4 (19%) of 16
patients with pancreatic adenocarcinoma, a cancer with embryologic and
morphologic similarities to BTC. Some cancers such as breast and prostate
cancer, appear to more commonly have CTCs in the blood (eg 61% in breast
cancer (Cristofanilli, Budd et al. 2004), 57% in prostate cancer (Allard, Matera
et al. 2004)) than other cancers. There are few data in pancreatic cancer
suggesting CTCs being identified in 19% to 48% of cases (Allard, Matera et
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al. 2004; Ko, Scott et al. 2007). However, we are aware of no reported data
for analysis of CTCs in BTC to date.
Obvious clinical applications of these technologies are to further investigate
measurement of CTCs (along with serum CYFRA 21-1) as markers of
diagnosis and prognosis in patients with BTC as well as investigation of its
role in determining resectability and surgical outcome. Protocols for these
studies are being developed in surgical and palliative patients with BTC as
well as pancreatic adenocarcinoma and could be extended to patients with
PSC-related or other indeterminate biliary strictures.
Another potential use of these assays is to isolate CTCs for further
investigation of the biology of BTC and for biomarker work. Gene expression
analysis can be performed using the small numbers of cells isolated with the
use of modern, sensitive RNA isolation and amplification kits. Several studies
have now been published demonstrating that CTCs can be used for multiple
gene expression analysis by qPCR (O'Hara, Moreno et al. 2004) and by
whole genome microarray analysis (Smirnov, Zweitzig et al. 2005). In addition
to the general investigation of BTC biology, there is the potential for assaying
individual patient samples to assess whether they may be suitable for
targeted individualised therapies using particular chemotherapy and biologic
regimens (Perou, Sorlie et al. 2000; Dressman, Hans et al. 2006).
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8.3.5 Detection of circulating mRNA of epithelial cell
markers as biomarkers for BTC
Following a similar hypothesis to the measurement of circulating epithelial cell
protein fragments such as CYFRA 21-1, an alternative approach to identifying
intact CTCs is to measure circulating levels of epithelial and cancer related
mRNA. This is now feasible using sample collection and RNA preservation
techniques and has been successfully demonstrated for other cancers. In a
study of 68 patients with pancreatic cancer and 31 healthy or benign disease
controls, CK19 mRNA was elevated in 64% of blood samples from patients
with pancreatic cancer when compared to the maximum level identified in the
benign controls (Hoffmann, Kerner et al. 2007). However, it is unclear
currently what represents ‘normal’ levels as demonstrated by another study
where CK20 mRNA in blood was reported in 34% of 154 patients with
pancreatic cancer but also reported as present in 17% of 54 benign disease
(chronic pancreatitis) controls (Soeth, Grigoleit et al. 2005). A recent study
addressed the question of comparison between different methods for the
detection of CTCs demonstrating a reasonable correlation (72% agreement, K
coefficient 0.356) using the CellSearch assay and qPCR for CK19 mRNA in
blood (Van der Auwera, Peeters et al. 2010).
High throughput qPCR techniques using 96- or 384 well plates and well tested
CK19 qPCR primer sets allows relatively easy measurement of circulating
CK19 mRNA in clinical samples in our laboratory. Measurement of circulating
CK19 mRNA in the blood of patients with benign and maligment biliary
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diseases may be possible using blood samples already in storage. However,
the rapid rate of RNA degradation by RNase activity and other means in blood
will likely result in low levels of positive results. This could be easily tested
with pilot studies, possibly using the same samples as the CYFRA 21-1 study
as a direct comparison. Low levels of CK19 mRNA amplification may
represent low levels of CTCs in BTC or degradation of the mRNA requiring
the collection of a fresh sample set with the addition of RNase inhibitors in the
collection tubes.
8.3.6 Validation of protein biomarkers using clinical
samples of blood and bile
The final aim of this project was to validate the clinical effectiveness of the
most promising biomarkers in clinical samples stored in our tissue bank. We
will assess a selection of the biomarkers for their diagnostic and prognostic
accuracy in patients with BTC. Studies will begin with the measurement of
COL17A1 levels in bile and/or blood. Other potential protein markers may
follow later. Another important clinical problem is appropriate surveillance of
CC in patients with PSC. We aim to test the effectiveness of the biomarker(s)
in patients with PSC and PSC related CC. A further level of validation may
require larger sample numbers in the form of multicentre studies which would
be feasible with collaborative work on sample collection in patients with BTC
and PSC.
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8.4 Other potential future directions
8.4.1 Multicentre studies of biomarkers in patients with
BTC and PSC
Most studies on biomarkers in BTC involve relatively small numbers with a
large range in reported accuracy of such markers. The only way of gaining
sufficient numbers for adequately powered studies and to obtain clear results
is to undertake prospective, multicentre studies involving sample collection
and storage. Such studies are feasible and are planned for patients with BTC
and those with PSC.
8.4.2 Gene expression profiling of PSC related biliary
strictures
The biology of PSC is poorly understood for a number of reasons including
the relative rarity of biopsy material, difficulty in isolation and culture of normal
or PSC related cholangiocytes and the small volume of the affected tissue for
sampling (i.e. biliary epithelium). The collection and processing of biliary
samples described in this project provides a method for further investigation of
disease biology using techniques such as gene expression profiling and DNA
mutational analysis.
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8.4.3 Gene expression profiling of radiographically or
cholangioscopically directed intra-ductal biliary
biopsies.
Some centres, including our centre at UCH, use radiographically directed
intra-ductal biopsies taken from strictures at the time of ERCP. Our own data
(see Abstract 2 (Figure 74) in appendix) and those of others suggest that the
sensitivity for confirming the diagnosis of BTC is between 44% and 53%,
higher than achieved in most studies of biliary brush cytology (Weber, von
Weyhern et al. 2008; Mills, Chapman et al. 2009). The recent introduction of
cholangioscopy has led to the possibility that similar work could be carried out
using directed biopsies of malignant biliary strictures. This may provide more
reliable sample acquisition. However, as yet, there are insufficient data to
demonstrate that cholangioscopically directed biopsies provide more accurate
tissue sampling and diagnosis. Also, the data on a field change in
macroscopically normal tissue taken at the time of bronchial brushings in
patients with lung cancer, and from patients undergoing surgery for
hepatocellular carcinoma suggest that directed biopsies may not be required.
8.4.4 Diagnostic gene chips for BTC
Most diagnostic tests to date involve measurement of protein levels. However,
methods such as qPCR are being simplified and standardised so that PCR
based tests are now available, for example in identification of bacterial DNA or
quantification of viral load in hepatitis B and C infection. Work using
microarray gene expression profiling has been applied in the clinical setting in
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patients with breast cancer in order to stratify patients at risk of metastases
and to direct decisions regarding the use of adjuvant chemotherapy (Perou,
Sorlie et al. 2000; Dressman, Hans et al. 2006). Similar work could be applied
to patients with hepatobiliary malignancy and may also include assessment of
protein receptor activity for tailoring therapies such as addition of biological
agents.
Now that techniques for RNA isolation and qPCR are also being simplified
with kits and chips, it has become realistic to perform such work using clinical
samples for diagnostic purposes. An obvious extension of our work is to use
whole genome expression data to design diagnostic qPCR chips or protein
arrays customised for a selection of sensitive and specific markers. The
accuracy of such chips is likely to be greatly improved by the addition of
multiple (24 to 96) genes or proteins and could reach levels that may mean
that biopsy confirmation is not required. Also, it is possible that disease in high
risk groups such as those with PSC, may be identified at a premalignant or
early malignant phase where curative treatments such as surgery or
transplantation may be appropriate.
8.4.5 miRNA profiling
Micro RNA (miRNA) are short RNA species that alter mRNA activity at the
post translational stage. The number of miRNA is far smaller than the number
of genes or mRNA but each miRNA interacts with many different mRNA
molecules with wide biological effects. miRNA have been implicated in many
cancers and have also been shown to be useful biomarkers for some cancers
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including cholangiocarcinoma (Meng, Henson et al. 2006). They also provide
a potential therapeutic approach as activation or inhibition of some miRNA
has been shown to alter cancer cell biology in vivo (Meng 2006).
Recent investigations have shown that microRNAs are now measurable in
blood and have the potential for being effective biomarkers for diagnosis,
prognosis and screening of patients with cancer. Examples include studies in
pancreatic cancer (Jones, Zhang et al. 2008) and a study investigating a
panel of 95 microRNAs in 90 patients with colorectal cancer in which a single
microRNA (miR-92) could distinguish patients with colorectal cancer from
those with inflammatory bowel disease (n=20) and healthy controls (n=50)
(sensitivity 89%, specificity 70%, AUC 88.5%) (Ng, Chong et al. 2009). During
this project we considered the option of miRNA profiling in biliary brushings,
but the methods we used for mRNA isolation unfortunately result in the loss of
very small RNA species (less than approximately 50bp), including miRNA,
which require different isolation techniques. However, the small size and
nature of miRNA mean that they are relatively resistant to degradation and
therefore may be a very useful material to investigate in bile or biliary
brushings. Microarray and qPCR arrays for investigating miRNA expression
are available and could be used in a similar way to that outlined in this project.
Another important finding in miRNA research is that their relative resistance to
degradation means that miRNA can be identified in relatively high quantities in
peripheral blood. (Mitchell, Parkin et al. 2008). This provides an opportunity
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for using easily accessible samples of blood for miRNA profiling in patients
with benign and malignant biliary disease
8.4.6 DNA mutation and methylation status analysis
The biliary brush cytology samples in TRI Reagent had the RNA recovered
but the DNA remains stored in a -800C freezer. The DNA could be easily
separated from the TRI Reagent and used for further applications such as
analysis of DNA mutations or methylation status in BTC.
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8.5 Final concluding remarks
In summary, we present data detailing the mRNA expression profiling of
ERCP biliary brushings in BTC with further validation of a selection of
identified genes at the protein level. We have shown that the the degraded
nature of the RNA isolated from biliary brushings that previously hampered
accurate gene expression profiling, can be overcome using current
techniques of molecular biology, with the most important factor being the use
of short nucleotide sequences for measurement of gene expression. We
demonstrate that samples of biliary brushings may be a better source of
material than archived FFPE tissue sections for investigation of biliary
disease. The results provide provisional data on potential novel biomarkers in
BTC including COL17A1, CD9 and HOX genes. These require further larger
validation studies before they can be studied in clinical practice. As far as we
are aware, this is one of the first comprehensive studies of gene expression of
ERCP biliary brushings and the methods described in this thesis may provide
a platform for further investigation of BTC and other biliary diseases such as
PSC and IgG4 disease in the future.
303
9 Appendix
9.1.1 Raw qPCR threshold data from the TaqMan Array
experiments and calculations of relative
expression
Table 31. TaqMan Array qPCR calculations of microarray set biliary brush samples
CT
CT (GAPDH-
18S) CT (GAPDH-18S) CT - CT,cal GAPDH rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 15.07 0.12
DA 13.69 0.19
JP 14.45 0.08 0.07 1.00 1.05 0.95
PK 13.23 0.18 14.11 0.07 0.00 0.10 1.00 0.07 0.05
BTC,
n=5 JH 14.08 0.25
LB 13.60 0.04
MT 15.22 0.30
PS 14.70 0.15 0.09 1.00 1.06 0.94
RB 12.92 0.06 14.11 0.09 0.00 0.11 1.00 0.08 0.06
CT
CT (18S-18S) CT (18S-18S) CT - CT,cal 18S rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1
DA
JP #DIV/0! #DIV/0! #DIV/0! #DIV/0!
PK #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0!
BTC,
n=5 JH
LB
MT
PS 0.09 #DIV/0! #DIV/0! #DIV/0!
RB #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0!
CT
CT (MUC4-18S) CT (MUC4-18S) CT - CT,cal MUC4 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 23.90
DA 26.03
JP 20.88 0.45 0.35 1.00 1.27 0.79
PK 21.85 0.53 23.16 0.35 0.00 0.49 1.00 0.34 0.24
BTC,
n=5 JH 19.95 0.09
LB 16.11 0.05
MT 17.83 0.53
PS 18.44 0.15 0.09 29.37 31.18 27.66
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RB 19.10 0.15 18.29 0.12 -4.88 0.37 29.37 7.47 2.34
CT
CT (MUC5AC-
18S) CT (MUC5AC-18S) CT - CT,cal MUC5AC rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 18.50 1.40
DA 18.05 0.08
JP 13.84 0.11 0.36 1.00 1.28 0.78
PK 13.60 0.24 16.00 0.36 0.00 0.50 1.00 0.35 0.25
BTC,
n=5 JH 14.40 0.09
LB 12.33 0.12
MT 10.38 0.18
PS 15.94 0.22 0.06 7.41 7.75 7.09
RB 12.49 0.07 13.11 0.06 -2.89 0.36 7.41 1.86 0.33
CT
CT (ACTB-18S) CT (ACTB-18S) CT - CT,cal ACTB rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 12.02 0.12
DA 13.03 0.07
JP 12.93 0.08 0.04 1.00 1.03 0.97
PK 11.40 0.08 12.34 0.04 0.00 0.06 1.00 0.04 0.03
BTC,
n=5 JH 11.25 0.06
LB 10.29 0.20
MT 12.49 0.13
PS 12.55 0.15 0.06 2.03 2.11 1.95
RB 10.03 0.02 11.32 0.06 -1.02 0.07 2.03 0.10 0.08
CT
CT (CD9-18S) CT (CD9-18S) CT - CT,cal CD9 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 18.21 0.38
DA 18.00 0.07
JP 17.05 0.08 0.11 1.00 1.08 0.93
PK 17.07 0.16 17.58 0.11 0.00 0.15 1.00 0.11 0.07
BTC,
n=5 JH 16.98 0.12
LB 14.99 0.06
MT 16.86 0.15
PS 18.09 0.16 0.05 2.15 2.23 2.07
RB 15.48 0.07 16.48 0.05 -1.10 0.12 2.15 0.18 0.08
CT
CT (Notch3-
18S) CT (Notch3-18S) CT - CT,cal Notch3 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 23.90
DA 23.79 0.26
JP 21.45 0.37 0.18 1.00 1.13 0.88
PK 21.05 0.30 22.55 0.18 0.00 0.25 1.00 0.18 0.12
BTC,
n=5 JH 21.02 0.14
LB 17.36 0.13
MT 20.68 0.32
PS 21.41 0.19 0.16 8.01 8.96 7.16
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RB 17.27 0.69 19.55 0.16 -3.00 0.24 8.01 1.34 0.90
CT
CT (ASPHD1-
18S) CT (ASPHD1-18S) CT - CT,cal ASPDH1 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 19.88 0.98
DA 18.32 0.10
JP 20.47 0.18 0.25 1.00 1.19 0.84
PK 17.58 0.07 19.06 0.25 0.00 0.35 1.00 0.25 0.17
BTC,
n=5 JH 19.21 0.09
LB 17.02 0.33
MT 18.73 0.14
PS 20.56 0.18 0.08 1.65 1.75 1.56
RB 16.18 0.02 18.34 0.08 -0.72 0.26 1.65 0.30 0.09
CT
CT (ATP6V0A2-
18S) CT (ATP6VOA2-18S) CT - CT,cal ATP6V0A2 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 19.56 0.29
DA 19.97 0.10
JP 21.12 0.36 0.12 1.00 1.09 0.92
PK 19.24 0.15 19.97 0.12 0.00 0.17 1.00 0.12 0.08
BTC,
n=5 JH 19.75 0.08
LB 18.71 0.17
MT 20.50 0.40
PS 21.38 0.23 0.11 1.10 1.18 1.02
RB 18.84 0.17 19.84 0.11 -0.14 0.16 1.10 0.12 0.08
CT (CEACAM1-
18S) CT (CEACAM1-18S) CT - CT,cal CEACAM1 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 18.25 0.05
DA 20.31 0.06
JP 20.86 0.08 0.09 1.00 1.06 0.94
PK 20.02 0.32 19.86 0.09 0.00 0.12 1.00 0.08 0.06
BTC,
n=5 JH 20.60 0.11
LB 18.28 0.04
MT 19.42 0.13
PS 19.05 0.17 0.05 2.08 2.16 2.00
RB 16.67 0.12 18.80 0.05 -1.05 0.10 2.08 0.15 0.08
CT (CELSR1-
18S) CT (CELSR1-18S) CT - CT,cal CELSR1 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 23.90
DA 24.28 0.27
JP 22.94 0.08 0.11 1.00 1.08 0.93
PK 21.56 0.18 23.17 0.11 0.00 0.16 1.00 0.11 0.08
BTC,
n=5 JH 20.85 0.58
LB 19.37 0.11
MT 19.72 0.40
PS 23.09 0.17 0.15 7.15 7.92 6.45
RB 18.64 0.08 20.33 0.15 -2.84 0.19 7.15 0.92 0.73
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CT (CFDP1 -
18S) CT (CFDP1-18S) CT - CT,cal CFDP1 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 19.05 0.79
DA 19.02 0.07
JP 20.33 0.11 0.21 1.00 1.15 0.87
PK 17.14 0.24 18.88 0.21 0.00 0.29 1.00 0.20 0.14
BTC,
n=5 JH 19.16 0.21
LB 17.12 0.06
MT 19.40 0.13
PS 20.19 0.20 0.07 1.11 1.16 1.06
RB 17.78 0.03 18.73 0.07 -0.15 0.22 1.11 0.17 0.05
CT (COL17A1-
18S) CT (COL17A1-18S) CT - CT,cal COL17A1 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 19.88
DA 25.32 0.27
JP 21.28 0.13 0.18 1.00 1.13 0.88
PK 21.62 0.45 22.02 0.18 0.00 0.25 1.00 0.18 0.12
BTC,
n=5 JH 22.56 0.51
LB 19.34 0.41
MT 16.15 0.19
PS 18.00 0.16 0.14 10.91 12.03 9.89
RB 16.84 0.04 18.58 0.14 -3.45 0.23 10.91 1.73 1.07
CT (COL1A1-
18S) CT (COL1A1-18S) CT - CT,cal COL1A1 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 23.90
DA 26.01
JP 22.84 0.38 0.36 1.00 1.28 0.78
PK 21.74 0.61 23.62 0.36 0.00 0.51 1.00 0.35 0.25
BTC,
n=5 JH 17.46 0.17
LB 16.68 0.04
MT 21.72 0.36
PS 20.52 0.39 0.11 21.59 23.36 19.96
RB 19.56 0.10 19.19 0.11 -4.43 0.38 21.59 5.62 1.70
CT (COL6A3-
18S) CT (COL6A3-18S) CT - CT,cal COL6A3 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 23.90
DA 29.10
JP 24.59 0.17 0.17 1.00 1.13 0.89
PK 22.33 24.98 0.17 0.00 0.24 1.00 0.17 0.12
BTC,
n=5 JH 18.58 0.17
LB 17.84 0.10
MT 21.67 0.21
PS 21.58 0.19 0.07 26.71 28.10 25.39
RB 21.53 0.12 20.24 0.07 -4.74 0.19 26.71 3.46 1.35
CT (CSPG4-
18S) CT (CSPG4-18S) CT - CT,cal CSPG4 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal, AS1 23.90
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n=4
DA 29.10
JP 28.95 #DIV/0! 1.00 #DIV/0! #DIV/0!
PK 22.36 26.08 #DIV/0! 0.00 #DIV/0! 1.00 #DIV/0! #DIV/0!
BTC,
n=5 JH 22.89 1.46
LB 17.50 0.09
MT 21.50 0.39
PS 24.62 1.11 0.38 19.52 25.46 14.97
RB 22.45 0.38 21.79 0.38 -4.29 #DIV/0! 19.52 #DIV/0! 5.18
CT (HOXA10-
18S) CT (HOXA10-18S) CT - CT,cal HOXA10 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 23.90
DA 21.90 0.91
JP 23.43 0.38 0.49 1.00 1.41 0.71
PK 22.36 22.90 0.49 0.00 0.70 1.00 0.48 0.34
BTC,
n=5 JH 13.97 0.14
LB 17.42 0.13
MT 20.45 0.27
PS 18.37 0.17 0.09 66.96 71.13 63.03
RB 13.95 0.24 16.83 0.09 -6.07 0.50 66.96 23.28 4.05
CT (HOXB6-
18S) CT (HOXB6-18S) CT - CT,cal HOXB6 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 18.95 0.07
DA 21.96 0.14
JP 20.80 0.16 0.07 1.00 1.05 0.95
PK 19.89 0.19 20.40 0.07 0.00 0.10 1.00 0.07 0.05
BTC,
n=5 JH 19.15 0.11
LB 15.88 0.10
MT 18.85 0.19
PS 19.48 0.15 0.06 4.99 5.20 4.80
RB 17.05 0.05 18.08 0.06 -2.32 0.09 4.99 0.32 0.20
CT (ITGB8-18S) CT (ITGB8-18S) CT - CT,cal ITGB8 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 20.74 0.14
DA 19.11 0.06
JP 20.31 0.23 0.15 1.00 1.11 0.90
PK 18.06 0.53 19.55 0.15 0.00 0.21 1.00 0.15 0.10
BTC,
n=5 JH 17.13 0.08
LB 16.98 0.29
MT 17.98 0.26
PS 19.35 0.38 0.11 3.99 4.31 3.69
RB 16.34 0.10 17.56 0.11 -1.99 0.19 3.99 0.52 0.31
CT (ITIH5-18S) CT (ITIH5-18S) CT - CT,cal ITIH5 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 16.86
DA 25.17 0.14
JP 28.95 0.08 0.08 1.00 1.06 0.95
PK 21.78 23.19 0.08 0.00 0.11 1.00 0.08 0.06
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BTC,
n=5 JH 17.66 0.08
LB 18.18 1.45
MT 16.60 1.14
PS 24.14 0.18 0.38 12.42 16.15 9.55
RB 21.21 0.38 19.56 0.38 -3.63 0.39 12.42 3.34 3.26
CT (KRAS-18S) CT (KRAS-18S) CT - CT,cal KRAS rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 18.07 0.06
DA 17.67 0.06
JP 18.79 0.09 0.04 1.00 1.03 0.97
PK 17.33 0.08 17.96 0.04 0.00 0.05 1.00 0.04 0.03
BTC,
n=5 JH 18.28 0.05
LB 17.27 0.07
MT 18.42 0.13
PS 18.72 0.15 0.05 1.05 1.08 1.02
RB 16.80 0.06 17.90 0.05 -0.07 0.06 1.05 0.04 0.03
CT (LAMC2-
18S) CT (LAMC2-18S) CT - CT,cal LAMC2 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 20.07 0.23
DA 17.79 0.24
JP 18.04 0.27 0.11 1.00 1.08 0.92
PK 17.94 0.15 18.46 0.11 0.00 0.16 1.00 0.11 0.08
BTC,
n=5 JH 17.50 0.15
LB 16.55 0.17
MT 16.39 0.19
PS 18.29 0.22 0.07 2.79 2.93 2.65
RB 16.16 0.05 16.98 0.07 -1.48 0.13 2.79 0.26 0.14
CT (LEF1-18S) CT (LEF1-18S) CT - CT,cal LEF1 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 23.90
DA 26.05
JP 23.16 0.22 0.22 1.00 1.16 0.86
PK 22.37 23.87 0.22 0.00 0.31 1.00 0.21 0.15
BTC,
n=5 JH 20.35 0.23
LB 19.66 0.43
MT 21.42 0.35
PS 22.95 0.25 0.13 7.13 7.80 6.52
RB 20.79 0.04 21.04 0.13 -2.83 0.25 7.13 1.25 0.64
CT (LIF-18S) CT (LIF-18S) CT - CT,cal LIF rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 19.83
DA 20.75 0.31
JP 20.35 0.09 0.13 1.00 1.10 0.91
PK 18.31 0.23 19.81 0.13 0.00 0.19 1.00 0.13 0.09
BTC,
n=5 JH 15.90 0.08
LB 14.63 0.04
MT 17.56 0.13
PS 18.93 0.24 0.06 7.51 7.83 7.20
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RB 17.50 0.10 16.90 0.06 -2.91 0.15 7.51 0.76 0.31
CT (LUM-18S) CT (LUM-18S) CT - CT,cal LUM rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 23.90
DA 23.60 0.24
JP 23.20 0.24 1.00 1.18 0.85
PK 22.25 23.24 0.24 0.00 0.34 1.00 0.24 0.17
BTC,
n=5 JH 24.08 0.16
LB 18.47 0.22
MT 21.55 0.45
PS 21.02 0.69 0.19 3.70 4.22 3.24
RB 21.62 0.39 21.35 0.19 -1.89 0.31 3.70 0.79 0.49
CT (MAML2-
18S) CT (MAML2-18S) CT - CT,cal MAML2 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 20.75
DA 21.59 0.15
JP 22.05 0.81 0.35 1.00 1.28 0.78
PK 21.66 0.67 21.51 0.35 0.00 0.50 1.00 0.35 0.25
BTC,
n=5 JH 19.24 0.05
LB 18.23 0.04
MT 20.69 0.19
PS 20.83 0.33 0.08 3.87 4.10 3.65
RB 18.80 0.16 19.56 0.08 -1.95 0.36 3.87 0.98 0.23
CT (MAML3-
18S) CT (MAML3-18S) CT - CT,cal MAML3 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 19.71 0.18
DA 20.07 0.06
JP 21.19 0.29 0.09 1.00 1.06 0.94
PK 19.13 0.11 20.02 0.09 0.00 0.13 1.00 0.09 0.06
BTC,
n=5 JH 21.02 0.20
LB 19.66 0.32
MT 21.54 0.30
PS 21.37 0.22 0.11 0.70 0.76 0.65
RB 19.07 0.05 20.53 0.11 0.51 0.14 0.70 0.07 0.05
CT (MAPK1-
18S) CT (MAPK1-18S) CT - CT,cal MAPK1 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 19.72 0.14
DA 18.53 0.07
JP 19.68 0.16 0.12 1.00 1.09 0.92
PK 18.20 0.45 19.04 0.12 0.00 0.18 1.00 0.12 0.09
BTC,
n=5 JH 18.57 0.19
LB 17.62 0.07
MT 19.39 0.27
PS 19.71 0.15 0.07 1.60 1.68 1.52
RB 16.52 0.04 18.36 0.07 -0.67 0.14 1.60 0.16 0.08
CT (MCM4-18S) CT (MCM4-18S) CT - CT,cal MCM4 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal, AS1 20.80 0.06
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n=4
DA 20.62 0.15
JP 21.68 0.18 0.07 1.00 1.05 0.95
PK 18.98 0.13 20.52 0.07 0.00 0.10 1.00 0.07 0.05
BTC,
n=5 JH 21.36 0.08
LB 18.87 0.22
MT 20.09 0.46
PS 21.87 0.23 0.11 1.50 1.62 1.38
RB 17.50 0.03 19.94 0.11 -0.58 0.13 1.50 0.14 0.12
CT (MMP2-18S) CT (MMP2-18S) CT - CT,cal MMP2 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 23.90
DA 24.41 3.46
JP 26.70 0.34 1.18 1.00 2.26 0.44
PK 21.71 0.66 24.18 1.18 0.00 1.67 1.00 1.15 0.82
BTC,
n=5 JH 18.95 0.06
LB 19.22 0.15
MT 23.07 0.33
PS 20.09 0.26 0.10 11.00 11.79 10.26
RB 22.25 0.22 20.72 0.10 -3.46 1.18 11.00 9.01 0.76
CT (MXRA5-
18S) CT (MXRA5-18S) CT - CT,cal MXRA5 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 23.90
DA 26.06
JP 22.97 0.44 0.44 1.00 1.35 0.74
PK 22.37 23.83 0.44 0.00 0.62 1.00 0.43 0.30
BTC,
n=5 JH 24.01 0.05
LB 18.38 0.20
MT 18.92 0.39
PS 20.03 0.15 0.10 10.41 11.14 9.74
RB 20.90 0.12 20.45 0.10 -3.38 0.45 10.41 3.23 0.70
CT (MYC-18S) CT (MYC-18S) CT - CT,cal MYC rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 20.84
DA 20.97 0.08
JP 20.56 0.09 0.05 1.00 1.03 0.97
PK 18.63 0.07 20.25 0.05 0.00 0.07 1.00 0.05 0.03
BTC,
n=5 JH 17.87 0.10
LB 16.03 0.05
MT 19.42 0.21
PS 19.55 0.18 0.06 5.96 6.22 5.72
RB 15.48 0.02 17.67 0.06 -2.58 0.08 5.96 0.31 0.25
CT (NCSTN-
18S) CT (NCSTN-18S) CT - CT,cal NCSTN rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 17.72 0.15
DA 18.02 0.06
JP 19.37 0.11 0.05 1.00 1.04 0.97
PK 17.34 0.07 18.11 0.05 0.00 0.07 1.00 0.05 0.04
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BTC,
n=5 JH 18.10 0.18
LB 17.90 0.14
MT 18.89 0.24
PS 18.80 0.16 0.07 0.95 1.00 0.90
RB 17.23 0.02 18.18 0.07 0.07 0.09 0.95 0.06 0.05
CT (PEAR1-
18S) CT (PEAR1-18S) CT - CT,cal PEAR1 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 23.90
DA 23.14 0.54
JP 25.90 0.54 1.00 1.45 0.69
PK 21.35 23.57 0.54 0.00 0.76 1.00 0.53 0.37
BTC,
n=5 JH 18.91 0.10
LB 21.00 0.04
MT 22.24 0.21
PS 21.54 0.29 0.09 6.61 7.02 6.24
RB 20.55 0.20 20.85 0.09 -2.73 0.54 6.61 2.49 0.39
CT (PNMA2-
18S) CT (PNMA2-18S) CT - CT,cal PNMA2 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 19.97 0.84
DA 23.54 0.06
JP 20.49 0.21 0.22 1.00 1.16 0.86
PK 25.40 0.07 22.35 0.22 0.00 0.31 1.00 0.21 0.15
BTC,
n=5 JH 24.08 0.21
LB 17.22 0.36
MT 20.50 0.13
PS 22.24 0.52 0.14 3.89 4.28 3.53
RB 17.92 0.10 20.39 0.14 -1.96 0.26 3.89 0.69 0.37
CT (POU5F1-
18S) CT (POU5F1-18S) CT - CT,cal POU5F1 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 19.41 0.46
DA 19.98 0.10
JP 20.39 0.08 0.12 1.00 1.09 0.92
PK 20.01 0.09 19.95 0.12 0.00 0.17 1.00 0.12 0.08
BTC,
n=5 JH 19.93 0.10
LB 17.97 0.30
MT 19.18 0.15
PS 19.54 0.20 0.08 2.52 2.66 2.38
RB 16.45 0.05 18.61 0.08 -1.33 0.15 2.52 0.25 0.14
CT (PRKCB1-
18S) CT (PRKCB1-18S) CT - CT,cal PRKCB1 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 19.97 0.11
DA 24.99 1.07
JP 21.80 0.48 0.30 1.00 1.23 0.81
PK 19.27 0.26 21.51 0.30 0.00 0.43 1.00 0.30 0.21
BTC,
n=5 JH 18.46 0.06
LB 16.72 0.13
MT 19.80 0.16
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PS 18.44 0.20 0.06 6.81 7.13 6.51
RB 20.28 0.15 18.74 0.06 -2.77 0.31 6.81 1.46 0.31
CT (PTK2-18S) CT (PTK2-18S) CT - CT,cal PTK2 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 18.31 0.45
DA 18.03 0.07
JP 19.73 0.14 0.12 1.00 1.09 0.92
PK 16.89 0.08 18.24 0.12 0.00 0.17 1.00 0.12 0.08
BTC,
n=5 JH 16.57 0.10
LB 16.93 0.11
MT 18.59 0.13
PS 18.37 0.15 0.05 1.94 2.01 1.87
RB 15.95 0.08 17.28 0.05 -0.95 0.13 1.94 0.18 0.07
CT (PVT1 -18S) CT (PVT1-18S) CT - CT,cal PVT1 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 23.90
DA 24.00 2.09
JP 21.54 0.18 1.05 1.00 2.07 0.48
PK 22.35 22.95 1.05 0.00 1.49 1.00 1.03 0.73
BTC,
n=5 JH 17.10 0.08
LB 21.54 0.17
MT 22.06 0.57
PS 18.69 0.20 0.13 12.07 13.17 11.05
RB 17.39 0.03 19.35 0.13 -3.59 1.06 12.07 8.85 1.06
CT (RAB27A-
18S) CT (RAB27A-18S) CT - CT,cal RAB27A rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 20.25 0.45
DA 20.11 0.09
JP 20.13 0.20 0.14 1.00 1.10 0.91
PK 19.54 0.22 20.01 0.14 0.00 0.19 1.00 0.13 0.10
BTC,
n=5 JH 19.78 0.05
LB 17.72 0.10
MT 18.57 0.17
PS 20.00 0.19 0.06 2.74 2.85 2.62
RB 16.71 0.12 18.56 0.06 -1.45 0.15 2.74 0.28 0.12
CT (RAD51-
18S) CT (RAD51-18S) CT - CT,cal RAD51 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 23.90
DA 23.73 0.41
JP 22.87 0.10 0.21 1.00 1.16 0.87
PK 21.37 22.97 0.21 0.00 0.29 1.00 0.20 0.14
BTC,
n=5 JH 22.87
LB 20.76 0.46
MT 20.82 0.35
PS 24.37 0.16 0.16 2.98 3.33 2.67
RB 18.14 0.23 21.39 0.16 -1.58 0.26 2.98 0.54 0.33
CT (SERPINA3-
18S) CT (SERPINA3-18S) CT - CT,cal SERPINA3 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
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Normal,
n=4 AS1 23.90
DA 23.65 0.13
JP 17.77 0.13 0.15 1.00 1.11 0.90
PK 21.56 0.40 21.72 0.15 0.00 0.21 1.00 0.14 0.10
BTC,
n=5 JH 13.77 0.09
LB 14.75 0.08
MT 17.10 0.13
PS 16.54 0.15 0.05 46.74 48.30 45.23
RB 18.71 0.03 16.17 0.05 -5.55 0.16 46.74 5.03 1.53
CT (SPARC-
18S) CT (SPARC-18S) CT - CT,cal SPARC rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 23.90
DA 29.10
JP 24.92 0.98 0.98 1.00 1.97 0.51
PK 22.37 25.07 0.98 0.00 1.39 1.00 0.96 0.68
BTC,
n=5 JH 18.80 0.19
LB 17.51 0.22
MT 20.90 0.48
PS 20.69 0.17 0.12 41.37 45.04 37.99
RB 20.62 0.17 19.70 0.12 -5.37 0.99 41.37 28.35 3.52
CT (STAT1-
18S) CT (STAT1-18S) CT - CT,cal STAT1 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 17.45 0.17
DA 17.02 0.06
JP 18.76 0.19 0.07 1.00 1.05 0.95
PK 16.11 0.07 17.33 0.07 0.00 0.10 1.00 0.07 0.05
BTC,
n=5 JH 16.81 0.20
LB 16.49 0.06
MT 16.78 0.14
PS 17.16 0.15 0.06 1.91 1.99 1.83
RB 14.76 0.12 16.40 0.06 -0.93 0.09 1.91 0.12 0.08
CT (TGFBI-
18S) CT (TGFBI-18S) CT - CT,cal TGFBI rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 19.75 0.16
DA 21.79 0.07
JP 21.66 0.14 0.11 1.00 1.08 0.93
PK 18.82 0.39 20.50 0.11 0.00 0.16 1.00 0.11 0.08
BTC,
n=5 JH 18.87 0.06
LB 17.13 0.18
MT 18.44 0.24
PS 20.72 0.15 0.07 3.28 3.45 3.12
RB 18.79 0.11 18.79 0.07 -1.71 0.13 3.28 0.30 0.16
CT (TM4SF18-
18S) CT (TM4SF18-18S) CT - CT,cal TM4SF18 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 8.63
DA 24.16 0.35
JP 25.89 0.48 1.00 1.40 0.72
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PK 15.39 0.90 18.52 0.48 0.00 0.68 1.00 0.47 0.33
BTC,
n=5 JH 23.74 0.47
LB 16.42 0.63
MT 18.06
PS 20.39 0.15 0.20 0.93 1.06 0.81
RB 14.53 0.03 18.63 0.20 0.11 0.52 0.93 0.34 0.13
CT (TRIB2-18S) CT (TRIB2-18S) CT - CT,cal TRIB2 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 19.15 0.72
DA 19.05 0.06
JP 19.56 0.26 0.19 1.00 1.14 0.87
PK 17.46 0.13 18.81 0.19 0.00 0.27 1.00 0.19 0.13
BTC,
n=5 JH 17.44 0.29
LB 15.89 0.30
MT 17.85 0.14
PS 18.02 0.15 0.09 3.39 3.61 3.18
RB 16.03 0.03 17.05 0.09 -1.76 0.21 3.39 0.50 0.22
CT (VEGFA-
18S) CT (VEGFA-18S) CT - CT,cal VEGFA rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 17.36 0.19
DA 17.00 0.11
JP 18.09 0.08 0.08 1.00 1.06 0.95
PK 16.67 17.28 0.08 0.00 0.11 1.00 0.08 0.05
BTC,
n=5 JH 15.83 0.05
LB 15.44 0.13
MT 17.13 0.14
PS 16.11 0.05 2.62 2.71 2.53
RB 14.95 0.04 15.89 0.05 -1.39 0.09 2.62 0.17 0.09
CT
CT (GAPDH-
18S) CT (GAPDH-18S) CT - CT,cal GAPDH rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 15.07 0.12
DA 13.69 0.19
JP 14.45 0.08 0.07 1.00 1.05 0.95
PK 13.23 0.18 14.11 0.07 0.00 0.10 1.00 0.07 0.05
BTC,
n=5 JH 14.08 0.25
LB 13.60 0.04
MT 15.22 0.30
PS 14.70 0.15 0.09 1.00 1.06 0.94
RB 12.92 0.06 14.11 0.09 0.00 0.11 1.00 0.08 0.06
CT
CT (18S-18S) CT (18S-18S) CT - CT,cal 18S rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1
DA
JP #DIV/0! #DIV/0! #DIV/0! #DIV/0!
PK #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0!
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BTC,
n=5 JH
LB
MT
PS 0.09 #DIV/0! #DIV/0! #DIV/0!
RB #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0!
CT
CT (MUC4-18S) CT (MUC4-18S) CT - CT,cal MUC4 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 23.90
DA 26.03
JP 20.88 0.45 0.35 1.00 1.27 0.79
PK 21.85 0.53 23.16 0.35 0.00 0.49 1.00 0.34 0.24
BTC,
n=5 JH 19.95 0.09
LB 16.11 0.05
MT 17.83 0.53
PS 18.44 0.15 0.09 29.37 31.18 27.66
RB 19.10 0.15 18.29 0.12 -4.88 0.37 29.37 7.47 2.34
CT
CT (MUC5AC-
18S) CT (MUC5AC-18S) CT - CT,cal MUC5AC rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 18.50 1.40
DA 18.05 0.08
JP 13.84 0.11 0.36 1.00 1.28 0.78
PK 13.60 0.24 16.00 0.36 0.00 0.50 1.00 0.35 0.25
BTC,
n=5 JH 14.40 0.09
LB 12.33 0.12
MT 10.38 0.18
PS 15.94 0.22 0.06 7.41 7.75 7.09
RB 12.49 0.07 13.11 0.06 -2.89 0.36 7.41 1.86 0.33
CT
CT (ACTB-18S) CT (ACTB-18S) CT - CT,cal ACTB rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 12.02 0.12
DA 13.03 0.07
JP 12.93 0.08 0.04 1.00 1.03 0.97
PK 11.40 0.08 12.34 0.04 0.00 0.06 1.00 0.04 0.03
BTC,
n=5 JH 11.25 0.06
LB 10.29 0.20
MT 12.49 0.13
PS 12.55 0.15 0.06 2.03 2.11 1.95
RB 10.03 0.02 11.32 0.06 -1.02 0.07 2.03 0.10 0.08
CT
CT (CD9-18S) CT (CD9-18S) CT - CT,cal CD9 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 18.21 0.38
DA 18.00 0.07
JP 17.05 0.08 0.11 1.00 1.08 0.93
PK 17.07 0.16 17.58 0.11 0.00 0.15 1.00 0.11 0.07
BTC, JH 16.98 0.12
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n=5
LB 14.99 0.06
MT 16.86 0.15
PS 18.09 0.16 0.05 2.15 2.23 2.07
RB 15.48 0.07 16.48 0.05 -1.10 0.12 2.15 0.18 0.08
CT
CT (Notch3-
18S) CT (Notch3-18S) CT - CT,cal Notch3 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 23.90
DA 23.79 0.26
JP 21.45 0.37 0.18 1.00 1.13 0.88
PK 21.05 0.30 22.55 0.18 0.00 0.25 1.00 0.18 0.12
BTC,
n=5 JH 21.02 0.14
LB 17.36 0.13
MT 20.68 0.32
PS 21.41 0.19 0.16 8.01 8.96 7.16
RB 17.27 0.69 19.55 0.16 -3.00 0.24 8.01 1.34 0.90
CT
CT (ASPHD1-
18S) CT (ASPHD1-18S) CT - CT,cal ASPDH1 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 19.88 0.98
DA 18.32 0.10
JP 20.47 0.18 0.25 1.00 1.19 0.84
PK 17.58 0.07 19.06 0.25 0.00 0.35 1.00 0.25 0.17
BTC,
n=5 JH 19.21 0.09
LB 17.02 0.33
MT 18.73 0.14
PS 20.56 0.18 0.08 1.65 1.75 1.56
RB 16.18 0.02 18.34 0.08 -0.72 0.26 1.65 0.30 0.09
CT
CT (ATP6V0A2-
18S) CT (ATP6VOA2-18S) CT - CT,cal ATP6V0A2 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 19.56 0.29
DA 19.97 0.10
JP 21.12 0.36 0.12 1.00 1.09 0.92
PK 19.24 0.15 19.97 0.12 0.00 0.17 1.00 0.12 0.08
BTC,
n=5 JH 19.75 0.08
LB 18.71 0.17
MT 20.50 0.40
PS 21.38 0.23 0.11 1.10 1.18 1.02
RB 18.84 0.17 19.84 0.11 -0.14 0.16 1.10 0.12 0.08
CT (CEACAM1-
18S) CT (CEACAM1-18S) CT - CT,cal CEACAM1 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 18.25 0.05
DA 20.31 0.06
JP 20.86 0.08 0.09 1.00 1.06 0.94
PK 20.02 0.32 19.86 0.09 0.00 0.12 1.00 0.08 0.06
BTC, JH 20.60 0.11
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n=5
LB 18.28 0.04
MT 19.42 0.13
PS 19.05 0.17 0.05 2.08 2.16 2.00
RB 16.67 0.12 18.80 0.05 -1.05 0.10 2.08 0.15 0.08
CT (CELSR1-
18S) CT (CELSR1-18S) CT - CT,cal CELSR1 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 23.90
DA 24.28 0.27
JP 22.94 0.08 0.11 1.00 1.08 0.93
PK 21.56 0.18 23.17 0.11 0.00 0.16 1.00 0.11 0.08
BTC,
n=5 JH 20.85 0.58
LB 19.37 0.11
MT 19.72 0.40
PS 23.09 0.17 0.15 7.15 7.92 6.45
RB 18.64 0.08 20.33 0.15 -2.84 0.19 7.15 0.92 0.73
CT (CFDP1 -
18S) CT (CFDP1-18S) CT - CT,cal CFDP1 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 19.05 0.79
DA 19.02 0.07
JP 20.33 0.11 0.21 1.00 1.15 0.87
PK 17.14 0.24 18.88 0.21 0.00 0.29 1.00 0.20 0.14
BTC,
n=5 JH 19.16 0.21
LB 17.12 0.06
MT 19.40 0.13
PS 20.19 0.20 0.07 1.11 1.16 1.06
RB 17.78 0.03 18.73 0.07 -0.15 0.22 1.11 0.17 0.05
CT (COL17A1-
18S) CT (COL17A1-18S) CT - CT,cal COL17A1 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 19.88
DA 25.32 0.27
JP 21.28 0.13 0.18 1.00 1.13 0.88
PK 21.62 0.45 22.02 0.18 0.00 0.25 1.00 0.18 0.12
BTC,
n=5 JH 22.56 0.51
LB 19.34 0.41
MT 16.15 0.19
PS 18.00 0.16 0.14 10.91 12.03 9.89
RB 16.84 0.04 18.58 0.14 -3.45 0.23 10.91 1.73 1.07
CT (COL1A1-
18S) CT (COL1A1-18S) CT - CT,cal COL1A1 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 23.90
DA 26.01
JP 22.84 0.38 0.36 1.00 1.28 0.78
PK 21.74 0.61 23.62 0.36 0.00 0.51 1.00 0.35 0.25
BTC,
n=5 JH 17.46 0.17
LB 16.68 0.04
MT 21.72 0.36
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PS 20.52 0.39 0.11 21.59 23.36 19.96
RB 19.56 0.10 19.19 0.11 -4.43 0.38 21.59 5.62 1.70
CT (COL6A3-
18S) CT (COL6A3-18S) CT - CT,cal COL6A3 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 23.90
DA 29.10
JP 24.59 0.17 0.17 1.00 1.13 0.89
PK 22.33 24.98 0.17 0.00 0.24 1.00 0.17 0.12
BTC,
n=5 JH 18.58 0.17
LB 17.84 0.10
MT 21.67 0.21
PS 21.58 0.19 0.07 26.71 28.10 25.39
RB 21.53 0.12 20.24 0.07 -4.74 0.19 26.71 3.46 1.35
CT (CSPG4-
18S) CT (CSPG4-18S) CT - CT,cal CSPG4 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 23.90
DA 29.10
JP 28.95 #DIV/0! 1.00 #DIV/0! #DIV/0!
PK 22.36 26.08 #DIV/0! 0.00 #DIV/0! 1.00 #DIV/0! #DIV/0!
BTC,
n=5 JH 22.89 1.46
LB 17.50 0.09
MT 21.50 0.39
PS 24.62 1.11 0.38 19.52 25.46 14.97
RB 22.45 0.38 21.79 0.38 -4.29 #DIV/0! 19.52 #DIV/0! 5.18
CT (HOXA10-
18S) CT (HOXA10-18S) CT - CT,cal HOXA10 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 23.90
DA 21.90 0.91
JP 23.43 0.38 0.49 1.00 1.41 0.71
PK 22.36 22.90 0.49 0.00 0.70 1.00 0.48 0.34
BTC,
n=5 JH 13.97 0.14
LB 17.42 0.13
MT 20.45 0.27
PS 18.37 0.17 0.09 66.96 71.13 63.03
RB 13.95 0.24 16.83 0.09 -6.07 0.50 66.96 23.28 4.05
CT (HOXB6-
18S) CT (HOXB6-18S) CT - CT,cal HOXB6 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 18.95 0.07
DA 21.96 0.14
JP 20.80 0.16 0.07 1.00 1.05 0.95
PK 19.89 0.19 20.40 0.07 0.00 0.10 1.00 0.07 0.05
BTC,
n=5 JH 19.15 0.11
LB 15.88 0.10
MT 18.85 0.19
PS 19.48 0.15 0.06 4.99 5.20 4.80
RB 17.05 0.05 18.08 0.06 -2.32 0.09 4.99 0.32 0.20
CT (ITGB8-18S) CT (ITGB8-18S) CT - CT,cal ITGB8 rel to Cal
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SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 20.74 0.14
DA 19.11 0.06
JP 20.31 0.23 0.15 1.00 1.11 0.90
PK 18.06 0.53 19.55 0.15 0.00 0.21 1.00 0.15 0.10
BTC,
n=5 JH 17.13 0.08
LB 16.98 0.29
MT 17.98 0.26
PS 19.35 0.38 0.11 3.99 4.31 3.69
RB 16.34 0.10 17.56 0.11 -1.99 0.19 3.99 0.52 0.31
CT (ITIH5-18S) CT (ITIH5-18S) CT - CT,cal ITIH5 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 16.86
DA 25.17 0.14
JP 28.95 0.08 0.08 1.00 1.06 0.95
PK 21.78 23.19 0.08 0.00 0.11 1.00 0.08 0.06
BTC,
n=5 JH 17.66 0.08
LB 18.18 1.45
MT 16.60 1.14
PS 24.14 0.18 0.38 12.42 16.15 9.55
RB 21.21 0.38 19.56 0.38 -3.63 0.39 12.42 3.34 3.26
CT (KRAS-18S) CT (KRAS-18S) CT - CT,cal KRAS rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 18.07 0.06
DA 17.67 0.06
JP 18.79 0.09 0.04 1.00 1.03 0.97
PK 17.33 0.08 17.96 0.04 0.00 0.05 1.00 0.04 0.03
BTC,
n=5 JH 18.28 0.05
LB 17.27 0.07
MT 18.42 0.13
PS 18.72 0.15 0.05 1.05 1.08 1.02
RB 16.80 0.06 17.90 0.05 -0.07 0.06 1.05 0.04 0.03
CT (LAMC2-
18S) CT (LAMC2-18S) CT - CT,cal LAMC2 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 20.07 0.23
DA 17.79 0.24
JP 18.04 0.27 0.11 1.00 1.08 0.92
PK 17.94 0.15 18.46 0.11 0.00 0.16 1.00 0.11 0.08
BTC,
n=5 JH 17.50 0.15
LB 16.55 0.17
MT 16.39 0.19
PS 18.29 0.22 0.07 2.79 2.93 2.65
RB 16.16 0.05 16.98 0.07 -1.48 0.13 2.79 0.26 0.14
CT (LEF1-18S) CT (LEF1-18S) CT - CT,cal LEF1 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 23.90
DA 26.05
JP 23.16 0.22 0.22 1.00 1.16 0.86
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PK 22.37 23.87 0.22 0.00 0.31 1.00 0.21 0.15
BTC,
n=5 JH 20.35 0.23
LB 19.66 0.43
MT 21.42 0.35
PS 22.95 0.25 0.13 7.13 7.80 6.52
RB 20.79 0.04 21.04 0.13 -2.83 0.25 7.13 1.25 0.64
CT (LIF-18S) CT (LIF-18S) CT - CT,cal LIF rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 19.83
DA 20.75 0.31
JP 20.35 0.09 0.13 1.00 1.10 0.91
PK 18.31 0.23 19.81 0.13 0.00 0.19 1.00 0.13 0.09
BTC,
n=5 JH 15.90 0.08
LB 14.63 0.04
MT 17.56 0.13
PS 18.93 0.24 0.06 7.51 7.83 7.20
RB 17.50 0.10 16.90 0.06 -2.91 0.15 7.51 0.76 0.31
CT (LUM-18S) CT (LUM-18S) CT - CT,cal LUM rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 23.90
DA 23.60 0.24
JP 23.20 0.24 1.00 1.18 0.85
PK 22.25 23.24 0.24 0.00 0.34 1.00 0.24 0.17
BTC,
n=5 JH 24.08 0.16
LB 18.47 0.22
MT 21.55 0.45
PS 21.02 0.69 0.19 3.70 4.22 3.24
RB 21.62 0.39 21.35 0.19 -1.89 0.31 3.70 0.79 0.49
CT (MAML2-
18S) CT (MAML2-18S) CT - CT,cal MAML2 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 20.75
DA 21.59 0.15
JP 22.05 0.81 0.35 1.00 1.28 0.78
PK 21.66 0.67 21.51 0.35 0.00 0.50 1.00 0.35 0.25
BTC,
n=5 JH 19.24 0.05
LB 18.23 0.04
MT 20.69 0.19
PS 20.83 0.33 0.08 3.87 4.10 3.65
RB 18.80 0.16 19.56 0.08 -1.95 0.36 3.87 0.98 0.23
CT (MAML3-
18S) CT (MAML3-18S) CT - CT,cal MAML3 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 19.71 0.18
DA 20.07 0.06
JP 21.19 0.29 0.09 1.00 1.06 0.94
PK 19.13 0.11 20.02 0.09 0.00 0.13 1.00 0.09 0.06
BTC,
n=5 JH 21.02 0.20
LB 19.66 0.32
MT 21.54 0.30
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PS 21.37 0.22 0.11 0.70 0.76 0.65
RB 19.07 0.05 20.53 0.11 0.51 0.14 0.70 0.07 0.05
CT (MAPK1-
18S) CT (MAPK1-18S) CT - CT,cal MAPK1 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 19.72 0.14
DA 18.53 0.07
JP 19.68 0.16 0.12 1.00 1.09 0.92
PK 18.20 0.45 19.04 0.12 0.00 0.18 1.00 0.12 0.09
BTC,
n=5 JH 18.57 0.19
LB 17.62 0.07
MT 19.39 0.27
PS 19.71 0.15 0.07 1.60 1.68 1.52
RB 16.52 0.04 18.36 0.07 -0.67 0.14 1.60 0.16 0.08
CT (MCM4-18S) CT (MCM4-18S) CT - CT,cal MCM4 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 20.80 0.06
DA 20.62 0.15
JP 21.68 0.18 0.07 1.00 1.05 0.95
PK 18.98 0.13 20.52 0.07 0.00 0.10 1.00 0.07 0.05
BTC,
n=5 JH 21.36 0.08
LB 18.87 0.22
MT 20.09 0.46
PS 21.87 0.23 0.11 1.50 1.62 1.38
RB 17.50 0.03 19.94 0.11 -0.58 0.13 1.50 0.14 0.12
CT (MMP2-18S) CT (MMP2-18S) CT - CT,cal MMP2 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 23.90
DA 24.41 3.46
JP 26.70 0.34 1.18 1.00 2.26 0.44
PK 21.71 0.66 24.18 1.18 0.00 1.67 1.00 1.15 0.82
BTC,
n=5 JH 18.95 0.06
LB 19.22 0.15
MT 23.07 0.33
PS 20.09 0.26 0.10 11.00 11.79 10.26
RB 22.25 0.22 20.72 0.10 -3.46 1.18 11.00 9.01 0.76
CT (MXRA5-
18S) CT (MXRA5-18S) CT - CT,cal MXRA5 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 23.90
DA 26.06
JP 22.97 0.44 0.44 1.00 1.35 0.74
PK 22.37 23.83 0.44 0.00 0.62 1.00 0.43 0.30
BTC,
n=5 JH 24.01 0.05
LB 18.38 0.20
MT 18.92 0.39
PS 20.03 0.15 0.10 10.41 11.14 9.74
RB 20.90 0.12 20.45 0.10 -3.38 0.45 10.41 3.23 0.70
CT (MYC-18S) CT (MYC-18S) CT - CT,cal MYC rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
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Normal,
n=4 AS1 20.84
DA 20.97 0.08
JP 20.56 0.09 0.05 1.00 1.03 0.97
PK 18.63 0.07 20.25 0.05 0.00 0.07 1.00 0.05 0.03
BTC,
n=5 JH 17.87 0.10
LB 16.03 0.05
MT 19.42 0.21
PS 19.55 0.18 0.06 5.96 6.22 5.72
RB 15.48 0.02 17.67 0.06 -2.58 0.08 5.96 0.31 0.25
CT (NCSTN-
18S) CT (NCSTN-18S) CT -CT,cal NCSTN rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 17.72 0.15
DA 18.02 0.06
JP 19.37 0.11 0.05 1.00 1.04 0.97
PK 17.34 0.07 18.11 0.05 0.00 0.07 1.00 0.05 0.04
BTC,
n=5 JH 18.10 0.18
LB 17.90 0.14
MT 18.89 0.24
PS 18.80 0.16 0.07 0.95 1.00 0.90
RB 17.23 0.02 18.18 0.07 0.07 0.09 0.95 0.06 0.05
CT (PEAR1-
18S) CT (PEAR1-18S) CT - CT,cal PEAR1 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 23.90
DA 23.14 0.54
JP 25.90 0.54 1.00 1.45 0.69
PK 21.35 23.57 0.54 0.00 0.76 1.00 0.53 0.37
BTC,
n=5 JH 18.91 0.10
LB 21.00 0.04
MT 22.24 0.21
PS 21.54 0.29 0.09 6.61 7.02 6.24
RB 20.55 0.20 20.85 0.09 -2.73 0.54 6.61 2.49 0.39
CT (PNMA2-
18S) CT (PNMA2-18S) CT - CT,cal PNMA2 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 19.97 0.84
DA 23.54 0.06
JP 20.49 0.21 0.22 1.00 1.16 0.86
PK 25.40 0.07 22.35 0.22 0.00 0.31 1.00 0.21 0.15
BTC,
n=5 JH 24.08 0.21
LB 17.22 0.36
MT 20.50 0.13
PS 22.24 0.52 0.14 3.89 4.28 3.53
RB 17.92 0.10 20.39 0.14 -1.96 0.26 3.89 0.69 0.37
CT (POU5F1-
18S) CT (POU5F1-18S) CT - CT,cal POU5F1 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 19.41 0.46
DA 19.98 0.10
JP 20.39 0.08 0.12 1.00 1.09 0.92
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PK 20.01 0.09 19.95 0.12 0.00 0.17 1.00 0.12 0.08
BTC,
n=5 JH 19.93 0.10
LB 17.97 0.30
MT 19.18 0.15
PS 19.54 0.20 0.08 2.52 2.66 2.38
RB 16.45 0.05 18.61 0.08 -1.33 0.15 2.52 0.25 0.14
CT (PRKCB1-
18S) CT (PRKCB1-18S) CT - CT,cal PRKCB1 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 19.97 0.11
DA 24.99 1.07
JP 21.80 0.48 0.30 1.00 1.23 0.81
PK 19.27 0.26 21.51 0.30 0.00 0.43 1.00 0.30 0.21
BTC,
n=5 JH 18.46 0.06
LB 16.72 0.13
MT 19.80 0.16
PS 18.44 0.20 0.06 6.81 7.13 6.51
RB 20.28 0.15 18.74 0.06 -2.77 0.31 6.81 1.46 0.31
CT (PTK2-18S) CT (PTK2-18S) CT - CT,cal PTK2 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 18.31 0.45
DA 18.03 0.07
JP 19.73 0.14 0.12 1.00 1.09 0.92
PK 16.89 0.08 18.24 0.12 0.00 0.17 1.00 0.12 0.08
BTC,
n=5 JH 16.57 0.10
LB 16.93 0.11
MT 18.59 0.13
PS 18.37 0.15 0.05 1.94 2.01 1.87
RB 15.95 0.08 17.28 0.05 -0.95 0.13 1.94 0.18 0.07
CT (PVT1 -18S) CT (PVT1-18S) CT - CT,cal PVT1 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 23.90
DA 24.00 2.09
JP 21.54 0.18 1.05 1.00 2.07 0.48
PK 22.35 22.95 1.05 0.00 1.49 1.00 1.03 0.73
BTC,
n=5 JH 17.10 0.08
LB 21.54 0.17
MT 22.06 0.57
PS 18.69 0.20 0.13 12.07 13.17 11.05
RB 17.39 0.03 19.35 0.13 -3.59 1.06 12.07 8.85 1.06
CT (RAB27A-
18S) CT (RAB27A-18S) CT - CT,cal RAB27A rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 20.25 0.45
DA 20.11 0.09
JP 20.13 0.20 0.14 1.00 1.10 0.91
PK 19.54 0.22 20.01 0.14 0.00 0.19 1.00 0.13 0.10
BTC,
n=5 JH 19.78 0.05
LB 17.72 0.10
MT 18.57 0.17
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PS 20.00 0.19 0.06 2.74 2.85 2.62
RB 16.71 0.12 18.56 0.06 -1.45 0.15 2.74 0.28 0.12
CT (RAD51-
18S) CT (RAD51-18S) CT - CT,cal RAD51 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 23.90
DA 23.73 0.41
JP 22.87 0.10 0.21 1.00 1.16 0.87
PK 21.37 22.97 0.21 0.00 0.29 1.00 0.20 0.14
BTC,
n=5 JH 22.87
LB 20.76 0.46
MT 20.82 0.35
PS 24.37 0.16 0.16 2.98 3.33 2.67
RB 18.14 0.23 21.39 0.16 -1.58 0.26 2.98 0.54 0.33
CT (SERPINA3-
18S) CT (SERPINA3-18S) CT - CT,cal SERPINA3 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 23.90
DA 23.65 0.13
JP 17.77 0.13 0.15 1.00 1.11 0.90
PK 21.56 0.40 21.72 0.15 0.00 0.21 1.00 0.14 0.10
BTC,
n=5 JH 13.77 0.09
LB 14.75 0.08
MT 17.10 0.13
PS 16.54 0.15 0.05 46.74 48.30 45.23
RB 18.71 0.03 16.17 0.05 -5.55 0.16 46.74 5.03 1.53
CT (SPARC-
18S) CT (SPARC-18S) CT - CT,cal SPARC rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 23.90
DA 29.10
JP 24.92 0.98 0.98 1.00 1.97 0.51
PK 22.37 25.07 0.98 0.00 1.39 1.00 0.96 0.68
BTC,
n=5 JH 18.80 0.19
LB 17.51 0.22
MT 20.90 0.48
PS 20.69 0.17 0.12 41.37 45.04 37.99
RB 20.62 0.17 19.70 0.12 -5.37 0.99 41.37 28.35 3.52
CT (STAT1-18S) CT (STAT1-18S) CT - CT,cal STAT1 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 17.45 0.17
DA 17.02 0.06
JP 18.76 0.19 0.07 1.00 1.05 0.95
PK 16.11 0.07 17.33 0.07 0.00 0.10 1.00 0.07 0.05
BTC,
n=5 JH 16.81 0.20
LB 16.49 0.06
MT 16.78 0.14
PS 17.16 0.15 0.06 1.91 1.99 1.83
RB 14.76 0.12 16.40 0.06 -0.93 0.09 1.91 0.12 0.08
CT (TGFBI-18S) CT (TGFBI-18S) CT - CT,cal TGFBI rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
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Normal,
n=4 AS1 19.75 0.16
DA 21.79 0.07
JP 21.66 0.14 0.11 1.00 1.08 0.93
PK 18.82 0.39 20.50 0.11 0.00 0.16 1.00 0.11 0.08
BTC,
n=5 JH 18.87 0.06
LB 17.13 0.18
MT 18.44 0.24
PS 20.72 0.15 0.07 3.28 3.45 3.12
RB 18.79 0.11 18.79 0.07 -1.71 0.13 3.28 0.30 0.16
CT (TM4SF18-
18S) CT (TM4SF18-18S) CT - CT,cal TM4SF18 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 8.63
DA 24.16 0.35
JP 25.89 0.48 1.00 1.40 0.72
PK 15.39 0.90 18.52 0.48 0.00 0.68 1.00 0.47 0.33
BTC,
n=5 JH 23.74 0.47
LB 16.42 0.63
MT 18.06
PS 20.39 0.15 0.20 0.93 1.06 0.81
RB 14.53 0.03 18.63 0.20 0.11 0.52 0.93 0.34 0.13
CT (TRIB2-18S) CT (TRIB2-18S) CT - CT,cal TRIB2 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 19.15 0.72
DA 19.05 0.06
JP 19.56 0.26 0.19 1.00 1.14 0.87
PK 17.46 0.13 18.81 0.19 0.00 0.27 1.00 0.19 0.13
BTC,
n=5 JH 17.44 0.29
LB 15.89 0.30
MT 17.85 0.14
PS 18.02 0.15 0.09 3.39 3.61 3.18
RB 16.03 0.03 17.05 0.09 -1.76 0.21 3.39 0.50 0.22
CT (VEGFA-
18S) CT (VEGFA-18S) CT - CT,cal VEGFA rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AS1 17.36 0.19
DA 17.00 0.11
JP 18.09 0.08 0.08 1.00 1.06 0.95
PK 16.67 17.28 0.08 0.00 0.11 1.00 0.08 0.05
BTC,
n=5 JH 15.83 0.05
LB 15.44 0.13
MT 17.13 0.14
PS 16.11 0.05 2.62 2.71 2.53
RB 14.95 0.04 15.89 0.05 -1.39 0.09 2.62 0.17 0.09
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Table 32. Biliary brushings validation set qPCR calculations for TaqMan Array qPCR
normalised to 18S rRNA.
6 CT
CT (GAPDH-
18S) CT (GAPDH-18S) CT - CT,cal GAPDH rel to Cal
SAMPLE CT STDEV AVERAGE ERROR Average ERROR ERROR
Benign AK 17.94 0.47
n=4 PH 18.59 0.23
JB 17.34 0.81 0.25 1.00 1.19 0.84
JS 17.48 0.34 17.84 0.25 0.00 0.36 1.00 0.25 0.18
BTC DC 16.33 0.78
n=5 JE 16.56 0.71
MJ 15.93 0.21
RC 18.22 0.25 0.09 1.90 2.01 1.79
RB 17.52 0.63 16.91 0.25 -0.92 0.36 1.90 0.47 0.33
CT
CT (MUC4-18S) CT (MUC4-18S) CT - CT,cal MUC4 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AK 21.15 0.67
PH 25.34 0.83
JB 23.77 0.95 0.37 1.00 1.29 0.78
JS 30.64 0.30 25.22 0.37 0.00 0.52 1.00 0.36 0.25
BTC, n=5 DC 21.74 0.39
JE 21.52 0.74
MJ 19.74 0.22
RC 19.77 0.31 0.09 15.53 16.49 14.63
RB 23.55 0.66 21.26 0.27 -3.96 0.46 15.53 4.92 2.96
CT
 
CT (MUC5AC-
18S) CT (MUC5AC-18S) CT - CT,cal MUC5AC rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AK 15.99 0.47
PH 20.21 0.06
JB 20.59 0.82 0.25 1.00 1.19 0.84
JS 21.77 0.30 19.64 0.25 0.00 0.35 1.00 0.24 0.17
BTC, n=5 DC 17.45 0.39
JE 18.36 0.69
MJ 20.01 0.29
RC 14.41 0.23 0.21 5.01 5.80 4.33
RB 16.35 0.63 17.31 0.21 -2.33 0.33 5.01 1.14 0.73
CT
CT (ACTB-18S) CT (ACTB-18S) CT - CT,cal ACTB rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AK 14.31 0.47
PH 16.12 0.08
JB 14.03 0.81 0.25 1.00 1.19 0.84
JS 14.14 0.31 14.65 0.25 0.00 0.35 1.00 0.24 0.17
BTC, n=5 DC 13.38 0.39
JE 13.45 0.69
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MJ 13.52 0.27
RC 13.54 0.12 0.21 2.31 2.68 2.00
RB 13.29 0.63 13.44 0.21 -1.21 0.32 2.31 0.52 0.34
CT
CT (CD9-18S) CT (CD9-18S) CT - CT,cal CD9 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AK 20.21 0.47
PH 23.07 0.39
JB 20.26 0.83 0.27 1.00 1.20 0.83
JS 21.56 0.32 21.28 0.27 0.00 0.38 1.00 0.26 0.19
BTC, n=5 DC 18.68 0.39
JE 19.85 0.69
MJ 20.22 0.16
RC 18.13 0.14 0.22 3.95 4.59 3.39
RB 19.61 0.63 19.30 0.22 -1.98 0.35 3.95 0.95 0.60
CT
CT (Notch3-
18S) CT (Notch3-18S) CT - CT,cal Notch3 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AK 21.95 0.47
PH 29.35
JB 19.71 0.82 0.82 1.00 1.76 0.57
JS 26.30 2.26 24.33 0.82 0.00 1.15 1.00 0.80 0.57
BTC, n=5 DC 24.33 0.45
JE 20.59 0.99
MJ 22.18 0.56
RC 20.11 0.63 0.30 4.72 5.79 3.84
RB 23.23 0.84 22.09 0.30 -2.24 0.87 4.72 2.84 0.97
CT
CT (ASPHD1-
18S) CT (ASPHD1-18S) CT - CT,cal ASPDH1 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AK 23.09 0.65
PH 22.49 0.83
JB 21.04 1.05 0.39 1.00 1.31 0.77
JS 17.82 0.41 21.11 0.39 0.00 0.55 1.00 0.38 0.27
BTC, n=5 DC 19.11 0.38
JE 20.45 0.78
MJ 19.37 0.18
RC 18.95 0.37 0.27 3.63 4.39 3.00
RB 18.38 0.63 19.25 0.27 -1.86 0.47 3.63 1.19 0.69
CT
CT (ATP6V0A2-
18S)
CT (ATP6VOA2-
18S) CT - CT,cal ATP6V0A2 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AK 22.73 1.51
PH 22.69 0.74
JB 20.14 0.88 0.63 1.00 1.55 0.65
JS 21.85 0.63 0.00 0.89 1.00 0.62 0.44
BTC, n=5 DC 20.47 0.47
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JE 20.03 0.70
MJ 19.46 0.16
RC 20.36 0.13 0.26 3.14 3.75 2.62
RB 20.71 0.63 20.21 0.26 -1.65 0.68 3.14 1.49 0.56
CT (CEACAM1-
18S) CT (CEACAM1-18S) CT - CT,cal CEACAM1 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AK 21.70 0.60
PH 25.37 1.26
JB 22.38 0.83 0.41 1.00 1.33 0.75
JS 22.19 0.32 22.91 0.41 0.00 0.59 1.00 0.41 0.29
BTC, n=5 DC 20.65 0.40
JE 21.38 0.69
MJ 21.47 0.29
RC 22.45 0.44 0.33 3.06 3.85 2.44
RB 20.52 0.65 21.29 0.33 -1.61 0.53 3.06 1.13 0.70
CT (CELSR1-
18S) CT (CELSR1-18S) CT - CT,cal CELSR1 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AK 24.84 0.79
PH 0.00
JB 24.59 0.92 0.32 1.00 1.24 0.80
JS 26.21 0.37 25.21 0.32 0.00 0.45 1.00 0.31 0.22
BTC, n=5 DC 22.78 0.41
JE 25.41 1.10
MJ 23.48 0.26
RC 22.89 0.25 0.27 3.19 3.85 2.64
RB 23.14 0.63 23.54 0.27 -1.67 0.42 3.19 0.92 0.60
CT (CFDP1 -
18S) CT (CFDP1-18S) CT - CT,cal CFDP1 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AK 21.57 0.56
PH 24.22 0.32
JB 20.33 0.80 0.27 1.00 1.21 0.83
JS 19.85 0.32 21.49 0.27 0.00 0.38 1.00 0.26 0.19
BTC, n=5 DC 21.32 0.40
JE 20.84 0.69
MJ 19.55 0.19
RC 21.29 0.27 0.22 1.70 1.98 1.46
RB 20.63 0.63 20.73 0.22 -0.77 0.35 1.70 0.41 0.25
CT (COL17A1-
18S) CT (COL17A1-18S) CT - CT,cal COL17A1 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AK 22.04 0.48
PH 30.03 0.00
JB 22.48 1.51 0.41 1.00 1.33 0.75
JS 22.86 0.41 24.35 0.41 0.00 0.58 1.00 0.40 0.28
BTC, n=5 DC 19.97 0.42
JE 21.21 1.20
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MJ 26.31 1.46
RC 22.83 0.52 0.41 4.93 6.54 3.72
RB 19.93 0.64 22.05 0.41 -2.30 0.58 4.93 1.97 1.39
CT (COL1A1-
18S) CT (COL1A1-18S) CT - CT,cal COL1A1 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AK 24.23 0.47
PH 30.03 0.00
JB 17.09 0.81 0.31 1.00 1.24 0.81
JS 27.34 24.67 0.31 0.00 0.44 1.00 0.30 0.22
BTC, n=5 DC 24.39 0.41
JE 21.58 0.72
MJ 22.43 0.22
RC 21.58 0.47 0.21 3.40 3.94 2.94
RB 24.53 0.63 22.90 0.21 -1.77 0.38 3.40 0.89 0.50
CT (COL6A3-
18S) CT (COL6A3-18S) CT - CT,cal COL6A3 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AK 23.95
PH 30.03 0.00
JB 14.27 0.80 0.30 1.00 1.23 0.81
JS 23.45 0.39 22.92 0.30 0.00 0.42 1.00 0.29 0.21
BTC, n=5 DC 23.63 0.53
JE 21.50 0.88
MJ 21.44 0.58
RC 19.08 1.25 0.27 2.26 2.72 1.87
RB 23.11 0.65 21.75 0.27 -1.17 0.40 2.26 0.63 0.42
CT (CSPG4-
18S) CT (CSPG4-18S) CT - CT,cal CSPG4 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AK 25.59
PH 30.03 0.00
JB 21.48 1.34 0.93 1.00 1.90 0.53
JS 23.03 2.43 25.03 0.93 0.00 1.31 1.00 0.91 0.64
BTC, n=5 DC 21.07 0.44
JE 30.20 0.69
MJ 24.24 1.40
RC 19.64 1.02 0.35 1.59 2.02 1.25
RB 26.68 0.67 24.36 0.35 -0.67 0.99 1.59 1.09 0.39
CT (HOXA10-
18S) CT (HOXA10-18S) CT - CT,cal HOXA10 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AK 25.78 2.32
PH 30.03 0.00
JB 23.54 0.78 1.00 1.72 0.58
JS 26.68 0.35 26.51 0.78 0.00 1.10 1.00 0.77 0.54
BTC, n=5 DC 18.83 0.44
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JE 23.18 0.94
MJ 26.87 2.49
RC 17.96 1.02 0.55 35.84 52.60 24.42
RB 19.87 0.63 21.34 0.55 -5.16 0.96 35.84 23.78 13.75
CT (HOXB6-
18S) CT (HOXB6-18S) CT - CT,cal HOXB6 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AK 19.40 0.49
PH 27.09
JB 21.15 0.83 0.48 1.00 1.40 0.72
JS 24.27 22.98 0.48 0.00 0.68 1.00 0.47 0.33
BTC, n=5 DC 18.67 0.44
JE 20.25 0.69
MJ 22.74 0.28
RC 16.18 0.36 0.21 10.19 11.81 8.79
RB 20.30 0.63 19.63 0.21 -3.35 0.53 10.19 3.72 1.50
CT (ITGB8-18S) CT (ITGB8-18S) CT - CT,cal ITGB8 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AK 20.84 0.46
PH 20.68 3.69
JB 20.43 0.92 0.96 1.00 1.95 0.51
JS 18.96 0.38 20.23 0.96 0.00 1.36 1.00 0.94 0.67
BTC, n=5 DC 18.73 0.52
JE 20.46 0.70
MJ 17.69 1.29
RC 18.79 0.86 0.81 2.60 4.56 1.48
RB 18.58 0.63 18.85 0.81 -1.38 1.26 2.60 2.27 1.46
CT (ITIH5-18S) CT (ITIH5-18S) CT - CT,cal ITIH5 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AK 25.12
PH 24.90
JB 21.59 1.37 0.83 1.00 1.78 0.56
JS 20.54 0.94 23.04 0.83 0.00 1.17 1.00 0.81 0.58
BTC, n=5 DC 23.70 0.60
JE 22.46
MJ 21.82 0.38
RC 22.46 0.56 0.44 1.45 1.98 1.07
RB 22.05 1.63 22.49 0.44 -0.54 0.94 1.45 0.95 0.45
CT (KRAS-18S) CT (KRAS-18S) CT - CT,cal KRAS rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AK 19.97 0.47
PH 20.68 0.20
JB 18.09 0.85 0.27 1.00 1.20 0.83
JS 18.67 0.38 19.35 0.27 0.00 0.38 1.00 0.26 0.18
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BTC, n=5 DC 18.62 0.55
JE 18.54 0.74
MJ 18.06 0.17
RC 19.04 0.52 0.23 1.46 1.71 1.25
RB 19.76 0.63 18.80 0.23 -0.55 0.35 1.46 0.35 0.23
CT (LAMC2-
18S) CT (LAMC2-18S) CT - CT,cal LAMC2 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AK 20.84 0.47
PH 23.56 0.08
JB 22.06 0.82 0.26 1.00 1.20 0.84
JS 21.78 0.42 22.06 0.26 0.00 0.37 1.00 0.25 0.18
BTC, n=5 DC 19.66 0.39
JE 21.15 0.73
MJ 21.31 0.22
RC 19.61 0.13 0.21 3.27 3.78 2.82
RB 20.05 0.63 20.35 0.21 -1.71 0.33 3.27 0.76 0.48
CT (LEF1-18S) CT (LEF1-18S) CT - CT,cal LEF1 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AK 24.94
PH 30.03 0.00
JB 21.73 0.94 0.82 1.00 1.77 0.57
JS 27.72 2.28 26.10 0.82 0.00 1.16 1.00 0.80 0.57
BTC, n=5 DC 24.19 0.57
JE 21.71 0.91
MJ 23.99 0.54
RC 25.12 0.16 0.27 4.94 5.96 4.09
RB 23.99 0.63 23.80 0.27 -2.30 0.86 4.94 2.96 0.93
CT (LIF-18S) CT (LIF-18S) CT - CT,cal LIF rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AK 20.96 0.57
PH 22.97 0.15
JB 21.02 0.80 0.26 1.00 1.20 0.83
JS 20.06 0.33 21.25 0.26 0.00 0.37 1.00 0.26 0.18
BTC, n=5 DC 19.79 0.41
JE 20.51 0.70
MJ 20.17 0.20
RC 20.16 0.46 0.21 1.97 2.28 1.70
RB 20.75 0.64 20.27 0.21 -0.98 0.34 1.97 0.46 0.29
CT (LUM-18S) CT (LUM-18S) CT - CT,cal LUM rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AK 24.90 1.15
PH 30.03 0.00
JB 17.37 1.05 0.52 1.00 1.43 0.70
332
JS 23.19 23.87 0.52 0.00 0.73 1.00 0.51 0.36
BTC, n=5 DC 23.99 0.70
JE 24.00 0.88
MJ 23.71 0.51
RC 21.61 0.38 0.30 1.07 1.32 0.87
RB 25.54 0.87 23.77 0.30 -0.10 0.60 1.07 0.45 0.22
CT (MAML2-
18S) CT (MAML2-18S) CT - CT,cal MAML2 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AK 23.34 0.47
PH 24.93
JB 21.72 1.05 0.40 1.00 1.32 0.76
JS 22.86 0.39 23.21 0.40 0.00 0.57 1.00 0.40 0.28
BTC, n=5 DC 22.31 0.38
JE 23.58 0.93
MJ 22.75 0.32
RC 22.97 0.43 0.25 1.39 1.66 1.18
RB 22.05 0.64 22.73 0.25 -0.48 0.47 1.39 0.46 0.24
CT (MAML3-
18S) CT (MAML3-18S) CT - CT,cal MAML3 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AK 21.88 0.48
PH 24.00 0.95
JB 21.41 0.85 0.35 1.00 1.27 0.79
JS 21.03 0.30 22.08 0.35 0.00 0.49 1.00 0.34 0.24
BTC, n=5 DC 21.21 0.44
JE 20.73 0.74
MJ 20.35 0.23
RC 17.43 0.37 0.29 3.74 4.57 3.06
RB 21.18 0.63 20.18 0.29 -1.90 0.45 3.74 1.17 0.75
CT (MAPK1-
18S) CT (MAPK1-18S) CT - CT,cal MAPK1 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AK 21.79 0.50
PH 22.74 0.06
JB 20.37 0.84 0.26 1.00 1.20 0.83
JS 20.57 0.37 21.37 0.26 0.00 0.37 1.00 0.26 0.18
BTC, n=5 DC 20.60 0.39
JE 20.05 0.71
MJ 19.74 0.17
RC 21.17 0.16 0.21 2.15 2.49 1.86
RB 19.76 0.63 20.26 0.21 -1.11 0.33 2.15 0.50 0.31
CT (MCM4-18S) CT (MCM4-18S) CT - CT,cal MCM4 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AK 23.86 0.58
333
PH 24.46 0.90
JB 21.40 1.54 0.48 1.00 1.39 0.72
JS 24.02 0.35 23.43 0.48 0.00 0.68 1.00 0.47 0.33
BTC, n=5 DC 22.68 0.54
JE 21.74 0.79
MJ 22.15 0.67
RC 22.99 1.15 0.32 2.49 3.11 2.00
RB 21.04 0.63 22.12 0.32 -1.32 0.58 2.49 0.99 0.56
CT (MMP2-18S) CT (MMP2-18S) CT - CT,cal MMP2 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AK 30.38
PH 30.03
JB 15.35 1.08 1.08 1.00 2.12 0.47
JS 25.25 1.08 0.00 1.53 1.00 1.06 0.75
BTC, n=5 DC 25.71 0.50
JE 24.48 2.20
MJ 23.62 0.23
RC 22.24 0.25 0.49 2.34 3.28 1.66
RB 24.10 0.92 24.03 0.49 -1.22 1.19 2.34 1.93 0.79
CT (MXRA5-
18S) CT (MXRA5-18S) CT - CT,cal MXRA5 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AK 22.66
PH 26.25 0.53
JB 17.71 0.81 0.34 1.00 1.26 0.79
JS 30.64 0.30 24.31 0.34 0.00 0.48 1.00 0.33 0.23
BTC, n=5 DC 23.73 0.57
JE 21.15 0.70
MJ 22.92 0.71
RC 21.42 0.41 0.28 3.55 4.32 2.91
RB 23.21 0.65 22.49 0.28 -1.83 0.44 3.55 1.08 0.70
CT (MYC-18S) CT (MYC-18S) CT - CT,cal MYC rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AK 22.83 0.76
PH 25.77 0.03
JB 20.95 0.81 0.29 1.00 1.22 0.82
JS 25.39 0.32 23.74 0.29 0.00 0.41 1.00 0.28 0.20
BTC, n=5 DC 19.44 0.38
JE 20.08 0.70
MJ 20.65 0.17
RC 22.09 0.29 0.21 11.52 13.30 9.99
RB 18.80 0.63 20.21 0.21 -3.53 0.36 11.52 2.84 1.65
CT (NCSTN-
18S) CT (NCSTN-18S) CT - CT,cal NCSTN rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
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Normal,
n=4 AK 21.19 0.71
PH 22.66 0.20
JB 19.48 0.81 0.28 1.00 1.22 0.82
JS 19.50 0.30 20.71 0.28 0.00 0.40 1.00 0.28 0.20
BTC, n=5 DC 20.00 0.39
JE 20.23 0.74
MJ 19.01 0.17
RC 19.66 0.22 0.22 1.89 2.20 1.63
RB 20.03 0.63 19.79 0.22 -0.92 0.36 1.89 0.47 0.28
CT (PEAR1-
18S) CT (PEAR1-18S) CT - CT,cal PEAR1 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AK 24.48 0.99
PH 30.03 0.00
JB 23.04 0.82 0.43 1.00 1.35 0.74
JS 25.58 25.78 0.43 0.00 0.60 1.00 0.42 0.30
BTC, n=5 DC 22.47 0.67
JE 24.77 0.72
MJ 28.34
RC 22.71 0.19 0.29 2.67 3.27 2.18
RB 23.55 0.64 24.37 0.29 -1.42 0.52 2.67 0.96 0.54
CT (PNMA2-
18S) CT (PNMA2-18S) CT - CT,cal PNMA2 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AK 25.06 0.47
PH 30.03 0.00
JB 26.47 0.86 0.25 1.00 1.19 0.84
JS 30.64 0.30 28.05 0.25 0.00 0.36 1.00 0.25 0.18
BTC, n=5 DC 20.61 0.42
JE 23.40 1.11
MJ 23.49 0.18
RC 17.29 0.12 0.27 112.33 135.72 92.97
RB 21.39 0.65 21.24 0.27 -6.81 0.37 112.33 29.07 21.25
CT (POU5F1-
18S) CT (POU5F1-18S) CT - CT,cal POU5F1 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AK 23.79 0.51
PH 24.66 0.93
JB 21.85 0.85 0.35 1.00 1.28 0.78
JS 22.82 0.38 23.28 0.35 0.00 0.50 1.00 0.35 0.24
BTC, n=5 DC 20.48 0.38
JE 23.05 0.85
MJ 23.02 0.45
RC 17.22 0.16 0.31 5.54 6.85 4.48
RB 20.27 0.63 20.81 0.31 -2.47 0.47 5.54 1.79 1.18
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CT (PRKCB1-
18S) CT (PRKCB1-18S) CT - CT,cal PRKCB1 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AK 21.92 0.47
PH 25.57
JB 19.81 0.81 0.34 1.00 1.27 0.79
JS 23.64 0.43 22.73 0.34 0.00 0.48 1.00 0.34 0.24
BTC, n=5 DC 20.13 0.42
JE 19.90 0.87
MJ 21.98 0.24
RC 20.36 0.53 0.24 3.13 3.69 2.66
RB 23.06 0.64 21.09 0.24 -1.65 0.42 3.13 0.90 0.51
CT (PTK2-18S) CT (PTK2-18S) CT - CT,cal PTK2 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AK 20.17 0.48
PH 22.74 0.34
JB 20.88 0.84 0.27 1.00 1.20 0.83
JS 19.55 0.30 20.83 0.27 0.00 0.38 1.00 0.26 0.18
BTC, n=5 DC 20.21 0.39
JE 20.21 0.76
MJ 19.48 0.21
RC 20.35 0.18 0.23 1.84 2.16 1.58
RB 19.52 0.64 19.95 0.23 -0.88 0.35 1.84 0.45 0.29
CT (PVT1 -18S) CT (PVT1-18S) CT - CT,cal PVT1 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AK 26.04 0.89
PH 30.03 0.00
JB 23.60 0.96 0.34 1.00 1.26 0.79
JS 30.64 0.30 27.57 0.34 0.00 0.48 1.00 0.33 0.23
BTC, n=5 DC 22.20 0.38
JE 25.20 1.13
MJ 26.44 1.12
RC 23.83 0.18 0.35 12.55 16.01 9.84
RB 21.95 0.63 23.92 0.35 -3.65 0.49 12.55 4.23 3.06
CT (RAB27A-
18S) CT (RAB27A-18S) CT - CT,cal RAB27A rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AK 21.22 0.49
PH 23.62 0.16
JB 21.47 0.80 0.25 1.00 1.19 0.84
JS 22.76 0.30 22.27 0.25 0.00 0.35 1.00 0.24 0.17
BTC, n=5 DC 20.97 0.41
JE 21.80 0.76
MJ 20.90 0.27
RC 20.57 0.16 0.22 2.73 3.19 2.34
RB 19.84 0.63 20.82 0.22 -1.45 0.33 2.73 0.63 0.42
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CT (RAD51-
18S) CT (RAD51-18S) CT - CT,cal RAD51 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AK 25.59 0.48
PH 30.03 0.00
JB 23.80 0.88 0.33 1.00 1.26 0.79
JS 25.65 26.27 0.33 0.00 0.47 1.00 0.33 0.23
BTC, n=5 DC 23.75 0.89
JE 23.09 0.74
MJ 26.54 0.47
RC 25.10 0.63 0.28 4.19 5.11 3.44
RB 22.52 0.69 24.20 0.28 -2.07 0.44 4.19 1.27 0.83
CT (SERPINA3-
18S) CT (SERPINA3-18S) CT - CT,cal SERPINA3 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AK 19.44 0.61
PH 22.98 1.00
JB 18.28 1.30 0.44 1.00 1.36 0.74
JS 22.32 0.30 20.76 0.44 0.00 0.63 1.00 0.43 0.31
BTC, n=5 DC 17.73 0.39
JE 18.77 0.90
MJ 17.78 0.29
RC 17.68 0.72 0.31 4.40 5.46 3.54
RB 21.14 0.63 18.62 0.31 -2.14 0.54 4.40 1.65 0.95
CT (SPARC-
18S) CT (SPARC-18S) CT - CT,cal SPARC rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AK 23.84 0.47
PH 26.66 1.83
JB 16.27 1.12 0.78 1.00 1.72 0.58
JS 25.94 2.23 23.18 0.78 0.00 1.11 1.00 0.77 0.54
BTC, n=5 DC 22.52 0.45
JE 19.68 0.69
MJ 21.67 0.37
RC 20.97 0.50 0.43 3.14 4.23 2.33
RB 22.80 0.69 21.53 0.43 -1.65 0.89 3.14 1.94 0.94
CT (STAT1-
18S) CT (STAT1-18S) CT - CT,cal STAT1 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AK 18.49 0.51
PH 20.74 0.03
JB 17.15 0.94 0.28 1.00 1.21 0.82
JS 17.32 0.33 18.42 0.28 0.00 0.40 1.00 0.27 0.19
BTC, n=5 DC 17.14 0.49
JE 18.02 0.80
MJ 15.16 0.20
RC 17.92 0.38 0.24 2.79 3.28 2.36
RB 16.49 0.70 16.95 0.24 -1.48 0.37 2.79 0.71 0.46
337
CT (TGFBI-
18S) CT (TGFBI-18S) CT - CT,cal TGFBI rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AK 22.76 0.60
PH 23.93
JB 18.08 0.83 0.46 1.00 1.38 0.73
JS 24.72 0.93 22.37 0.46 0.00 0.65 1.00 0.45 0.32
BTC, n=5 DC 21.53 0.62
JE 19.64 0.71
MJ 21.22 0.16
RC 20.45 0.32 0.23 2.49 2.93 2.13
RB 22.44 0.64 21.05 0.23 -1.32 0.52 2.49 0.89 0.40
CT (TM4SF18-
18S) CT (TM4SF18-18S) CT - CT,cal TM4SF18 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AK 23.57
PH 26.63
JB 20.13 0.86 0.50 1.00 1.42 0.71
JS 22.90 0.51 23.31 0.50 0.00 0.71 1.00 0.49 0.35
BTC, n=5 DC 22.95 0.45
JE 21.37 1.11
MJ 20.28 0.59
RC 20.21 0.59 0.29 5.26 6.45 4.29
RB 19.75 0.63 20.91 0.29 -2.39 0.58 5.26 2.12 1.07
CT (TRIB2-18S) CT (TRIB2-18S) CT - CT,cal TRIB2 rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AK 20.92 0.50
PH 23.36 1.01
JB 20.88 0.87 0.36 1.00 1.29 0.78
JS 21.51 0.30 21.67 0.36 0.00 0.52 1.00 0.36 0.25
BTC, n=5 DC 19.46 0.50
JE 19.36 0.71
MJ 20.36 0.16
RC 20.97 0.41 0.30 3.12 3.83 2.54
RB 20.00 0.63 20.03 0.30 -1.64 0.47 3.12 1.02 0.64
CT (VEGFA-
18S) CT (VEGFA-18S) CT - CT,cal VEGFA rel to Cal
SAMPLES CT STDEV AVERAGE ERROR Average ERROR ERROR
Normal,
n=4 AK 20.22 0.47
PH 22.24 0.10
JB 19.40 0.86 0.33 1.00 1.26 0.80
JS 19.53 20.35 0.33 0.00 0.46 1.00 0.32 0.23
BTC, n=5 DC 18.70 0.40
JE 18.75 0.70
MJ 18.81
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RC 18.75 0.17 0.26 2.92 3.48 2.44
RB 18.99 0.63 18.80 0.26 -1.54 0.42 2.92 0.84 0.52
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9.1.2 Abstracts related to the thesis.
Figure 72 (Abstract 1). Copy of abstract presented at the Bile Acid Biology and
Therapeutics meeting, Amsterdam, June 2008 outlining our local experience of
dominant strictures and cholangiocarcinoma in PSC.
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Figure 73 (Abstract 2). Copy of abstract poster presented at the BASL annual meeting
2009 outlining local success rates in reaching a tissue diagnosis in BTC using
currently available diagnostic modalities.
341
Figure 74 (Abstract 3). Copy of abstract poster presented at the EASL monothematic
conference on PSC (Copenhagen, 2009) demonstrating the diagnostic and prognostic
utility of CYFRA 21-1 in patients with sporadic and PSC related BTC.
342
Figure 75 (Abstract 4). Copy of poster abstract presented at the AASLD single topic
conference; Pathobiology of Biliary Epithelia and Cholangiocarcinoma, Atlanta, USA,
June 2008
343
Figure 76 (Abstract 5). Copy of abstract poster presented at the AASLD meeting,
Boston, 2009
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9.1.3 Ethical approval, clinical databases and sample
biobank
9.1.3.1 Ethical approval
Ethical approval for this work and related translational research was granted
at the start of the project. The approval includes prospective sample collection
of blood, bile, brushings and tissue from patients with benign and malignant
hepatopancreatobiliary disorders, as well as access to similar archived
samples for laboratory research. Ethical approval was granted by the Joint
UCL/UCH Local Research Ethics Committee (ref 06/Q0152/106) with Site
Specific Assessment at the Royal Free Hampstead NHS Trust (Dr James
Dooley).
9.1.3.2 Clinical databases
Clinical databases for research purposes already in use have been
maintained and new databases have also been established during the time of
this project. The databases are crucial for identifying patients and data related
to this and other ongoing projects. Databases include;
 Patients with primary sclerosing cholangitis
 Patients with autoimmune pancreatitis
 Patients recruited into BTC-related clinical trials e.g. PHOTOSTENT-02
 Patients with sphincter of Oddi dysfunction
 Patients discussed at the joint UCH and Royal Free Hospital HPB
cancer multi-disciplinary meeting.
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 Clinical samples stored in the laboratory for translational research.
 ERCP databases of archived data from the previous endoscopy
software and ongoing collection with current software in use by hospital
departments
 Patients listed as having had biliary brush cytology at UCH.
9.1.3.3 Biobank of clinical samples
A standard operating procedure is in place to optimise and standardise clinical
sample collection. Following informed patient consent, patient samples are
collected, processed, separated into multiple cryotubes and stored at -80oC in
freezers in our laboratory at the Institute of Hepatology. Samples are stored
racked and dated in colour coded boxes for convenience. Samples are coded
for anonymity and a database of stored samples is used to identify samples
and record relevant basic clinical information.
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9.1.4 Real Time quantitative PCR – calculation of
relative gene expression using the comparative
cycle threshold (Ct) method
Calculation of relative gene expression using qPCR data is performed using
the comparative Ct method first described for use in qPCR by Livak and
Schmittgen (Livak and Schmittgen 2001)
Calculation of relative gene expression using qPCR requires a stably
expressed ‘house keeping’ gene (e.g. GAPDH, ACTB, 18SRNA) for reference
and normalization. All cells from all tissues should ideally have the same
expression of the reference gene in health and disease. The relative (or
comparative) expression (Ct) of a gene of interest is compared to the
reference gene using the equation:
Ct= Cttarget gene – Ctreference gene
The relative gene expression of one sample (e.g. cancer) compared to
another (e.g. benign) is calculated and expressed using the Ct method:
Ct = Ctsample - Ctcontrol
Relative gene expression = 2-Ct
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9.1.5 Cholangiocarcinoma Staging
The staging system most commonly used in BTC is the TNM staging outlined
as follows;
“The American Joint Committee on Cancer guidelines in the AJCC Cancer
Staging Manual, Fifth Edition, following the tumour, node, and metastasis
(TNM) classification system, with depth of tumour penetration and regional
spread defined pathologically, should be followed.”
T - Primary tumour
TX - Primary tumour cannot be assessed
T0 - No evidence of primary tumour
TIS - Carcinoma in situ
T1a - Tumour invades mucosa
T1b - Tumour invades muscularis
T2 - Tumour invades perimuscular connective tissue
T3 - Tumour invades liver, gallbladder, duodenum, stomach, pancreas, or
colon
N - Regional lymph nodes
NX - Regional lymph nodes cannot be assessed
N0 - No metastases in regional lymph nodes
N1 - Metastases in cystic duct or pericholedochal or hilar lymph nodes of
hepatoduodenal ligament
N2 - Metastases in peripancreatic (head only), periduodenal, posterior
pancreatoduodenal, periportal, celiac, or superior mesenteric regional lymph
nodes
M - Metastasis
MX - Presence of metastases cannot be assessed
M0 - No distant metastases
M1 - Distant metastases (includes lymph node metastases beyond N2)
TNM groupings by stage
Stage 0 - TIS N0 M0
Stage I - T1 N0 M0
Stage II - T2 N0 M0
Stage III - T1-2 N1-2 M0
Stage IVa - T3 N0-2 M0
Stage IVb - T1-3 N0-2 M1
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9.1.6 Techniques used in this thesis and details of
assistance given
All laboratory techniques performed by myself were done following instruction
and supervision of Dr Fausto Andreola, Post-Doctoral Scientist. His help and
teaching is particularly appreciated.
 Conception of ideas and design of experiments
Myself with guidance of Dr Stephen Pereira, Dr Fausto Andreola and Dr
James Dooley
 Ethical and R&D approval
Myself with guidance of Dr Stephen Pereira and Dr James Dooley (Royal
Free Hospital)
 Sample collection, storage and maintenance of databases
Myself, Dr Neomal Sandanayake, Robert Tidswell.
Biliary brushings were taken by other clinicians at the time of ERCP
procedures (Dr Stephen Pereira, Dr George Webster, Dr Adrian Hatfield &
Dr James Dooley (Royal Free Hospital))
 RNA isolation and assessment of quality
Myself with guidance of Dr Fausto Andreola
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 cDNA synthesis
Myself with guidance of Dr Fausto Andreola
 Standard PCR
Myself with guidance of Dr Fausto Andreola
 Single gene qPCR (SYBR Green and TaqMan)
Myself with guidance of Dr Fausto Andreola. Experiments with CD9 were
done also with the help of Robert Tidswell (iBSc student)
 Mutliple gene qPCR using the TaqMan Array platform
These were performed at the CRUK Lincolns Inn Fields laboratories by
Alvin Lee and myself with guidance of Dr Charles Swanton (CRUK)
 qPCR data analysis
Myself and Robert Tidswell with guidance of Dr Fausto Andreola
 Microarray experiments
Performed as a paid service by Scientific Support Services, UCL
 Microarray data analysis
Done as a paid service by Dr Sonia Shah, Bloomsbury Centre for
Bioinformatics, UCL
350
 Tissue culture
Cells from tissue culture were provided by Dr Virginie Cerec
 Gel electrophoresis
Myself with guidance of Dr Fausto Andreola
 Western blot
Myself with guidance of Dr Virginie Cerec and Dr Fausto Andreola
 ELISA
Myself with guidance of Dr Fausto Andreola
 Immunohistochemistry
Done as a paid service by UCL Advanced Diagnostics (Philipa Munson).
 Reporting of immunohistochemistry slides
Dr Maesha Deheragoda, Department of Pathology, UCL.
 Laser Capture Microdissection
Myself with instruction and supervison by Dr Simon Leedham, CRUK
 Statistical analysis
Myself with guidance of Dr Fausto Andreola and Dr Dipok Dhar
351
 Preparation of images, tables and figures
Myself
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